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Success is not final, failure is not fatal: 
it is the courage to continue that counts.
— Winston Churchill
To my mother Elisabete, who inspired this work
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1. ABSTRACT / RESUMO
Aortic stenosis is the most common type of valvular heart disease and its recent increase in preva-
lence is related to aging. The progressive reduction in aortic valve area imposes a chronic systolic 
pressure overload to the left ventricle (LV). In response, the LV hypertrophies in an attempt to nor-
malize the increased wall stress, and changes in cardiomyocytes and extracellular matrix connective 
tissue occur, being some of them irreversible. This helps to explain the deterioration of diastolic and 
systolic function that takes place after longstanding overload. At histopathological level, LV fibrosis 
has been implicated in the progression to heart failure and has been associated with lower long-term 
survival rates. Indeed, late outcome after AVR depends mainly on the stage of myocardial disease 
before surgery, besides prosthetic related complications, and co-morbidities.  
However, the LV hypertrophic response is not uniform under similar degrees of stenosis and its 
regression after surgical correction is variable, suggesting that non-hemodynamic factors can help to 
explain these differences. This work intended to better understand LV hypertrophy in aortic stenosis, 
find load-independent factors that could influence hypertrophic response variability, and identify 
markers of more advanced myocardial disease with potential impact in clinical outcomes. 
For that purpose, we followed for eight years a cohort of 132 patients with isolated severe aortic stenosis, 
referred for aortic valve replacement at Centro Hospitalar S. João, between January 2006 and December 
2009. Comprehensive clinical and echocardiographic characterization was done before and after surgery. 
In a subgroup of 56 patients myocardial biopsies were also performed at the time of valve replacement.
We have found that an excessive LV hypertrophy, by LV mass predicted according to load, gender 
and height, is associated with a maladaptive response, with a more advanced form of myocardial 
disease and worse prognosis. Likewise, the lack of normalization of LV mass after surgery helps to 
identify patients with worse long-term prognosis. Specific subgroups of patients, such as women 
and hypertensive were particularly vulnerable to this maladaptive response.
Some specific subgroups of patients are particularly vulnerable to this maladaptive response, such as 
women and hypertensive patients. At the structural and molecular level, we have described differences 
in ECM remodeling and higher degrees of interstitial fibrosis in those with impaired reverse remodeling 
and those with worse outcomes.  Moreover, we found more severe preoperative fibrosis and evidence 
of a specific ECM remodeling in women, which raises the hypothesis that ECM may be a determinant 
of gender differences in LV remodeling and may justify gender-specific therapeutic interventions. 
Early surgery and the use of pharmacological anti-fibrotic therapies after valve replacement, par-
ticularly in patients with non-invasive evidence of preoperative fibrosis and maladaptive response, 
might help to improve prognosis in aortic stenosis.
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A estenose aórtica é a doença valvular mais frequente no mundo ocidental e a sua crescente pre-
valência está associada ao envelhecimento populacional. A progressiva redução da área valvular 
aórtica leva à sobrecarga crónica de pressão sobre o ventrículo esquerdo, sendo que a resposta 
hipertrófica resulta de uma tentativa de normalização do stress de parede para preservar a contrac-
tilidade miocárdica. Concomitantemente, ao nível histológico e molecular, ocorrem alterações nos 
cardiomiócitos e matriz extracelular, com hipertrofia miocitária e fibrose intersticial, por vezes irre-
versíveis, que, a longo prazo,  levam à deterioração da função diastólica e sistólica, comprometendo 
a sobrevida. De facto, um dos principais determinantes do prognóstico após substituição valvular 
aórtica é a gravidade do atingimento miocárdico, para além das comorbilidades e das complicações 
relacionadas com a prótese.   
No entanto, a resposta hipertrófica para níveis semelhantes de sobrecarga na estenose aórtica não 
é uniforme e há grande variabilidade na regressão de massa após cirurgia, sugerindo que este pro-
cesso depende também de factores independentes da carga. Este trabalho pretendeu melhorar a 
compreensão da resposta hipertrófica na estenose aórtica, encontrar determinantes da hipertrofia 
ventricular, e identificar potenciais marcadores de doença miocárdica mais avançada, com potencial 
impacto nos eventos clínicos.
Foi estudada uma coorte prospectiva de 132 doentes com estenose aórtica grave isolada e indicação 
para cirurgia de substituição valvular aórtica. Os doentes foram selecionados de Janeiro de 2006 a 
Dezembro de 2009 e seguidos durante 8 anos. Dados clínicos e ecocardiográficos foram recolhidos 
antes e após substituição valvular aórtica. Num subgrupo de 56 doentes foram recolhidas biopsias 
miocárdicas durante a cirurgia. 
Os nossos resultados mostraram que doentes com hipertrofia inapropriada e excessiva para aquilo 
que seria esperado de acordo com a carga, o sexo e a altura, apresentam uma resposta inadequada 
com uma forma mais grave de atingimento miocárdico e pior prognóstico. Para além disso, a hi-
pertrofia residual após cirurgia, provavelmente um indicador de doença irreversível, identifica um 
subgrupo de doentes com pior prognóstico.
Alguns doentes são particularmente vulneráveis a este tipo de resposta, como as mulheres e os 
hipertensos, e podem merecer tratamento diferenciado. O nosso grupo descreveu diferenças na 
remodelagem da matriz extracelular e fibrose no sexo feminino, levantado hipóteses sobre os me-
canismos responsáveis pelas diferenças entre sexos na remodelagem ventricular com potenciais 
consequências no tratamento.
A indicação de cirurgia mais precoce e o uso de terapêutica farmacológica com efeito anti-fibrótico 
após o alívio da carga, em particular em doentes com evidência não invasiva de fibrose e resposta 
inadequada, poderão contribuir para melhorar o prognóstico na estenose aórtica. 
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Abstract: Aortic stenosis is the most common type of valvular heart disease and its recent increase is related to aging. 
The decreased aortic valve area imposes a chronic systolic pressure overload to the left ventricle. In response, the ventricle 
hypertrophies in an attempt to normalize the increased wall stress, but this response is not uniform in patients with similar 
degrees of stenosis and its regression after surgical correction is variable, suggesting that several factors, other than load, 
can explain these differences. These findings are particularly important since the presence of left ventricular hypertrophy 
after aortic valve replacement is an independent predictor of worse outcome, probably because it indicates irreversible 
remodeling. Age, gender, hypertension, patient-prosthesis mismatch and interstitial remodeling also play an important role 
in this setting, raising the possibility of intervention beyond valve replacement. The possibility of combining estrogen 
treatment, antihypertensive agents, antioxidants and modulators of the renin-angiotensin-aldosterone system with surgical 
treatment to promote reverse remodeling is very appealing. On the other hand, a preventive strategy to intervene earlier in 
patients with significant left ventricular mass and avoid patient-prosthesis mismatch, especially in the younger and those 
with systolic dysfunction, can have a significant impact on prognosis. Further evidence, with well designed clinical trials, 
is needed but the spotlight must be in the ventricle, not the valve. 
Keywords: Left ventricular hypertrophy, isolated aortic stenosis, aortic valve replacement, remodeling, prognosis. 
INTRODUCTION 
 Aortic stenosis (AS) is the most prevalent of all valvular 
diseases in developed countries. Its increase has a direct rela-
tion with population aging. In the Cardiovascular Health 
Study, in which 5201 men and women older than 65 years 
were analyzed, 26% had aortic sclerosis while 2% had frank 
stenosis [1].  
 Once considered a degenerative process, it is now be-
lieved to be similar to atherosclerosis, sharing the same risk 
factors and presenting evidence of active inflammation [2,3]. 
 Progressive narrowing of the aortic orifice, to less than 
half of its usual size, leads to a significant pressure overload 
to the left ventricle (LV). The onset of symptoms like heart 
failure, syncope and angina, mark the decline in prognosis 
and, together with LV dysfunction, is the major determinant 
for aortic valve replacement [4,5]. Indeed, treatment of AS 
has been a mechanistic one, based on the relief of pressure 
overload. Only recently has attention been directed to the 
valve, considering the possibility of prevention of progres-
sion with drugs used in atherosclerosis, namely statins [6]. 
Small retrospective and prospective trials have shown that 
statins could delay the progression of AS [6,8], but large 
prospective studies have not confirmed these findings [9,10]. 
No specific medical therapy is recommended for protection 
of the ventricle before or after aortic valve replacement 
 
*Address correspondence to this author at the Department of Physiology 
and Cardiothoracic Surgery, Faculty of Medicine, Alameda Professor Her-
nâni Monteiro, 4200-319 Porto, Portugal; Tel: +351 225 513 644; Fax: +351 
225 513 646;  E-mail: amoreira@med.up.pt 
(AVR), except if there is systolic dysfunction or hyperten-
sion. 
LEFT VENTRICULAR HYPERTROPHY IN PRES-
SURE OVERLOAD DUE TO AS 
 In chronic pressure overload states, like systemic hyper-
tension (HT) and AS, the LV responds with hypertrophy and 
altered geometry as an adaptative mechanism that helps to 
maintain contractile performance despite abnormal loading 
conditions. LV hypertrophy (LVH) allows for normalization 
of systolic wall stress and has been considered as compensa-
tory [11,13], but it is also associated with impaired coronary 
blood-flow reserve [14,15] and changes in cardiomyocytes 
and extracellular matrix connective tissue, some of them 
irreversible. The later might explain the deterioration of dia-
stolic and systolic function that take place after longstanding 
overload [16].  
 In epidemiological studies and in landmark hypertension 
clinical trials the increase in indexed left ventricular mass 
[17-20] is accompanied by an increase in cardiovascular 
events and overall mortality. In aortic stenosis, preoperative 
LVM has been identified as a strong predictor of poor out-
come after AVR [21-24]. Increased preoperative LVM index 
is a strong independent predictor of operative morbidity and 
in-hospital mortality, with a striking incidence of low cardiac 
output syndrome despite normal ejection fraction [22, 24]. 
These patients are mostly older women and typically have a 
concentric remodeling with a marked increased in relative 
wall thickness and small LV cavity, associated with a supra-
normal systolic function [21]. With the sudden unloading of 
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the LV after AVR some develop abnormal intra-cavitary 
flow acceleration and hypotension. The use of intra-aortic 
ballon pump and inotropics increase contractility and wor 
sens the intra-ventricular gradient, resulting in a low cardiac 
output syndrome, the main cause of death in this subgroup 
[22]. Hypotension in this setting should be treated with vol-
ume and alfa agonists, avoiding the routine use of positive 
inotropic support.  
 Several mechanisms can explain the association between 
preoperative LVH and morbimortality after AVR: (1) effec-
tive cardioprotection of the hypertrophied LV during 
ischemic arrest is challenging and can lead to perioperative 
ischemia, (2) diminished coronary flow reserve, even in the 
presence of normal epicardial coronary arteries [14,15], (3) 
transient exacerbation of diastolic dysfunction due to super-
imposed ischemia [25], (4) propensity for cardiac arrhyth-
mias [26].  
 But not all ventricles respond with the same degree of 
LVH under identical loading conditions [27,28]. Severity of 
left ventricular hypertrophy in the presence of aortic stenosis 
is multifactorial and not affected only by the hemodynamic 
severity as assessed by aortic valve area or pressure gradient 
estimation. Patient age, gender, systolic blood pressure, ven-
tricular function and genetics should also be considered 
when evaluating the degree of left ventricular hypertrophy in 
these patients [28-33].  
 About 10 % of patients with severe AS do not have LVH 
[34]. This challenges the paradigm that hypertrophy is 
needed to maintain wall stress and contractility. Experimen-
tal studies in animal models of aortic stenosis have shown 
that LVH is not necessary to maintain LV function [35,36] 
and that deficient hypertrophy can, in fact, prevent rather 
than promote systolic dysfunction. In a mouse model of car-
diorestricted deficiency in Gq signaling with blunted hyper-
trophic response, after 1 week of aortic constriction control 
mice showed completed normalization of wall stress, while 
gene modified mice were unable to reduce wall stress. After 
8 weeks, control mice had an increase in chamber dimension 
and progressive deterioration of LV function, whilst mice 
with a blunted hypertrophy and persistent elevation of wall 
stress had only limited LV dilatation and preserved LV func-
tion [36]. Similar findings were observed after inhibition of 
calcineurin-NFAT pathway [37]. These findings suggest that 
the LV was better off “stressed out” than being hypertro-
phied. In a prospective cohort of patients with isolated AS, 
increased LV mass (LVM) alone predicted systolic dysfunc-
tion and heart failure, regardless of the severity of the ob-
struction [38]. Even in patients with critical AS (valvular 
area < 0,4 cm
2
/m
2
), one fifth did not have LVM increase and 
had better preserved ejection fraction and less heart failure 
when compared to those with increased LVM [38]. But the 
lack of LVH does not imply persistent elevation of LV wall 
stress. Patients without LVH had, nevertheless, concentric 
remodeling with augmented relative wall thickness (RWT) 
due to small LV cavities in response to pressure overload. 
LV ejection fraction was related directly to RWT and in-
versely with LVM, raising the idea that concentric LV re-
modeling may be the key compensatory mechanism in AS, 
and multifactorial LVH a maladaptive response. More re-
cently, concentric hypertrophy and concentric remodeling 
had similar early mortality risk after AVR and both were 
associated with worse outcomes than nonconcentric remod-
eling [39]. Unfortunately, since there was no data on LV 
wall stress, the paradigm that wall stress normalization is 
needed for maintaining LV function has yet to be clinically 
tested.  
 In a single-center observational study involving more 
than 3000 patients who underwent AVR with a single type of 
bioprosthesis, severe preoperative LVH (defined as LVM 
index  185 g/m2), which preceded symptoms in 17% of 
patients, decreased long-term survival [40].  
 Given the clinical and experimental evidence of in-
creased morbimortality in patients with higher LVM index, 
the indication for early AVR in asymptomatic patients 
should take into consideration significant LVH. So far, re-
cent guidelines advice AVR in asymptomatic patients with 
severe AS if there is rapid disease progression, very severe 
stenosis or abnormalities in exercise testing [5, 41]. Only the 
European guidelines refer to excessive LV hypertrophy (15 
mm), unless this is due to hypertension, as a class IIb indica-
tion for AVR [41].  
 More recently, much has been published regarding risk 
stratification in asymptomatic patients for early AVR. Pro-
posed parameters include jet velocity, progression of valvu-
lar narrowing, response to exercise testing, comorbidity, ab-
normally raised biomarkers and ventricular dysfunction 
[42,43]. But one should also take into consideration signifi-
cant LVH. 
RESIDUAL LEFT VENTRICLE HYPERTROPHY  
AFTER AVR 
 Aortic valve replacement increases long-term survival, 
which becomes similar to age-matched population, reduces 
symptoms and improves quality of life in patients with aortic 
valve stenosis [44,45]. Late outcome after AVR depends 
mainly on the stage of heart disease before surgery, pros-
thetic related complications, and co-morbidities. Late deaths 
after AVR are mostly due to sudden cardiac death and con-
gestive heart failure [46]. Risk factors for poor post-
operative outcomes include age, co-morbidities, severe func-
tional limitation, irreversible myocardial damage such as a 
large myocardial scar, severe LV hypertrophy, more severe 
AS, ventricular arrhythmias, and untreated co-existing coro-
nary disease [47]. In addition, poor post-operative outcomes 
may result from prosthesis-related complications or sub-
optimal prosthetic valve hemodynamic performance [48,49]. 
 After successful AVR, LV pressure and wall stress are 
significantly reduced [50] and, as a consequence, LVH re-
gression is expected. But since LV wall stress is not the only 
predictor of LVH, reduction of intraventricular pressure can-
not solely predict regression after AVR. Significant LVM 
regression seems to occur as early as 5 days after AVR [51], 
is maximal after the first year, and has only non significant 
slight decrease after 18 months to 10 years [52-56]. Early 
regression of LVM reflects pressure unloading and is a con-
sequence of reduction of LV diameters while wall thickness 
is maintained [57]. Additional regression of LVM occurs in 
the late period, mainly as a consequence of a reduction in 
wall thickness, probably as a result of normalization of car-
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diomyocyte hypertrophy and reduction of the fibrous content 
in the extracellular matrix [57,58]. 
 Nearly half of patients with aortic stenosis have residual 
LVH late after surgery [16, 59]. This persistent increase in 
LVM is an independent predictor of cardiac-related morbid-
ity [59] and mortality [46, 60].  
 The worse long-term outcome of patients with residual 
LVH after AVR can be explained by the existence of more 
extensive preoperative disease and persistent diastolic and/or 
systolic dysfunction [57, 61]. Indeed, an important inde-
pendent predictor of incomplete regression of LVH is LVM 
before AVR [62,63]. These patients have more severe symp-
toms and worse pre and postoperative ventricular function 
[16]. At the histological level, these findings correlate with 
the degree of myocyte abnormalities (higher nucleus vol-
ume), higher muscle cell mass index and increased amount 
of fibrous tissue at the time of surgery, altogether suggesting 
the presence of irreversible remodeling [16].  
 Regression of LVH after AVR is mostly the result of 
pressure overload relief. Hemodynamic factors, such as type 
of valve and residual gradients, hypertension, are not the 
only determinants of incomplete regression. Age, gender, 
genetic polymorphisms and irreversible interstitial remode 
ling also play an important role in this setting. 
DETERMINANTS OF LEFT VENTRICULAR  
REMODELING AFTER AVR 
Age 
 Given the increase in calcific AS prevalence with age, 
most patients undergoing AVR are older than 65 years. In 
the large multicenter Cardiovascular Health Study, LVM 
increased with age but, after adjustment for body weight, the 
age effect was attenuated (less than one gram per year in-
crease) [64]. Although this may be due to the highly narrow 
age range (all subjects were 65 years or older) these results 
are in accordance with those obtained in a healthy subgroup 
of 862 participants aged 18 to 79 years from the Framingham 
cohort (n=177 subjects) and offspring (n=685 subjects), 
where only minimal changes in LVM were noted with ad-
vancing age. Multivariate analyses in this normotensive, 
nonobese subgroup with no clinical evidence of cardiovascu-
lar disease revealed that age was not significantly associated 
with LVM in men and only weakly associated with LVM in 
women [65]. 
 In conclusion, the relation of incomplete LVH regression 
after AVR with age is controversial. Some authors advocate 
that older patients have higher LVM index after surgery [55, 
59] and speculate that older age could negatively affect col-
lagen turnover and lead to less fibrous degradation with 
slower remodeling. Most studies, however, do not support 
this hypothesis and found no relation between age and in-
dexed post-operatory LVM [62,63, 66].  
Gender 
 It has been long recognized that men have higher left 
ventricular mass when compared to women, even though 
these differences are attenuated after indexation to body sur-
face area [67-69]. In epidemiological studies, ventricular 
mass increases with age in healthy women, whereas it re-
mains constant in men [65]. In an autopsy series, which ex-
cluded primary cardiac pathology, LVM decreased in men 
but remained constant in women [68]. In women aging did 
not lead to myocyte cell loss or reactive hypertrophy, 
whereas in men there was a significant decrease in myocyte 
number associated with an increase in volume [68]. This 
 
 
Fig. (1). Left ventricular hypertrophy and reverse remodeling before and after aortic valve replacement (AVR) surgery, respectively. The 
grey boxes show some factors that contribute to residual hypertrophy after AVR. LV – left ventricle. 
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suggests an age-related involution of the heart in men, but 
LVH was not addressed in this study since hypertrophic 
hearts were excluded.  
 In pressure overload states, such as hypertension and 
aortic stenosis, many studies have reported different remod-
eling responses between sexes, with similar LVM index but 
higher prevalence of LVH in women, according to sex spe-
cific criteria [31, 70,71]. Women have smaller LV chamber 
size, higher relative wall thickness, higher LVM/volume 
ratio, supernormal LV function and less wall stress, while 
men exhibit ventricular dilatation and earlier ventricular dys-
function [31, 71-73]. These data in humans are consistent 
with animal studies showing higher depression of contractile 
reserve in male animals, despite similar magnitude of LVH 
and systolic load [74]. At molecular level, this translated into 
a greater expression of beta-myosin heavy chain and atrial 
natriuretic factor, as well as, depressed levels of SERCA-2a 
in male hearts compared to female [74], which could help 
explain the early signs of ventricular dysfunction. 
 The effect of gender-related differences in LVH regres-
sion is less well established. Some have found the associa-
tion of female sex with more complete regression [48, 63], 
but others described similar normalization of LVM 1 year 
after surgery [62]. Male gender was found an independent 
predictor of regression after AVR with stentless bioprosthe-
sis, but patients with previous myocardial infarction were not 
excluded and may have influenced results [75]. The clinical 
impact of gender-related LV geometry is still under debate 
since most authors failed to identify sex as an independent 
predictor of adverse outcome after AVR [23, 73, 76].  
 These distinctive LV remodeling responses to pressure 
overload can be explained by the effect of sex hormones. 
This is supported by evidence of the presence of myocardial 
estrogen and androgen receptors in animals and humans [74, 
77]. In sinoaortic denervated rats, Cabral et al. have found 
that testosterone exerts a facilitator and estradiol an inhibi-
tory action in the development of LVH [78]. Estrogens also 
seem to have antiproliferative effects on cardiac fibroblasts 
[79] and vascular smooth–muscle cells, while androgens 
have opposite effects [80]. Given that older patients have 
relative hypogonadal hormone concentrations, with a de-
crease in estrogens and ovarian production of androgens in 
postmenopausal women and decrease in androgens in men, 
there is a hypothetical explanation for the gender differences 
in LVM with aging. Hormone replacement therapy (HRT) in 
postmenopausal women seems to be associated with lower 
LVM [81-83] arguing in favor of this hypothesis. 
 The beneficial effect of estrogens at myocardial level is 
supported by the presence of functional estrogen receptors 
(ER)  and  in humans [84] and evidence of local synthesis 
in animals [85]. Estrogen receptors belong to the steroid 
hormone receptor superfamily, and estrogen binding has 
both genomic and nongenomic effects [86]. They can act as a 
transcription factor on downstream genes and also exert non 
genomic effects, inducing intracellular signaling cascades, 
such as activation of protein kinase C, extracellular signal-
regulated kinase, and modulating signaling by growth factors 
such as insulin-like growth factor (IGF)-1, epidermal growth 
factor or transforming growth factor [87]. In patients with 
aortic valve stenosis, Nordmeyer et al. have shown that ER  
and  expression is increased in comparison with controls, 
and found an inverse correlation between ER  and cal-
cineurin A- expression [88]. The isoform calcineurin A- 
mRNA of the phosphatase calcineurin is particularly relevant 
for the development of cardiac hypertrophy since isolated 
knockout of this gene prevents the development of an 
hypertrophic response [89]. These findings suggest an 
association between the increase in ER  and the suppression 
of the calcineurin-induced hypertrophic stimuli, although the 
underlying mechanism is not yet completely understood.  
 The possibility of combining estrogen treatment with 
antihypertensive and surgical treatment to prevent/regress 
LVH is very appealing. Further evidence with well designed 
clinical trials is needed.  
Hypertension 
 When investigating hemodynamic factors that influence 
LVM regression after AVR, most studies focused solely on 
pressure gradient and valve related parameters. But the trig-
ger stimulus for LVH is not pressure gradient itself but the 
elevated LV pressure, which depends also of systemic blood 
pressure.  
 Around 30-60% of patients with aortic stenosis are hy-
pertensive [33, 90]. Data on systemic blood pressure before 
and after AVR is absent in most studies on incomplete LVH 
regression and only recently some authors have reported its 
relation to postoperative LVM [55, 66, 91]. In a retrospective 
observational study with 79 patients with pure aortic steno-
sis, all underwent valve replacement with bileaflet mechani-
cal values. The only independent predictors of postoperative 
LVM index were preoperative LVM and postoperative sys-
tolic blood pressure (defined as normal if < 130 mmHg) 
[91]. None of the prosthesis related variables had significant 
influence, although it is controversial if indexed orifice area 
provided by manufacturers should be used as an indicator of 
patient-prosthesis mismatch [91]. Uncontrolled hypertension 
is not only related to higher LVM after AVR but also with 
worse survival, with higher incidence of heart failure and 
bleeding as causes of death [66].  
 Blood pressure control, which can be reduced more ef-
fectively than transprosthetic gradients, has a significant im-
pact in LVM regression. This can be particularly important 
in patients with large residual pressure gradients and severe 
LVH.  
Patient-Prosthesis Mismatch 
 The immediate expected result of AVR is the reduction 
of transvalvular pressure gradients (TPG) with improvement 
in afterload. This is thought to allow for normalization of 
LVM and function, but the impact of hemodynamic variables 
on the extent of LVM regression is controversial. In the 
Strong Heart Study, in American Indians demographic and 
hemodynamic factors could account for only about half the 
LVM variance [92].  
 Patient-prosthesis mismatch (PPM) was first described in 
1978 by Rahimtoola as being present when the effective 
prosthetic valve area was less than that of a normal human 
valve [93]. This is a very broad concept and it is well known 
that most of the prosthetic valves are, at least, mildly steno-
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tic. In a more restrict definition, it implies the existence of a 
smaller than needed effective orifice area (EOA) in relation 
to the patient’s body surface area (BSA) and, therefore, car-
diac output requirements. Given that TPG is directly related 
to the square of transvalvular flow and inversely related to 
the square of the valve area, PPM will ultimately result in 
persistent abnormally high TPGs [94] despite normal pros-
thesis function.  
 Several parameters have been used to define PPM. Inter-
nal geometric area (IGA) is a static manufacturer specifica-
tion based in ex vivo measurement of the diameter of the 
prosthesis. It differs from one type of prosthesis to another, 
tends to overestimate the EOA, especially in bioprosthesis, 
and does not predict postoperative gradients or functional 
improvement after AVR [95-97]. In contrast, indexed EOA 
(patients EOA divided by BSA) is the only parameter that 
has consistently correlated with postoperative gradients [95] 
and has become the most used in recent studies. It has been 
demonstrated that, in order to avoid any significant gradient 
at rest and during exercise, the indexed EAO of a prosthetic 
valve should ideally be no less than 0.85 to 0.9 cm
2
/m
2
, un-
der which gradients increase exponentially. The threshold for 
PPM in the aortic position is an indexed EOA  0.85 cm2/m2. 
Values between 0.65-0.85 cm
2
/m
2
 are considered moderate 
PPM and those < 0.65 cm2/m2 as severe PPM [98]. Thus, 
the objective of AVR should be to ensure an indexed EOA 
above these levels to avoid residual stenosis. Even so, the 
prevalence of moderate PPM varies from 10-70% and that of 
severe mismatch from 2-28%, reflecting great heterogeneity 
in these studies [99]. The high number of patients with PPM 
reported result, most of the times, from surgical difficulties 
in implanting adequate sized prosthesis in small and severely 
calcified aortic roots.  
 There has been great controversy regarding the impact of 
PPM on postoperative outcomes. Several studies reported 
that PPM is an independent predictor of cardiac events and 
early and late mortality after AVR [100-108], while others 
failed to demonstrate a significant impact on outcomes [97, 
109-113]. These apparently contradictory results may be 
explained by differences in baseline characteristics of patient 
populations included, valve substitutes used and compared, 
parameters for defining mismatch (indexed IGA vs indexed 
EOA) and different surgical approaches. Theses discrepan-
cies make it impossible to compare results or perform meta-
analysis.  
 Despite studies discrepancies, some consensus might be 
drawn from the existing evidence. First, severe PPM is a 
predictor of early and mid-term mortality irrespective of LV 
function [99-101, 108, 114], especially for patients under 70 
years and body mass index below 30, and should be always 
avoided [101]. In moderate PPM evidence is weak for pa-
tients with normal ejection fraction, but in the presence of 
LV dysfunction it is clear that moderate mismatch is associ-
ated with increased operative and late mortality [99, 101, 
103, 106]. This can be explained by the greater vulnerability 
of the failing heart to increased afterload, particularly in the 
immediate postoperative period.  
 When LVH regression after AVR is analyzed, some 
authors have found that persistent PPM results in less regres-
sion [48, 75, 107], but even patients with PPM or small pros-
thesis can have significant reduction in LVM, suggesting that 
PPM is not a determinant issue [115-117]. The extent of re-
gression varies from patient to patient in the presence of 
PPM, and is largely dependent on the extent of EOA increase 
after AVR [49]. Given the curvilinear relation of indexed 
EOA and TPG, the degree of regression seems to be depend-
ent on the original and final positions of an individual patient 
on the indexed EOA-gradient curve [98]. The extent of pre-
operative LVM is also important for regression in PPM. 
Fuster et al. have found that, in the group with higher LVM, 
only those with evidence of moderate or severe mismatch 
had impaired regression after AVR [107]. Moreover, PPM 
was not found as an independent predictor of mortality by 
itself, but was a promoter of the impact of LVM index in in-
hospital mortality. In the presence of mismatch, increased 
LVM was the strongest predictor of mortality [107]. 
 The possibility of avoiding PPM with the use of a pre-
ventive strategy at the time of surgery [96] makes it an im-
portant factor, particularly in younger patients (with higher 
basal metabolic rate and physically more active) [101, 105], 
in those with higher preoperative LVM and those with LV 
dysfunction.  
Cardiomyocyte and Extracellular Matrix Remodeling 
 The normal adult heart consists of highly differentiated 
parenchymal cells, cardiomyocytes, and stroma formed by 
the extracellular matrix (ECM), tissue fluid and undifferenti-
ated multipotent mesenchymal cells. About one third of the 
cellular compartment is made of cardiomyocytes, the rest 
being mainly fibroblasts. The major ECM proteins are type I 
and III collagen, but type IV and V collagen, elastin fibers, 
proteoglycans and integrins are also present. Fibrillar colla-
gen serves as a structural framework, connecting the contrac-
tile elements of adjacent cardiomyocytes to translate into 
ventricular pump function, and maintaining the alignment of 
the myofibrils within the myocytes through a collagen-
integrin-cytoskeletal myofibril relation.  
 In the end of the seventies and early eighties, many stu 
dies established a relationship between myocardial structure 
and left ventricular function in aortic stenosis [118-120]. 
Pressure overload results more frequently in concentric hy-
pertrophy, with an increase in relative wall thickness and 
mass, but with little or no change in chamber volume. In this 
pattern of remodeling myocyte hypertrophy (with addition of 
sarcomeres in parallel and lateral growth of individual car-
diomyocytes) and perivascular and intersticial fibrosis are 
the histological hallmark [58, 121]. The rate of regression of 
LV hypertrophy after AVR is different with regard to the 
muscular and nonmuscular compartments of the LV [58, 
120]. This behavior of the different structures of the myocar-
dium influences systolic and diastolic function differently. 
 In AS, myocardial stiffness is increased before surgery 
when compared with controls, increases even further early 
after AVR, but tends to normalize late after surgery [120, 
122]. It appears not to be influenced by left ventricular mus-
cle mass or muscle fiber size, but by the presence of massive 
left ventricular interstitial fibrosis [121]. Interestingly, in 
contrast to diastolic heart failure (DHF) patients, myofila-
ments stiffness from AS patients was not increased [123]. 
The In DHF high Fpassive was positively correlated both with 
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hypertrophy and concentric remodeling [124], being cor-
rected by in vitro administration of protein kinase A (PKA) 
acting directly on the phosphorylatable cytoskeletal protein 
titin [125]. This giant protein determines Fpassive through iso-
form shifts [126,127], phosphorylation status [125, 128] and 
via Ca
2+
 interaction [129].  
 Postoperative changes in myocardial structure are charac-
terized by an initial decrease in muscle fiber diameter and a 
relative increase in interstitial fibrosis, whereas total ven-
tricular fibrous content remains unchanged [58, 120]. This 
could explain why myocardial stiffness is increased early 
after AVR [120, 122]. In a later phase, LVM regression con-
tinues more slowly, with no further change in muscle fiber 
diameter but an additional reduction in percentual fibrosis 
[58], thus allowing for the normalization of myocardial stiff-
ness. Nevertheless the impact of fibrosis in myocardial stiff-
ness is dependent on LV geometry, being particularly impor-
tant in small ventricles with concentric hypertrophy [120]. 
 In the progression to HF, there is a significant correlation 
between myocyte degeneration and fibrosis, and both have 
shown an inverse relation with ejection fraction [130,131]. 
With worsening of fibrosis, LVEDP increases and, later on, 
EF decreases. This suggests a close association between 
structure and function in aortic stenosis [131]. However EF 
may not be the best parameter to evaluate systolic function in 
AS, since it is mainly related to global radial function, which 
is reduced only in end-stage disease [132]. Fibrotic changes 
in AS hypertrophic hearts are initially subendocardial and 
affect basal segments (where regional wall stress is highest). 
This will impact mainly longitudinal function, which is not 
well represented by ejection fraction [133]. In a recent study, 
in patients with severe symptomatic AS, radial function was 
relatively preserved, even in patients with severe fibrosis, 
while mitral ring displacement, a surrogate of overall longi-
tudinal function of the septum, was reduced in the presence 
of severe fibrosis. This finding is relevant once only parame-
ters of longitudinal systolic function predicted functional 
improvement [133]. 
 Fibrosis is an early morphological alteration in patients 
with AS and has been pointed as one of the reasons for im-
paired LVH regression after AVR [58]. It is a major deter-
minant of diastolic and systolic dysfunction and it is one of 
the structural substrates for arrhythmogenicity, thus playing 
a major role for sudden death and the progression of HF 
[122, 131]. While myocyte hypertrophy is dependent on 
load, fibrosis seems also to be regulated by non-hemodynamic 
factors such as neurohormones [134]. 
 Myocardial fibrosis is the result of both increased synthe-
sis of collagen types I and III and unchanged or decreased 
extracellular collagen degradation [135-137].  
 Involved in the regulation of collagen turnover is a highly 
complex enzymatic system of proteolysis and antiproteolysis 
of the extracellular matrix (ECM). Matrix metalloproteinases 
(MMPs), the major proteolytic system, and their tissue in-
hibitors (TIMPs) are determinant for cardiac remodeling, and 
their activity varies in different cardiac diseases. Besides 
inhibiting MMPs, TIMPs seem to have direct profibrotic 
activity, stimulating collagen production by cardiac fibro-
blasts [138].  
 In pathological conditions, fibroblasts assume a profi-
brotic phenotype with transformation into myofibroblasts 
[139,140]. Myofibroblasts stain positive for smooth muscle 
alfa actine and, with the exception of heart valve leaflets, are 
not found in normal cardiac tissue. They have the ability of 
autocrine and paracrine regulation, producing growth factors, 
cytokines, ECM proteins and proteases [139-141].  
 In LVH associated with aortic stenosis, there seems to be 
an increased production of collagen and a shift towards inhi-
bition of collagen degradation [136,137, 142]. When com-
pared with controls, myocardial biopsies of aortic stenosis 
patients have higher expression of collagens and transcripts 
of collagen synthesis [137]. When evaluating the levels of 
MMPs and their inhibitors (TIMPs), there is an upregulation 
of TIMP 1 and 2 mRNA, which significantly related to the 
degree of fibrosis, while MMP 1, 2 and 9 mRNA did not 
differ significantly. Also the ratio between TIMP1/MMP2, 
TIMP2/ MMP2 and TIMP2/MMP9 were significantly in-
creased in aortic stenosis patients, favoring inhibition of col-
lagen degradation [137].  
 In animal models of hypertension, the progression from 
compensated LVH to LV dysfunction is accompanied by a 
change in the balance between MMPs and their inhibitors, 
now favoring MMPs activity [143]. This appears also to be 
the case in pressure overload due to aortic stenosis, where 
several MMPs levels (including MMP1 and 9) are progres-
sively higher with decreasing EF, with insufficient increase 
in TIMP1 when compared to collagen type I and MMP1 in-
crease [144]. Thus, collagen turnover in aortic stenosis is a 
highly dynamic process and varies depending on the degree 
of hypertrophy and dysfunction progression. Changes in 
MMPs and TIMPs expression can serve as early markers of 
disease progression in pressure overloaded myocardium. 
Also in reverse remodeling, the ECM seems to play an im-
portant role. Such has been demonstrated in several studies 
that described collagen shift from stiff collagen type I, which 
transient increases in early phase of reverse remodeling, to 
the extensible types III and VIII a few days later [83]. Other 
experimental studies have described total regression of MMP 
and TIMP gene expression as well as an association between 
changes in LVMI and MMP/TIMP gene expression after 
corrective surgical therapy and LV hypertrophy regression 
[84]. 
 Several stimuli contribute to myocardial fibrosis, such as 
cytokines (TGF-1, TNF-, interleukin family), angiotensin 
II, aldosterone, endothelin-1 (ET-1) and catecholamines 
[141, 145]. The most important of these systems is the renin-
angiotensin-aldosterone (RAA). Mechanical stretch induces 
local production of angiotensin II, which in turn stimulates 
the release of multiple growth factors and cytokines from 
cardiac fibroblasts that act in an autocrine and paracrine 
fashion, affecting the progression of hypertrophy and remod-
eling [146-148]. Although the paracrine factors released by 
cardiac fibroblasts are required for induction of cardiomyo-
cyte hypertrophy, there is a crosstalk between both cell 
types, with cardiomyocytes being also crucial for fibroblasts 
regulation [149]. In an animal model of chimeric mice that 
expressed both AT1a receptor intact and null cells, after an-
giotensin II infusion, mice developed mild cardiac hypertro-
phy and fibrosis. Interestingly, most proliferating fibroblasts 
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were found around cardiomyocytes with intact AT1a gene, 
while fibroblasts adjacent to AT1a null cardiomyocytes 
showed a lesser degree of cell proliferation [149].  
 In isolated human cardiac fibroblasts, angiotensin II does 
not directly increase collagen or fibronectin expression 
[150], but it contributes to the phenotype switch into myofi-
broblasts, which is followed by the secretion of local media-
tors (TGF-1, ET-1; IL-6; osteopontin) that induce collagen 
and tissue metalloproteinases production [141,150,151]. The 
main mediator of angiotensin II effects on ECM synthesis is 
the transforming growth factor 1 (TGF-1) [150,152,153]. 
Angiotensin II upregulates TGF-1 levels in human AS with 
normal and impaired systolic function, and this increase is 
correlated with the upregulation of ACE mRNA [136]. In 
animal models, an early increase in TGF-1 mRNA precedes 
the increase in collagen and fibronectin mRNA, suggesting it 
mediates the profibrotic effect of angiotensin II [154,155]. 
 Other signaling pathways, such as NOS uncoupling and 
oxidative stress, have been linked to LV hypertrophy pro-
gression. An experimental study has recently demonstrated 
that tetrahydrobiopterin (BH4) levels, a nitric oxide synthase 
(NOS) cofactor, decline in pressure-overload remodeling in 
conjunction with NOS uncoupling [156]. Additionally, its 
supplementation was able to recouple eNOS and reverse 
advanced hypertrophy/dilation more effectively than a less 
specific antioxidant Tempol. These data highlight the impor-
tance of myocyte NOS uncoupling in hypertrophic heart  
disease and support BH4 as a potential new approach to treat 
this disorder [157]. 
 The understanding of the molecular mechanisms underly-
ing LVH and fibrosis is relevant because it opens avenues 
for future intervention in order to prevent/regress these 
events. In a sheep model of supracoronary aortic banding 
and debanding, after development of LVH, there was a sig-
nificant increase in ACE and AT1 receptor mRNA expres-
sion, with complete reversal of these changes after surgical 
treatment [158]. Also the inhibition of the angiotensin con-
verting enzyme (ACE) has been shown to prevent the deve 
lopment of LVH in rats [159,160] and to reduce its extent in 
humans with pressure-overload hypertrophy [161,162]. Lo-
cal inhibition of the cardiac renin-angiotensin system, 
achieved through the infusion of enalaprilat for 15 minutes 
into the left coronary arteries during coronary angiography, 
results in improvement in abnormal LV diastolic properties 
in patients with severe concentric pressure-overload hyper-
trophy due to AS. In contrast, in patients with nonischemic 
dilated cardiomyopathy, intracoronary enalaprilat does not 
affect LV relaxation, distensibility, or stiffness [163]. This is 
evidence of the importance of local RAA system for reverse 
remodeling in AS. 
 After AVR for aortic stenosis, additional medical therapy 
modulating the RAA system (ACE inhibitor or AT1 receptor 
antagonists) may be an attractive strategy to promote ven-
tricular reverse remodeling. 
CONCLUSION 
 Residual LVH late after AVR, as a marker of irreversible 
myocardial disease, is responsible for increased cardiovascu-
lar morbidity and mortality. Given the ominous significance 
of residual LVH after AVR, its regression is an important 
endpoint. Early surgery could ensure a more complete hyper-
trophy regression and, therefore, improve long term survival. 
An effort should be made to ensure the conduction of pro-
spective randomized clinical trials with medical treatment 
aimed to regression of LVH. It is time to look attentively at 
the ventricle. 
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ABBREVIATIONS 
AS = Aortic Stenosis 
AVR = Aortic Valve Replacement 
BSA = Body Surface Area 
DHF = Diastolic Heart Failure 
EOA = Effective Orifice Area 
ER = Estrogen Receptors 
ECM = Extracellular Matrix 
HRT = Hormone Replacement Therapy 
HT = Hypertension 
IGF-1 = Insulin-like Growth Factor 
IGA = Internal Geometric Area 
LV = Left Ventricle 
LVH = LV Hypertrophy 
LVM = LV Mass 
PPM = Patient-Prosthesis Mismatch 
RWT = Relative Wall Thickness 
TPG = Transvalvular Pressure Gradients 
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3. AIMS
Our aim was to achieve clinical, functional and molecular characterization of patients with isolated 
aortic stenosis before and after aortic valve replacement (AVR). In addition, we intended to better 
understand the prognostic importance of LV hypertrophy and determine its predictors.  
For that purpose we established the following objectives: 
1. Clinical characterization of patients with isolated aortic stenosis referred to AVR.
2. Evaluation of clinical outcomes after AVR.
3. Evaluation of echocardiographic parameters of left ventricular (LV) remodeling, before and after AVR.
4. Echocardiographic evaluation of systolic and diastolic function, before and after AVR.
5. Evaluation of left ventricular mass regression after AVR.
6. Evaluation of the changes induced by chronic cardiac pressure overload (aortic stenosis) in myo-
cardial expression of genes related to neurohormoral regulation and extracellular matrix (ECM) 
remodeling.
7. Histologic evaluation of myocardial fibrosis induced by aortic stenosis, and its correlation with 
LV function and prognosis.
8. Determination of plasma biomarkers of extracellular matrix remodeling.
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4. METHODS
Patient selection and follow-up
Between January 2006 and December 2009 we included 141 consecutive patients over 18 years 
old with severe symptomatic AS (aortic valve area <1 cm2 or mean transaortic gradient ≥40 mmHg) 
referred for AVR at the Cardiothoracic Surgery Department of Centro Hospitalar São João, Porto, 
Portugal. We excluded patients with aortic regurgitation >II/IV or other significant valve diseases 
(>mild), significant coronary artery disease (lesions >50% on coronary angiography) or previous car-
diac surgery. All patients were in sinus rhythm at the time of inclusion.  From the initial 141 patients 
included, 132 were considered for this prospective analysis: one was refused for surgery, other died 
before surgery from non-cardiovascular reason, and there was incomplete clinical data in seven of 
them. All patients had clinical follow-up up-to 98 months (8.2 years), and echocardiographic follow 
up was achieved in 123 (93.2%) patients. Mean follow-up was 6.0±1.5 years.
Clinical endpoints were defined as all cause of death or non-fatal cardiovascular hospitalization (heart 
failure, myocardial infarction, re-operation for prosthesis dysfunction, new-onset atrial fibrillation or 
advanced AV block requiring hospitalization) and by a composite endpoint of both events. 
The diagnosis of hypertension was defined by clinical records. Chronic Kidney disease (CKD) was 
determined when estimated glomerular filtration rate (GFR) <60 ml/min/1.73m2 by the Cockcroft-Gaul 
formula and perioperative acute renal lesion if there was an increase in serum creatinine >25% the 
preoperative value. Medical therapy was at the discretion of assistant physician.
This investigation conforms to the Declaration of Helsinki, had institutional ethical review board ap-
proval and each study participant signed an informed consent before enrolment. 
Surgical technique 
All surgeries were performed using standard procedure for AVR. The patients were placed on car-
diopulmonary bypass and cardiac arrest was induced and maintained with cold blood cardioplegia. 
The majority of patients received a bioprosthesis (73.3%). Two patients also had ascending aorta 
aneurism and underwent aortic root replacement with valved composite grafts (Bentall technique). 
At the time of surgery, 56 patients underwent myocardial biopsy from the LV interventricular septum. 
In 9 mitral stenosis patients undergoing mitral valve replacement, excised papillary muscles were 
collected and used as control myocardial biopsies. In both cases, excised myocardium was immedi-
ately snap-frozen in liquid nitrogen and stored at -80ºC.
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Echocardiographic studies
All patients had echocardiographic assessment one month before surgery and final echocardio-
graphic evaluation was performed 5.0±2.2 years after surgery in 123 patients. The reason for not 
having postoperative echocardiographic information was early death in 5 of them (2 perioperative 
deaths and 3 sudden deaths in the first 30 days after surgery) and refusal to come to our hospital to 
do a follow-up examination in 4 (3 were alive at the end of follow-up but one had died 4 months after 
surgery from non-cardiovascular cause). 
Echocardiographic examinations were performed by a trained cardiologist and recorded on digital 
support. All recordings were examined by an experienced echocardiographer in an accredited in-
dependent echocardiography laboratory (Hospital Clínico San Carlos in Madrid, Spain), blinded to 
patient details. Studies were performed using Phillips IE-33 equipment with a S5-1 transducer and 
M-mode, two dimensional, pulsed, continuous, color-flow and tissue Doppler capabilities. 
Correct orientation of imaging planes, cardiac chambers dimensions and function measurements 
were performed according to the European Association of Echocardiography (EAE)/American Society 
of Echocardiography (ASE) recommendations1.
LV mass (LVM) was estimated according to the joint recommendations of the ASE and EAE 1 using 
Devereux’s formula for ASE measurements in diastole: LV mass=0.8 x (1.04 x ([LV internal dimension 
+ posterior wall thickness + interventricular septal thickness]3 – [LV internal dimension]3) + 0.6 g . Left 
ventricular hypertrophy was defined by LV mass index greater than 115 g/m2 in men and greater than 
95 g/m2 in women.
Appropriateness of LVM was evaluated as the deviation from the value predicted individually from 
hemodynamic load, body size and sex, as previously described 2. LVM was predicted from stroke 
work, gender and body size (as height (m) to the 2.7 power) by the following equation 3:
Predicted LVM = 55.37 + (6.63 x height 2.7) + (0.64 x stroke work) - (18.1 x gender)
Stroke work was estimated from brachial systolic blood pressure (measured at the beginning of the 
echo exam) plus continuous wave (CW) Doppler transaortic peak gradient times stroke volume and 
converted to grammeters by multiplying by 0.0144. Gender was assigned the value of 1 for men 
and 2 for women. Using this equation, measured echocardiographic LVM could be expressed as the 
deviation (excess) from the predicted value (for convenience expressed as % of predicted, %LVMobs/
pred). An excess of LVM was considered present when the ratio between the observed and predicted 
value >100%.
Relative wall thickness (RWT) was calculated for the assessment of LV geometry using the formula 
2x posterior wall thickness/ LV diastolic diameter. Increased RWT was present when this ratio was 
greater than 0.42 1. Left atrial (LA) volume was measured in LV end systole in the frame preceding 
mitral valve opening. The volume was measured using the biplane area length method and corrected 
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for body surface area. Peak transvalvular gradient was estimated using the simplified Bernoulli equa-
tion. Aortic valve area (or effective orifice area, EOA) was estimated using quantitative Doppler by 
the continuity equation. The EOA values were then indexed to body surface area (EOAI). Patient pros-
thesis mismatch was considered present if EOAI ≤0.85 cm2/m2 and severe when EOAI≤ 0.65 cm2/m2 4.
Peak wall stress (WS) was estimated using a previously validated formula: 0.86 x (0.334 x SAP x EDD / 
[PWTd x (1 + PWTd / EDD)] - 2) x 103 dynes/cm2, where SAP=systolic arterial pressure, MaxG=maximal 
transvalvular pressure gradient, LVID=LV internal diameter, and PWTd=posterior wall thickness in 
diastole 5. 
As a measure of global LV load, we calculated the valvuloarterial impedance: Zva=(SAP+MG)/SVI, 
where SAP is the systolic arterial pressure, MG is the mean transvalvular pressure gradient and SVI 
is stroke volume index. Blood pressure was measured before echocardiography with patients in 
supine position, and a mean of 3 measurements was considered.
Mitral inflow was assessed in the apical 4-chamber view using pulsed wave Doppler with the sample 
volume placed at the tips of mitral leaflets during diastole. From the mitral inflow profile, the peak 
flow velocity of early filling (E wave), peak flow velocity of atrial contraction (A wave), the E/A ratio, 
and early filling deceleration time (DT) were measured. Doppler tissue imaging (DTI) of the mitral 
annulus was obtained from the apical 4-chamber using a sample volume placed in the septal mi-
tral valve annulus. Peak systolic annular velocity (Sm) and early diastolic septal velocity (e’) were 
determined, and the E/e’ ratio was derived. Patients with an E/e’septal >15 were considered to have 
increased filling pressure, whereas patients with E/e’septal <8 were considered to have normal fill-
ing pressure. In the remaining patients with an indeterminate E/e’, those with LAVI ≥34mL/m2 were 
considered to have increased filling pressure 6. The presence of increased filling pressures was con-
sidered indicative of diastolic dysfunction.
All indexed values were obtained by dividing by body surface area according to the method of 
Mosteler.
Histological determination of fibrosis
Light microscopic quantification of fibrosis has previously been described and validated. Fibrosis anal-
ysis of myocardial biopsies was performed using picrosirius-red–stained, 4-μm-thick-sections of tissue 
(± 5 sections of each sample). Images of these sections were acquired with a projection microscope 
(x50). Subsequent image analysis with Slidebook 4.0 software (3I, Denver, Colo) was performed to de-
termine the extent of reactive interstitial fibrosis, which was expressed as collagen volume fraction (%). 
Areas of reparative and perivascular fibrosis were excluded. Myocardial fibrosis was calculated as the 
sum of all connective tissue areas divided by the sum of connective tissue and muscle areas averaged 
over 4 to 6 representative fields of the section of 56 random AS patients (18 male and 38 female). In our 
laboratory, normal values of fibrosis for LV myocardial biopsy material are 5.4±2.2% 7. 
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mRNA quantification
For gene expression evaluation, RNA was extracted with TriPure (Roche) according to manufacture 
instructions. RT-PCR was performed with total RNA, followed by real time PCR analyses using the 
SYBR Green method, in a LightCycler 2.0 (Roche) as previously described (13). Results are normal-
ized for GAPDH and expressed in arbitrary unit. Specific PCR primer pairs for the studied genes were: 
hGAPDH – fw 5’- GGT GGT CTC CTC TGA CTT CAA CA -3’ and rev 5’- GTTGCTGTAGCCAAATTCGTTGT 
-3’; hMMP2 – fw 5’ – GGCGCGCTCACGGGT – 3’ and rev 5’ – TGTTCAGGTATTGCACTGCCAACT – 3’; 
hTIMP2 – fw 5’ – ATCTACACGGCCCCCTCCTCG – 3’ and rev 5’ – CCCCTCGGCCTTTCCTGCAATG – 3’; 
hCollagen type I – fw 5’- GAGCGGACGCTAACCCCCTC – 3’ and rev 5’ – TCCTCTTGGCCGTGCGTCAG – 
3’; hCollagen type III – fw 5’- CCCGTCGGCATTCCTGGAGC – 3’ and rev 5’ – GGCTCACCTGCACCACCTCG 
– 3’; hCTGF – fw 5’ – TGCCCGGGAAATGCTGCGAG – 3’ and rev 5’ – CAGTCGGTAAGCCGCGAGGG – 3’; 
hTGF-β1 – fw 5’ – GGCTTTCGCCTTAGCGCCCA – 3’ and rev 5’ – CGGCCGGTAGTGAACCCGTTG – 3’.
Serum determination of biomarkers of extracellular matrix remodeling 
Blood samples from forty AS patients were collected prior to AVR surgery in ethylenediamine-tetra-
acetic acid-containing tubes. The samples were centrifuged at 5000 rpm for 15 min at 4 ºC and plasma 
separated and frozen at -80 ºC until analysis. Endogenous plasma levels of connective tissue growth 
factor (CTGF, USCN), metalloproteinase-1 (MMP1, Amersham), MMP9 (Amersham), procollagen 
type I carboxy-terminal peptide (PIP, Takara), tumor growth factor-β (TGF-β, Biorbyt), tissue inhibitor 
of metalloproteinase-1 (TIMP1, Amersham) and TIMP2 (Amersham) were quantified using an ELISA 
Kits accordingly to manufacturer’s instructions. Each sample was analyzed in duplicate. Absorbance 
was recorded at 450nm using an ELISA plate reader (Perkin-Elmer, Wellesley, Massachusetts) and 
standard logarithmic curve was plotted and used to calculate PIP, MMP1, TIMP1 and TIMP2 concentra-
tion in the plasma samples.
Statistical analysis
Categorical variables were expressed as percentages and continuous variables as mean ± stan-
dard deviation or median and interquartile range, unless otherwise specified. Continuous variables 
were compared between groups using an unpaired t-test (for normally distributed variables) or the 
Mann–Whitney U-test (for non-normally distributed variables). For comparison between baseline 
and follow-up a paired Student’s t-test was applied (normally distributed variables). 
In the study of gender differences in hypertrophic response to aortic stenosis, continuous variables 
were expressed as mean (standard deviation), after logarithm transformation, as most of them proved 
to have non-normal distribution (Kolmogorov-Smirnov test). Continuous variables (after logarithm 
transformation in order to obtain normal distributed variables; mean and standard deviation were ob-
tained using the resulting statistics after inverting the transformation used) were compared between 
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groups using the independent t-test (non-adjusted) or the ANCOVA (for age adjusted comparison). 
For comparison between baseline and follow-up a paired sample t-test was used (non-adjusted) and 
repeated measures ANCOVA was applied (for age adjusted comparison). 
Chi-square test or the Fisher exact test (small samples), were used to compare proportions. In the 
chapter/study of gender differences in hypertrophic response to aortic stenosis, chi-square test 
was used to compare proportions and age adjusted proportion with a Z-test (adjustment by Direct 
Standardization, done with the following age groups: <50, 50-59, 60-69 and ≥70 years). 
Spearman’s rank correlation was used for the assessment of correlations between LVM index and 
clinical, echocardiographic and molecular continuous variables.
Cut-off points for several continuous variables were calculated using the point of highest sensitivity 
and specificity obtained under the receiver operating characteristic (ROC) curve for a particular out-
come. In these cases, the probability function used for the ROC curve was produced by the logistic 
regression model, using the continuous variables as independent variables. 
The stepwise binary logistic multivariate regression model (Wald backward stepwise method, p = 
0.05 for covariate inclusion and 0.2 for exclusion) was performed in several occasions: for LVM index 
regression analysis 1 year after AVR; for NYHA improvement regression analysis 6 months after AVR; 
for independent predictors of gender-specific residual LVH after surgery; and for predicting residual 
LVH and the outcome of all-cause death and cardiovascular hospitalization.
The models validity was evaluated through the determination coefficients of Cox and Snell, 
NagelKerke, and the Hosmer and Lemeshow test. Furthermore, it was assessed using the area under 
the ROC curve (AUC).
The Kaplan-Meier and Cox models were used to evaluate survival times after surgery for all-cause 
death, for non-fatal cardiovascular hospitalization, and for all-cause death and cardiovascular hospi-
talization, and the log-rank test was used to compare survival curves.
All reported probability values are two-tailed, and p<0.05 was considered statistically significant. 
Analyses were performed with the IBM® SPSS® Statistics software package versions 19.0, 20.0 and 
21.0 (along this thesis) (IBM Corporation, USA).
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5. RESULTS
5.1 Characterization of the total cohort
The study group included 132 patients with severe symptomatic AS referred for AVR, 58.3% women, 
with a mean age of 66.6±12.0 years.
At baseline, patients had a mean indexed effective orifice area (EOAI) of 0.42±0.12 cm2/m2 and 23.7% 
were in NYHA class III. Mean indexed left ventricular mass (LVMI) was 131.0±32.5 g/m2 and 80.6% of 
patients had sex-specific criteria for left ventricular hypertrophy (LVH) before surgery. Most patients 
had preserved ejection fraction (EF) with a mean value of 61.7±10.3%.
Detailed demographic, clinical and echocardiographic (before and after AVR) characterization can be 
found in tables 1 and 2.
A bioprosthesis was used in 73.3% of patients and the most used valve size was 21 mm (0.8% 17 mm, 
9.8% 19 mm, 0.8% 20 mm, 46.2% 21 mm, 28% 23 mm, 14.4% 25 mm). All mechanical valves were 
bileaflet. There were 2 perioperative deaths (one fatal stroke and one severe sepsis), and the me-
dian time of hospitalization was 6 days (P25-75: 6-8 days, minimum 4 days and maximum 76 days). 
Perioperative complications included atrial fibrillation (23.3%), acute renal lesion (18.3%), AV-block 
requiring permanent pacemaker implantation (6.9%), stroke (2.3%), re-operation for bleeding (1.5%), 
pneumonia (1.5%) and death (1.5%). 
Mean follow-up was 6.0±1.5 years and, on the top of perioperative deaths, fifteen (11.5%) additional 
patients died during this period.
Six years after AVR, 22.4% patients were in NYHA class II, and the remainder were in NYHA class I. 
There was a significant increase in EOAI and a decrease in transprosthetic gradients, wall stress and 
total hemodynamic load evaluated by valvuloarterial impedance (table 2). Patient-prosthesis mismatch 
was present in 62.3% of patients and it was severe in 10.8%. Left ventricular geometry was improved, 
with a significant decrease in LVMI and relative wall thickness (RWT). Nevertheless, 54 (43.9%) of pa-
tients still had left ventricular hypertrophy (LVH) at echocardiographic evaluation 5.0±2.2 years after 
surgery. There was a median absolute left ventricular mass (LVM) regression of 23.7 g/m2 (P25-75: 
44.8-2.6 g/m2), and relative mass regression of 18.5% (P25-75: 31.6-2.3%).
Parameters of LV systolic function showed a trend for an increase in EF and a significant enhance-
ment in longitudinal systolic function, evaluated by peak systolic annular velocity (Sm) (table 2). 
The number of patients with increased left ventricular filling pressures had no significant change after 
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surgery (71.6% before surgery vs 70.2% after AVR, p=0.788) and there was a worsening in parameters 
of diastolic function like left atrium volume index (LAVI) and E/e’ (table 2), despite an improvement in 
E/A ratio and e’ velocity.
Table 1. Clinical characterization of aortic stenosis patients.
Age (years) 66.6±12.0
BSA (m2) 1.8±0.2
Euroscore II 1.6±1.4
HT [n (%)] 74 (56.5%)
DM [n (%)] 27 (20.6%)
CKD [n (%)] 48 (36.4%)
GFR (ml/min) 68.9±18.5
NYHA≥3 [n (%)] 31 (23.7%)
LVH baseline [n (%)] 104 (80.6%)
Values are presented as mean±SD, unless otherwise indicated.
BSA= body surface area; HT= hypertension; DM= diabetes mellitus; CKD= chronic kidney disease; GFR= glomerular filtration rate (MDRD); NYHA= functional 
class of New York Heart Association; LVH= left ventricle hypertrophy.
Table 2. Baseline and follow-up echocardiographic characterization of aortic stenosis patients.
Baseline Final p*
LV geometry
Interventricular septum (cm) 1.46±0.25 1.33±0.2 <0.001
Posterior wall (cm) 1.09±0.18 0.99±0.16 <0.001
Relative wall thickness 0.47±0.1 0.43±0.08 <0.001
LV mass index (g/m2) 130.9±32.5 107.8±31.2 <0.001
LV end-diastolic volume index (ml/m2) 51.5±16.1 50.6±17.9 0.282
LV end-systolic volume index (ml/m2) 20.8±11.9 20.1±11.8 0.530
Aortic/Prosthesis stenosis severity
Maximal transaortic velocity (cm/s) 463.8±60.9 261.7±59.1 <0.001
Medium transaortic gradient (mmHg) 54.3±14.3 15.9±7.1 <0.001
Effective orifice area index (cm/m2) 0.42±0.12 0.86±0.24 <0.001
Increase in effective orifice area (%) 121.8±85.4
Hemodynamic load
Valvuloarterial impedance (mm Hg/ml/m²) 6.43 ±2.29 5.45±1.92 0.003
Peak LV wall stress (dynes/cm2) 226.2±78.6 175.6±44.5 <0.001
Diastolic function      
LA volume index (ml/m2) 35.4±12.9 38.7±10.1 <0.001
E/A 0.85±0.36 1.15±1.20 0.075
e’ (cm/s) 5.42 ±2.23 5.81±1.90 <0.001
E/e’ 15.8 ±6.4 16.4±6.7 <0.001
Systolic function  
Ejection fraction (%) 61.7±10.3 63.6±7.7 0.062
Peak systolic annular velocity (cm/s) 5.49±1.24 6.32±1.31 <0.001
Values are presented as mean±SD unless otherwise indicated. Bold values indicate statistical significance. * Wilcoxon test
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Analysis of clinical outcomes
At the end of 8.2 years of follow-up, the overall mortality was 12.9% (17 patients). The cause was 
cardiovascular in twelve (1 perioperative fatal stroke, 6 sudden deaths and 5 due to heart failure) and 
non-cardiovascular in five (1 perioperative sepsis, 3 from cancer and 1 with no information). There 
were 12 non-fatal cardiovascular hospitalizations (9.2%, after excluding perioperative deaths), 5 for 
heart failure, 3 re-operations for prosthesis dysfunction, 2 for symptomatic new-onset atrial fibrilla-
tion, and 2 for advanced AV block requiring pacemaker implantation. 
Patients who died were older, had higher operative risk, worse longitudinal systolic function (evalu-
ated by Sm) and higher levels of collagen volume fraction (CVF) in myocardial biopsies (table 3). In 
univariate analysis, age and baseline value of Sm were associated with an increased risk of death. In 
multivariate analysis, after adjustment for age, Euroscore II and baseline E/e’ and Sm, %LVMobs/pred 
was the only independent predictor of all-cause mortality (HR 1.020; 95%CI: 1.005-1.036 for each 1% 
increase), although age had marginal statistical significance (HR 3.023; 95%CI: 0.986-9.269) (table 4).
Table 3. Characterization of aortic stenosis patients according to death status.  
  Death
  No (n=115) Yes (n=17) p
Age 65.4±12.2 75.3±5.3 0.001*
Glomerular filtration rate (MDRD) 68.9±18.1 68.8±22.4 0.992
Euroscore II 1.60±1.46 2.14±1.43 0.039*
Relative wall thickness 0.51±0.10 0.54±0.12 0.221*
LA volume index (ml/m2) 35.7±13.1 38.1±11.3 0.245*
LV mass index (g/m2) 129.6±32.0 141.0±38.6 0.307*
LVMobs/pred (%) 149.3±46.3 171.3±54.7 0.131
Maximal aortic velocity (m/s) 4.59±0.59 4.64±0.54 0.812
Effective oriffice area index (cm2/m2) 0.41±0.11 0.41±0.12 0.991
Stroke volume index (ml/m2) 31.1±8.1 30.2±7.1 0.654
Valvuloarterial impedance  (mm Hg/ml/m²) 6.43±2.00 6.51±1.63 0.598*
Sm (cm/s) 5.54±1.23 4.24±0.72 0.009*
E/e’ 16.4±6.5 19.1±8.3 0.225*
LV end-diastolic volume index (ml/m2) 52.3±16.1 51.0±17.7 0.452*
LV end-systolic volume index (ml/m2) 21.2±11.5 21.5±16.1 0.847*
Ejection fraction (%) 61.3±10.4 60.1±11.5 0.468*
BNP (pg/ml) 392.0±498.6 774.9±1055.8 0.344*
Decrease in LVMI (g) 22.9±37.6 25.5±27.6 0.778*
Gender (female) 65 (66.5%) 12 (70.6%) 0.272
Hypertension 49 (42.6%) 8 (47.1%) 0.752
Diabetes 22 (19.1%) 5 (29.4%) 0.336
Chronic kidney disease 40 (34.8%) 8 (47.1%) 0.326
NYHA ≥ 3 27 (23.5%) 4 (23.5%) 0.989
Patient Prosthesis Mismatch 56 (48.7%) 5 (29.4%) 0.443
Collagen volume fraction (%) ** 15.4±11.8 27.1±20.7 0.035*
Values are presented as mean (±SD) unless otherwise indicated. Bold values indicate statistical significance. 
* Mann-Whitney test  ** Measured in 56 patients
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Table 4. Univariate and multivariate associations with all-cause death.
  Univariate analysis Multivariate Analysis 
  p Unadjusted HR (95% C.I.) p Adjusted HR (95% C.I.)
Sex (female) 0.319 1.700 (0.598-4.831)    
Age (10 y increment) 0.002 2.813 (1.482-5.34) 0.053 3.023 (0.986-9.269)
HT 0.830 0.901 (0.347-2.34)    
DM 0.262 1.818 (0.640-5.167)    
GFR (MDRD) 0.877 0.998 (0.971-1.026)    
Euroscore II 0.195 1.146 (0.932-1.410)    
NYHA ≥ 3 0.922 0.945 (0.308-2.901)    
LVMI 0.224 1.008 (0.995-1.022)    
LVMobs/pred (%) 0.131 1.008 (0.998-1.019) 0.009 1.020 (1.005-1.036)
EOAI 0.813 1.682 (0.023-123.273)    
SVI 0.567 0.981 (0.917-1.049)    
EF 0.630 0.988 (0.941-1.037)
Sm 0.017 2.456 (1.175-5.131)    
E/e’ 0.122 1.065 (0.983-1.154)    
Variables entered in Cox regression multivariate model: age, Euroscore II, LVMobs/pred (%), and baseline E/e’ and Sm
HT= hypertension; DM= diabetes mellitus; GFR= glomerular filtration rate (MDRD formula); NYHA= functional class of New York Heart Association; LVMI= left 
ventricular mass index; EOAI= effective orifice area index; SVI= stoke volume index; Sm= peak systolic annular velocity; EF= ejection fraction. 
Patients with a non-fatal cardiovascular hospitalization had more concentric geometry, evaluated 
by RWT and lower baseline BNP levels, but with great overlap of values between groups. These 
patients also tended to have lower stroke volume (SV) index (table 5). In multivariate Cox regression 
analysis, after adjustment for Euroscore II and baseline values of RWT, EOAI, EF, E/e’, SVI, Zva and 
BNP, %LVMobs/pred (HR 1.021, 95%CI: 1.003-1.039) was the only independent predictor of this event 
(table 6). 
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Table 5. Characteristics of aortic stenosis patients, according to the outcome of non-fatal 
cardiovascular hospitalization.
Non-fatal cardiovascular hospitalization
N=120 Y=12 p
Age 66.6±11.8 67.5±14.1 0.695
Glomerular filtration rate (MDRD) 68.6±18.1 71±23.1 0.633
Euroscore II 1.53±1.06 2.78±3.25 0.142
Relative wall thickness 0.48±0.10 0.41±0.07 0.024
LA volume index (ml/m2) 35.8±13.2 36.7±11.2 0.714
LV mass index (g/m2) 130.6±32.5 135.7±39.3 0.752
LVMobs/pred (%) 148.6±45.0 176.4±60.9 0.114
Maximal aortic velocity (m/s) 459.7±58.1 460.2±66.2 0.890
Effective oriffice area index (cm2/m2) 0.41±0.12 0.47±0.12 0.069
Stroke volume index (ml/m2) 31.4±7.7 26.9±9.1 0.053
Valvuloarterial impedance  (mm Hg/ml/m²) 6.32±1.83 7.41±2.84 0.200
Sm (cm/s) 5.43±1.18 5.04±1.50 0.215
E/e’ 16.4±6.0 19.2±10.6 0.518
LV end-diastolic volume index (ml/m2) 52.3±15.6 50.2±20.3 0.557
LV end-systolic volume index (ml/m2) 21.0±11.4 23.3±16.5 0.834
Ejection fraction (%) 61.6±10.0 56.8±13.6 0.334
BNP (pg/ml) 461.9±595.8 141.1±126.6 0.039
Decrease in LVMI (g) 23±37.1 24.7±33.8 0.919
Gender (female) 70 (58.3%) 7 (58.3%) ≈1.000
Hypertension 66 (55.5%) 8 (66.7%) 0.456
Diabetes 23 (19.3%) 4 (33.3%) 0.268
Chronic kidney disease 43 (35.8%) 5 (41.7%) 0.757
NYHA ≥ 3 27 (22.7%) 4 (33.3%) 0.477
Patient Prosthesis Mismatch 56 (52.8%) 5 (45.5%) 0.641
Collagen volume fraction (%) ** 16.3±13.2 24.8±17.7 0.227
  
Values are presented as mean±SD unless otherwise indicated. Bold values indicate statistical significance. 
* Mann-Whitney test; ** Measured in 56 patients
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Table 6. Univariate and multivariate associations with non-fatal cardiovascular hospitalization.
Univariate analysis Multivariate Analysis **
P Unadjusted HR (95% C.I.) p Adjusted HR (95% C.I.)
Sex (female) 0.944 0.96 (0.304-3.03)
Age (10 y increment) 0.543 1.174 (0.705-1.953)
HT 0.430 1.622 (0.488-5.387)
DM 0.211 2.152 (0.647-7.152)
GFR (MDRD) 0.919 1.002 (0.971-1.033)
Euroscore II 0.009 1.264 (1.061-1.505)
NYHA ≥ 3 0.482 1.538 (0.463-5.112)
RWT (1 unit decrease) 0.036 500 (1.506-250000)
LVMI 0.688 1.003 (0.987-1.02)
LVMobs/pred (%) 0.070 1.01 (0.999-1.021) 0.020 1.021 (1.003-1.039)
EOAI 0.049 52.927 (1.022-2741.138)
SVI 0.077 0.935 (0.867-1.007)
ZVA 0.138 1.17 (0.951-1.44)
EF 0.140 0.968 (0.928-1.011)
Sm (1 unit decrease) 0.279 1.289 (0.814-2.045)
E/e’ 0.110 1.064 (0.986-1.149)
BNP (1 pg/ml increase) 0.125 0.996 (0.991-1.001) 0.054 0.991 (0.983-1.000)
Variables entered in Cox regression  multivariate model: Euroscore II, RWT, LVMobs/pred, EOAI, EF, E/e’, SVI, ZVA, BNP 
HT= hypertension; DM= diabetes mellitus; GFR= glomerular filtration rate (MDRD formula); NYHA= functional class of New York Heart Association; RWT= 
relative wall thickness; LVMI= left ventricular mass index; EOAI= effective orifice area index; SVI= stoke volume index; Sm= peak systolic annular velocity; EF= 
ejection fraction. 
The combined outcome all-cause death or non-fatal cardiovascular hospitalization was more fre-
quent in those who were older, had higher Euroscore II, an excessive increase in LVM in response 
to AS (%LVMobs/pred), worse longitudinal systolic function (evaluated by Sm), residual LVH and 
higher levels of collagen volume fraction (CVF) (table 7). In multivariate analysis, after adjustment 
for age, DM, Euroscore II, and baseline EOAI, SVI, EF, E/e’ and Sm, %LVMobs/pred (HR 1.008, 95%CI: 
1.001-1.016) and E/e’ (HR 1.057, 95%CI: 1.001-1.116) were independent predictors of all-cause death or 
non-fatal cardiovascular hospitalization (table 8). Diabetes also increased the risk of combined events 
but had a borderline significance and wide confidence intervals. 
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Table 7. Characterization of aortic stenosis patients according to the outcome of all-cause death or 
non-fatal cardiovascular hospitalization.
  All-cause death and non-fatal cardiovascular hospitalization  
  No (n=104) Yes (n=28) P
Age 65.3±12.1 71.6±10.3 0.006
Glomerular filtration rate (MDRD) 68.3±17.7 71.0±21.9 0.520
EuroSCORE II 1.53±1.00 2.30±2.31 0.017*
Relative wall thickness 0.51±0.13 0.52±0.10 0.562
LA volume index (ml/m2) 35.7±13.4 36.6±10.8 0.428* 
LV mass index (g/m2) 128.9±31.1 138.9±39.0 0.157
LVMobs/pred (%) 146.3±43.4 171.7±56.9 0.022
Maximal aortic velocity (m/s) 4.59±0.59 4.64±0.60 0.857* 
Effective oriffice area index (cm2/m2) 0.42±0.10 0.44±0.12 0.233
Stroke volume index (ml/m2) 31.5±7.8 28.7±8.2 0.124
Valvuloarterial impedance (mm Hg/ml/m²) 6.30±1.81 6.91 ±2.30 0.278* 
Sm (cm/s) 5.53±1.20 4.81±1.44 0.021
E/e’ 16.1±5.7 18.9±9.3 0.259*
LV end-diastolic volume index (ml/m2) 52.4±15.4 51.1±18.8 0.430*
LV end-systolic volume index (ml/m2) 20.8±10.7 22.7±16.2 0.859*
Ejection fraction (%) 61.8±9.8 58.4±12.6 0.226*
BNP (pg/ml) 425.4±520.3 436.9±770 0.368*
Decrease LVMI (g) 22.7±38.0 25.0±30.8 0.938*
Gender (female) 59 (56.7%) 18 (64.3%) 0.472
Hypertension 58 (55.8%) 16 (%57.1) 0.937
Diabetes 18(17.3%) 9 (32.1%) 0.089
Chronic kidney disease 36 (34.6%) 12(42.9%) 0.326
NYHA ≥ 3 24 (23.1%) 7 (25.0%) 0.421
PPM 51 (49.0%) 10 (41.7%) 0.486
Collagen volume fraction (%) ** 15.3±12.0 24.0±18.2 0.038*
Values are presented as mean±SD unless otherwise indicated. Bold values indicate statistical significance. 
* Mann-Whitney test   ** Measured in 56 patients
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Table 8. Univariate and multivariate associations with all-cause death or non-fatal cardiovascular 
hospitalization.
  Univariate analysis Multivariate Analysis
  p Unadjusted HR (95% C.I.) p Adjusted HR (95% C.I.)
Sex (female) 0.576 1.247 (0.575-2.705)    
Age (10 y increment) 0.010 1.704 (1.137-2.551)    
HT 0.859 1.07 (0.506-2.265)    
DM 0.077 2.046 (0.925-4.524) 0.056 2.320 (0.978-5.501)
GFR (MDRD) 0.841 1.002 (0.981-1.024)    
Euroscore II 0.013 1.193 (1.038-1.371)    
NYHA ≥ 3 0.996 1.002 (0.426-2.359)    
LVMI 0.245 1.006 (0.996-1.017)    
LVMobs/pred (%) 0.046 1.008 (1-1.016) 0.033 1.008 (1.001-1.016)
EOAI 0.146 9.166 (0.462-181.68)
SVI 0.158 0.964 (0.916-1.014)    
EF 0.164 0.977 (0.946-1.009)    
Sm (1 unit decrease) 0.030 1.562 (1.044-2.337)    
E/e’ 0.045 1.061 (1.001-1.123) 0.046 1.057 (1.001-1.116)
Variables entered in Cox regression multivariate model: age, DM, Euroscore II, LVMobs/pred (%), and baseline EOAI, SVI, EF, E/e’ and Sm
HT= hypertension; DM= diabetes mellitus; GFR= glomerular filtration rate (MDRD formula); NYHA= functional class of New York Heart Association; LVMI= left 
ventricular mass index; EOAI= effective orifice area index; SVI= stoke volume index; Sm= peak systolic annular velocity; EF= ejection fraction. 
Kaplan-Meier Survival Analysis 
For event-free survival analysis the cutoff of 178% of %LVMobs/pred, correspondent to the 75th per-
centil in this cohort, was chosen after ROC curve analysis (AUC=0.63, 95%CI:0.49-0.77 for the com-
bined event; AUC=0.76, 95%CI:0.66-0.85 for residual LVH). Those with %LVMobs/pred ≥178% were 
considered to have inappropriate LVM.
Patients with %LVMobs/pred ≥178% had worse survival after 8 years of follow-up, comparing with 
those with <178% (72.7% vs 90.8%, p=0.028) (Fig.1). 
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For the endpoint of non-fatal cardiovascular hospitalization, prognosis was also worse for those with 
higher excess in LVM (60.7% for %LVMobs/pred ≥178% vs 93.6% for %LVMobs/pred <178%, p=0.004) 
(Fig.2). 
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Fig. 1 Relationship between 
inappropriate LVM 
(%LVMobs/LVMpred ≥178%) 
and long-term survival after 
aortic valve replacement.
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Event-free survival analysis for the combined endpoint of all-cause mortality or non-fatal cardio-
vascular hospitalization also shows that patients with %LVMobs/pred ≥178% had a worse outcome 
after 8 years of follow-up, when comparing with those with a minor excess in LVM (46.2% vs 84.8%, 
p=0.001) (Fig.3). 
Characterization of patients with inappropriate LVM
In our cohort, inappropriate LVM was present in 25.2% patients. These patients tended to be older 
(table 9) and more frequently women (30.6% vs 17.8%, p=0.18), hypertensive (31.1% vs 17.7%, p=0.18) 
and diabetic (40% vs 22.1%, p=0.15). Moreover, they had more concentric geometry (evaluated by 
LVMI/LVEDVI), worse systolic function (lower EF and Sm) and lower values of e’, indicating more 
impaired LV relaxation (table 9). 
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Table 9. Characterization of aortic stenosis patients according to the existence of inappropriate LVM.
  AS patients  
  Appropriate LVM Inappropriate LVM p
Age 65.6±12.5 71.0±12.2 0.09
LV end-diastolic volume index (ml/m2) 88.5±23.8 93.0±39.9 0.89*
LV end-systolic volume index (ml/m2) 32.3±12.0 48.9±34.4 0.17*
LV mass index (g/m2) 119.7±26.7 161.9±31.0 <0.001*
LVMI/LVEDVI 2.40±0.68 3.31±0.91 <0.001
Relative wall thickness 0.48±0.10 0.45±0.12 0.42
Peak wall stress (dynes/cm2) 214.1±53.5 213.1±57.8 0.46
LA volume index (ml/m2) 36.2±14.2 37.8±10.1 0.30* 
Maximal aortic velocity (m/s) 4.55±0.56 4.66±0.68 0.34* 
Sm (cm/s) 5.6±1.1 4.4±1.0 <0.001
E/e’ 16.2±6.8 18.8±7.3  0.15*
Ejection fraction (%) 62.3±7.0 52.0±13.7 <0.001*
LVMI= left ventricular mass index; LVEDVI= left ventricular en-diastolic index. Values are presented as mean (±SD) unless otherwise indicated. 
Bold values indicate statistical significance. * Mann-Whitney test  
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5.2 Gender differences in hypertrophic response to aortic stenosis 
Cristina Gavina 1, Inês Falcão-Pires 2, João Rodrigues 3, Benjamim Marinho 4, Jorge Almeida 4, Paulo 
Pinho 4, Alexandra Gonçalves1, Francisco Rocha-Gonçalves 1, Adelino Leite-Moreira 2,4
1 Department of Medicine, Faculty of Medicine, University of Porto, 2 Department of Physiology and Cardiothoracic Surgery, 
Faculty of Medicine, University of Porto, 3 Department of Cardiology, Centro Hospitalar São João, Porto, 4 Department of 
Cardiothoracic Surgery, Centro Hospitalar São João, Porto 
Abstract
Objectives: We aimed to evaluate gender differences in left ventricular (LV) remodeling, myocardial 
fibrosis and biomarkers of extracellular matrix (ECM) turnover in severe aortic stenosis (AS). 
Background: Hypertrophic response to pressure overload is gender-specific. Women develop a more 
concentric geometry with supra-normal function while men more often have ventricular dilatation and 
earlier systolic dysfunction.
Methods: A prospective cohort of 132 severe AS patients, 77 females (58.3%), was evaluated at 
baseline and 6 months after surgical aortic valve replacement (AVR). Predicted LV mass (LVM) was 
calculated (according to gender, height and stroke work) and %observed/predictedLVM was derived. 
Quantification of fibrosis was performed by picrosirius-red staining of 56 myocardial biopsies. In 40 
patients baseline ECM serum biomarkers procollagen type I carboxy-terminal peptide (PIP), metal-
loproteinase (MMP) 1 and 9, and tissue inhibitor of MMP (TIMP) 1 and 2 were measured. 
Results: Women had similar indexed LV mass but, when comparing the observed with predicted 
LVM, they had a more excessive increase than men (%observed/predictedLVM: 166.45±54.28% vs 
137.44±36.40%, age-adjusted p=0.016). Six months after AVR, LVM regression was similar between 
genders but women more often had residual hypertrophy (68.8% vs 39.6%, p=0.002). In multivari-
ate analysis, female gender [OR:4.83(1.58-14.77)], hypertension [OR:3.39(1.23-9.36)] and baseline 
LVM [OR:1.04(1.02-1.06) per 1 g/m2 increase] were independent predictors of residual hypertro-
phy. Histologically, women had more interstitial fibrosis than men (18.98±15.20% vs 12.41±7.61%, 
p=0.036). In women, but not in men, TIMP1/MMP1 levels positively correlated with LVM (rs=0.681, 
p=0.003) and higher TIMP2 and TIMP1/MMP1 levels correlated with lesser 6 month LVM regression 
(TIMP2:rs=-0.650, p=0.022; TIMP1/MMP1:rs=-0.748, p=0.005).
Conclusions: In severe AS, women have a higher than predicted LVM increase compared to men, 
and female gender was an independent predictor of residual hypertrophy. A gender-specific ECM 
remodeling, might contribute to explain these differences.
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Introduction:
Hypertrophy in aortic stenosis (AS) is multifactorial and the degree of LVH varies under identical 
loading conditions (1,2). In a reference population of normotensive and normal weight individuals, 
the combination of stroke work, gender and body height could explain up to 82% of the variability 
in left ventricular mass (LVM) (3). Additionaly, a regression equation was derived for predicting LVM 
and evaluate the adequacy of left ventricular (LV) hypertrophic response to different load conditions 
(4). In hypertension and, more recently in AS, the comparison of the observed LVM with that pre-
dicted according to gender, height and load, has helped to identify those with a more “inappropriate” 
hypertrophy and worse prognosis (5,6). Moreover, cardiac hypertrophy in AS is accompanied by an 
increase in interstitial fibrosis and higher levels of fibrosis have been associated with the presence of 
irreversible remodeling and all-cause mortality (7). 
In AS, many studies have reported different remodeling responses between men and women, with 
similar left ventricular mass (LVM) index but higher prevalence of left ventricular hypertrophy (LVH) 
in women, according to sex specific criteria (8-11). Women have smaller LV chamber size, higher 
relative wall thickness, higher LVM/volume ratio, supernormal LV function and less wall stress, while 
men exhibit ventricular dilatation and earlier ventricular dysfunction (8,10,12,13). At histological 
level, some authors have described a higher gene expression of collagen I and III in males (14), and 
it has been suggested that estrogens could have a protective role in the fibrotic response to pressure 
overload (15).
Our aim was to evaluate gender differences in LV remodeling,  before and after aortic valve replace-
ment (AVR), in patients with isolated severe aortic stenosis (AS).
Methods: 
Patient selection and follow-up
Between January 2006 and December 2009 we included 141 consecutive patients over 18 years old 
with severe symptomatic AS (aortic valve area <1 cm2 or mean transaortic gradient ≥40 mmHg), 
evaluated preoperatively by the same Cardiologist (CG) for aortic valve replacement (AVR) at the 
Cardiothoracic Surgery Department of Centro Hospitalar São João, Porto, Portugal. We excluded 
patients with aortic regurgitation >II/IV or other significant valve diseases (>mild), and significant 
coronary artery disease (lesions >50% on coronary angiography). All patients were in sinus rhythm at 
the time of inclusion. From the initial 141 patients, 132 were considered for this prospective analysis: 
one was refused for surgery, other died before surgery from non-cardiovascular reason (cholangitis 
with sepsis), and there was incomplete clinical data in seven of them. There were 2 perioperative 
deaths and one additional cardiovascular death at six months. At six months, clinical and echocar-
diographic follow up was achieved in 117 (88.6%) patients. 
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The diagnosis of hypertension was performed by the clinical records of the assistant physician. Renal 
insufficiency was determined when creatinine clearance <60 ml/kg by the Cockcroft-Gaul formula. 
The study was approved by local institutional review committee and all patients gave their informed 
consent.
Surgical technique 
All surgeries were performed using standard procedure for AVR. The patients were placed on car-
diopulmonary bypass and cardiac arrest was induced and maintained with cold blood cardioplegia. 
The majority of patients received a bioprosthesis (73.3%). Two patients also had ascending aorta an-
eurysm and underwent aortic root replacement with valved composite grafts (Bentall technique). At 
the time of surgery, 56 patients underwent myocardial biopsies from the LV interventricular septum.
Echocardiographic studies
Echocardiographic examination was performed by a trained cardiologist and recorded on digital sup-
port. All recordings were examined by an experienced echocardiographer in an accredited indepen-
dent echocardiography laboratory (Hospital Clínico San Carlos in Madrid, Spain) blinded to patient 
details. Studies were performed using Phillips IE-33 equipment with a S5-1 transducer and M-mode, 
two dimensional, pulsed, continuous, color-flow and tissue Doppler capabilities. Correct orientation 
of imaging planes, cardiac chambers dimension and function measurements were performed accord-
ing to the European Association of Echocardiography (EAE)/American Society of Echocardiography 
(ASE) recommendations (16).
LV mass was estimated according to the joint recommendations of the ASE and EAE using Devereux’s 
formula for ASE measurements in diastole(16): LV mass=0.8 x (1.04 x ([LV internal dimension + pos-
terior wall thickness + interventricular septal thickness]3 – [LV internal dimension]3) + 0.6 g. Left ven-
tricular hypertrophy was defined by LV mass index greater than 115 g/m2 in men and greater than 
95 g/m2 in women. Appropriateness of LVM was assessed using the ratio between the observed and 
predicted value and an excess in LVM was considered present when > 100%. LVM was predicted from 
stroke work, gender and body size (as height (m) to the 2.7 power) by the following equation (5):
Predicted LVM = 55.37 + (6.63 x height 2.7) + (0.64 x stroke work) - (18.1 x gender)
Stroke work was estimated from brachial systolic blood pressure (measured at the beginning of the echo 
exam) plus continuous wave (CW) Doppler transaortic peak gradient times stroke volume and converted 
to grammeters by multiplying by 0.0144. Gender was assigned the value of 1 for men and 2 for women. 
Relative wall thickness (RWT) was calculated for the assessment of LV geometry using the formula 
2x posterior wall thickness/ LV diastolic diameter. Increased RWT was present when this ratio was 
greater than 0.42 (16). LA volume was measured in LV end systole in the frame preceding mitral valve 
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opening. The volume was measured using the biplane area length method and corrected for body 
surface area. Aortic valve area was estimated using quantitative Doppler by continuity equation.
Peak wall stress (WS) was estimated using a previously validated formula: 0.86 x (0.334 x SAP 
x EDD / [PWTd x (1 + (PWTd / EDD)] - 2)  x 103 dynes/cm2, where SAP=systolic arterial pressure, 
MaxG=maximal transvalvular pressure gradient, LVID=LV internal diameter, and PWTd=posterior 
wall thickness in diastole (17). As a measure of global LV load, we calculated the valvuloarterial 
impedance: Zva=(SAP+MG)/SVI, where SAP is the systolic arterial pressure and MG is the mean 
transvalvular pressure gradient and SVI is stroke volume index (18). 
Histological determination of fibrosis
Light microscopic quantification of fibrosis has previously been described and validated(19). Fibrosis 
analysis of myocardial biopsies was performed using picrosirius-red–stained, 4-μm-thick-sections of 
tissue (± 5 sections of each sample). Images of these sections were acquired with a projection micro-
scope (x50). Subsequent image analysis with Slidebook 4.0 software (3I, Denver, Colo) was performed 
to determine the extent of reactive interstitial fibrosis, which was expressed as collagen volume fraction 
(%). Areas of reparative and perivascular fibrosis were excluded. Myocardial fibrosis was calculated as 
the sum of all connective tissue areas divided by the sum of connective tissue and muscle areas aver-
aged over 4 to 6 representative fields of the section in 56 random AS patients (18 male and 38 female). 
In our laboratory, normal values of fibrosis for LV myocardial biopsy material are 5.4±2.2%.
Serum determination of biomarkers of extracellular matrix remodeling 
Blood samples from forty AS patients were collected prior to aortic valve replacement surgery in 
ethylenediamine-tetra-acetic acid-containing tubes. The samples were centrifuged at 5000 rpm for 
15 min at 4 ºC and plasma separated and frozen at -80 ºC until analysis. Endogenous plasma levels 
of connective tissue growth factor (CTGF, USCN), metalloproteinase-1 (MMP1, Amersham), MMP9 
(Amersham), procollagen type I carboxy-terminal peptide (PIP, Takara), tumor growth factor-β (TGF-β, 
Biorbyt), tissue inhibitor of metalloproteinase-1 (TIMP1, Amersham) and TIMP2 (Amersham) were 
quantified using an ELISA Kits accordingly to manufacturer’s instructions. Each sample was ana-
lyzed in duplicate. Absorbance was recorded at 450nm using an ELISA plate reader (Perkin-Elmer, 
Wellesley, Massachusetts) and standard logarithmic curve was plotted and used to calculate PIP, 
MMP1, TIMP1 and TIMP2 concentration in the plasma samples.
Statistical analysis
Categorical variables were expressed as percentages. Continuous variables were expressed as mean 
(standard deviation), after logarithm transformation as most of them proved to have non-normal 
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distribution (Kolmogorov-Smirnov test). Continuous variables (after logarithm transformation in or-
der to obtain normal distributed variables; mean and standard deviation were obtained after inverting 
the transformation used) were compared between groups using the unpaired t-test (non-adjusted) 
or the ANCOVA (for age adjusted comparison). For comparison between baseline and follow-up a 
paired sample t-test was used (non-adjusted) and a repeated measures ANCOVA was applied (for age 
adjusted comparison). Chi-square test was used to compare proportions and age adjusted propor-
tion with a Z-test (adjustment by Direct Standardization, done with the following age groups: <50, 50-
59, 60-69 and ≥70). Spearman’s rank correlation was used for the assessment of correlations between 
LVM index and its variation and clinical, echocardiographic and biomarker continuous variables. A 
multivariate logistic regression model (Wald backward stepwise method, p=0.05 for covariate inclu-
sion and p=0.10 for exclusion) was built to detect independent predictors of gender-specific residual 
LVH after surgery. Variables that in univariate analysis showed to be associated with residual LVH 
(p<0.05) entered the multivariable model, and renal disease (CKD) was also included although it did 
not showed significantly association with the LVH outcome. For better clinical interpretation patterns, 
a second multivariable model was obtained, where the baseline LVM was categorized in tercils ac-
cording to gender and, furthermore, the %observed/predicted LVM was dichotomized (≤142% and 
>142%) using cutoff value that produces the maximum sensitivity and specificity in relation with 
residual LVH outcome. All reported probability values are two-tailed, and P< 0.05 was considered 
statistically significant. Analyses were performed with the SPSS statistical software package (version 
19.0) (SPSS Inc, Chicago, IL, USA).
Results
The study group included 132 patients with severe symptomatic AS, 58.33% women, with a mean 
age of 66.5±11.8 years. 
Demographic, clinical and echocardiographic characteristics according to sex are displayed at tables 
1 and 2. Women were older and had smaller body surface area (BSA) but similar body mass index. 
Chronic kidney disease (CKD) was also significantly more frequent in women, but this difference 
disappeared after adjustment for age. Their operative risk, estimated by Euroscore II, was also higher, 
reflecting older age and worse creatinine clearance. When analyzing the age-adjusted preoperative 
echocardiographic data, maximal aortic velocity and mean aortic gradient were similar, but indexed 
aortic valve area tended to be smaller in women. Total hemodynamic load, evaluated by valvuloarte-
rial impedance (Zva), was higher in women, but peak wall stress showed no differences between 
genders.
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Table 1: Clinical characterization of aortic stenosis patients according to gender. 
    Female (n=77) Male (n=55) p Age-adjusted p
Age Mean (st. dev) 69.1 (11.3) 63.2 (12.2) 0.005
BMI Mean (st. dev) 28.7 (4.6) 27.7 (3.9) 0.183 0.204
BSA Mean (st. dev) 1.67 (0.15) 1.87 (0.16) <0.001 <0.001
Euroscore II Mean (st. dev) 2.02 (1.69) 1.11 (0.64) <0.001 0.003
HT n (%) 48 (62.3%) 26 (48.1%) 0.107
Age adjusted % 36.5% 36.9% 0.518
DM n (%) 16 (20.8%) 11 (20.4%) 0.955
Age adjusted % 41.1% 34.8% 0.233
CKD n (%) 36 (46.8%) 12 (21.8%) 0.003
Age adjusted % 42.3% 33.8% 0.164
GFR (ml/min) Mean (st. dev) 64.5 (19.9) 75.3 (14.3) 0.001 0.005
NYHA ≥3 n (%) 20 (26.0%) 11 (20.4%) 0.458
Age adjusted % 41.0% 35.9% 0.279
LVH n (%) 65 (85.5%) 39 (73.6%) 0.091
Age adjusted % 36.8% 28.5% 0.164
LV mass (g) Mean (st. dev) 216.7 (62.0) 248.9 (58.6) 0.003 0.005
LV mass index (g/m2) Mean (st. dev) 129.8 (35.1) 132.8 (30.0) 0.618 0.557
BSA= body surface area; BMI= body mass index; HT= hypertension; DM= diabetes mellitus; CKD= chronic kidney disease; GFR= glomerular filtration rate (MDRD 
formula); NYHA= functional class of New York Heart Association; LVH= left ventricle hypertrophy. Results are presented as mean (standard deviation) unless 
otherwise noted.
When comparing age-adjusted ratio of observed LVM with the predicted LVM according to load, 
gender and height, women had a significantly higher excessive LVM increase than men (%observed/
predicted LVM: 166.45±54.28% vs 137.44±36.40%, age-adjusted p=0.016, fig.1). There was a trend for 
a more concentric geometry in women, with a numerically higher relative wall thickness.
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Fig 1. Comparison by 
gender of the ratio of 
observed and predicted left 
ventricular mass (LVM) in 
aortic stenosis before valve 
replacement. 
56
DETERMINANTS OF LEFT VENTRICULAR HYPERTROPHY BEFORE AND AFTER SURGICAL TREATMENT OF AORTIC STENOSIS
Ta
bl
e 
2:
 B
as
el
in
e 
an
d 
si
x 
m
on
th
s e
ch
oc
ar
di
og
ra
ph
ic
 c
ha
ra
ct
er
iz
at
io
n 
of
 a
or
tic
 st
en
os
is
 p
at
ie
nt
s a
cc
or
di
ng
 to
 g
en
de
r, 
ag
e 
ad
ju
st
ed
 c
om
pa
ris
on
s.
 
Fe
m
al
e
Ag
e 
ad
ju
st
ed
 p
 
M
al
e
Ag
e 
ad
ju
st
ed
 p
 
Ag
e 
ad
ju
st
ed
 p
 
(b
as
el
in
e F
-M
)
Ag
e 
ad
ju
st
ed
 p
 
(6
 m
on
th
s F
-M
)
 
Ba
se
lin
e
6 
m
on
th
s
Ba
se
lin
e
6 
m
on
th
s
LV
 g
eo
m
et
ry
LV
 e
n
d
-d
ia
st
o
lic
 d
ia
m
et
er
 (
cm
) 
4.
53
 (
0.
64
)
4.
32
 (
0.
48
)
0.
74
8
4.
91
 (
0.
64
)
4.
72
 (
0.
51
)
0.
13
2
0.
00
7
<0
.0
01
LV
 e
n
d
-s
ys
to
lic
 d
ia
m
et
er
 (
cm
) 
4.
53
 (
0.
64
)
4.
32
 (
0.
48
)
0.
45
2
4.
91
 (
0.
64
)
4.
72
 (
0.
51
)
0.
15
2
0.
42
3
0.
50
1
LV
 e
n
d
-d
ia
st
o
lic
 d
ia
m
et
er
 in
d
ex
2.
75
 (
0.
4)
2.
62
 (
0.
31
)
0.
75
4
2.
64
 (
0.
37
)
2.
54
 (
0.
36
)
0.
12
7
0.
14
3
0.
29
2
LV
 e
n
d
-s
ys
to
lic
 d
ia
m
et
er
 in
d
ex
1.
80
 (
0.
47
)
2.
47
 (
3.
43
)
0.
45
9
1.
77
 (
0.
38
)
1.
67
 (
0.
34
)
0.
14
7
0.
55
8
0.
37
8
In
te
rv
en
tr
ic
u
la
r 
se
p
tu
m
 (
cm
) 
1.
44
 (
0.
29
)
1.
37
 (
0.
26
)
0.
73
3
1.
43
 (
0.
21
)
1.
34
 (
0.
19
)
0.
12
2
0.
81
8
0.
66
5
Po
st
er
io
r 
w
al
l (
cm
)
1.
09
 (
0.
17
)
1.
00
 (
0.
15
)
0.
48
4
1.
11
 (
0.
17
)
1.
07
 (
0.
14
)
0.
69
9
0.
51
8
0.
01
1
R
el
at
iv
e 
w
al
l t
h
ic
kn
es
s 
0.
49
 (
0.
11
)
0.
47
 (
0.
09
)
0.
28
4
0.
46
 (
0.
09
)
0.
45
 (
0.
08
)
0.
13
9
0.
13
7
0.
52
3
LV
 m
as
s 
in
d
ex
 (
g
/m
2 )
13
2.
22
 (
33
.7
9)
11
0.
15
 (
28
.2
9)
0.
64
4
13
3.
08
 (
31
.7
3)
11
5.
32
 (
28
.5
5)
0.
98
8
0.
78
4
0.
30
8
O
b
se
rv
ed
/p
re
d
ic
te
d
 L
V
M
 (
%
)
16
6.
45
 (
54
.2
8)
17
0.
15
 (
47
.1
5)
0.
67
2
13
7.
44
 (
36
.4
0)
14
1.
36
 (
32
.8
9)
0.
06
2
0.
01
6
0.
01
9
LV
 e
n
d
-d
ia
st
o
lic
 v
o
lu
m
e 
(m
l)
 
84
.3
1 
(2
7.
04
)
75
.4
8 
(2
5.
2)
0.
61
1
10
5.
74
 (
33
.8
3)
98
.4
7 
(3
1.
13
)
0.
35
5
0.
00
2
<0
.0
01
LV
 e
n
d
-s
ys
to
lic
 v
o
lu
m
e 
(m
l)
 
36
.4
2 
(2
4.
66
)
40
.8
2 
(1
6.
27
)
0.
19
0
42
.1
6 
(2
3.
47
)
50
.5
5 
(1
8.
08
)
0.
14
7
0.
37
0
0.
01
9
LV
 e
n
d
-d
ia
st
o
lic
 v
o
lu
m
e 
in
d
ex
51
.0
7 
(1
5.
72
)
45
.0
4 
(1
3.
84
)
0.
59
1
55
.3
8 
(1
8.
19
)
53
.2
4 
(1
7.
62
)
0.
29
6
0.
26
7
0.
01
5
LV
 e
n
d
-s
is
to
lic
 v
o
lu
m
e 
in
d
ex
21
.9
6 
(1
4.
37
)
24
.7
0 
(9
.3
8)
0.
22
7
22
.4
8 
(1
2.
04
)
27
.4
5 
(1
0.
54
)
0.
18
2
0.
96
4
0.
26
8
A
o
rt
ic
/P
ro
st
h
es
is
 s
te
n
o
si
s 
se
ve
ri
ty
M
ax
im
al
 t
ra
n
sa
o
rt
ic
 v
el
o
ci
ty
 (
cm
/s
)
47
3.
02
 (
64
.5
5)
25
6.
66
 (
68
.5
2)
0.
01
2
45
8.
21
 (
53
.5
8)
27
6.
28
 (
72
.4
7)
0.
01
4
0.
60
9
0.
64
6
M
ax
im
al
 t
ra
n
sa
o
rt
ic
 g
ra
d
ie
n
t 
(m
m
H
g
)
90
.3
0 
(2
3.
43
)
28
.3
8 
(1
6.
31
)
0.
00
1
85
.6
4 
(2
1.
04
)
31
.7
0 
(1
9.
11
)
0.
01
2
0.
56
7
0.
99
1
M
ed
iu
m
 t
ra
n
sa
o
rt
ic
 g
ra
d
ie
n
t 
(m
m
H
g
) 
56
.4
8 
(1
5.
15
)
15
.6
3 
(9
.5
8)
0.
00
9
51
.8
 (
12
.3
4)
17
.4
 (
10
.9
2)
0.
01
7
0.
19
6
0.
92
3
E
ff
ec
ti
ve
 o
ri
fi
ce
 a
re
a 
in
d
ex
 (
cm
/m
2 )
 
0.
39
 (
0.
12
)
0.
83
 (
0.
25
)
0.
60
8
0.
45
 (
0.
12
)
0.
84
 (
0.
24
)
0.
04
5
0.
09
4
0.
54
9
In
cr
ea
se
 e
ff
ec
ti
ve
 o
ri
fi
ce
 a
re
a 
(%
)
13
6.
87
 (
76
.7
1)
10
5.
08
 (
55
.4
4)
0.
07
0
H
em
o
d
yn
am
ic
 lo
ad
 
V
al
vu
lo
ar
te
ri
al
 im
p
ed
an
ce
6.
98
 (
2.
47
)
6.
16
 (
1.
79
)
0.
95
4
5.
65
 (
1.
51
)
4.
98
 (
1.
59
)
0.
46
6
0.
02
0
0.
00
7
Pe
ak
 L
V
 w
al
l s
tr
es
s 
(d
yn
es
/c
m
2 )
 
22
1.
7 
(8
4.
91
)
16
9.
22
 (
46
.8
3)
0.
20
9
22
0.
26
 (
46
.5
3)
16
8.
07
 (
38
.8
5)
0.
41
4
0.
90
1
0.
63
2
S
ys
to
lic
 f
u
n
ct
io
n
E
je
ct
io
n
 f
ra
ct
io
n
 (
%
)
60
.6
 (
11
.8
)
63
.4
 (
8.
2)
0.
37
0
61
.6
 (
10
.4
)
64
.2
 (
9.
3)
0.
22
7
0.
55
3
0.
44
9
Re
su
lts
 a
re
 p
re
se
nt
ed
 a
s 
m
ea
n 
(s
ta
nd
ar
d 
de
vi
at
io
n)
57
RESULTS
Fibrosis and serum levels of biomarkers of extracellular matrix remodeling 
Intraoperative myocardial biopsy was performed in 56 patients (38 women), allowing for histological 
analysis of collagen volume fraction (CVF). The demographic data of this subgroup was similar to 
that of the overall group (table 3).
Women had significantly more fibrosis than men (18.98±15.20% vs 12.41±7.61%, p=0.036) at the time 
of valve replacement (fig.2). Since women were older, there could be the interference of age in these 
results. Although age tended to show a weak correlation with CVF (rs=0.25, p=0.064), when analyzing 
for gender, in women CVF increase was not associated with age (rs=0.13, p=0.443). Inversely, in men 
age positively correlates with CVF (rs=0.48, p=0.043). 
Table 3: Clinical characterization of aortic stenosis patients with collagen volume fraction 
measurement, according to gender. 
    Female (n=38) Male (n=18) p Age-adjusted p
Age Mean (st. dev) 69.8 (9.8) 58.9 (11.4) 0.001
BMI Mean (st. dev) 28.6 (4.7) 28.5 (2.8) 0.900 0.981
BSA Mean (st. dev) 1.65 (0.16) 1.90 (0.13) <0.001 <0.001
Euroscore II Mean (st. dev) 1.90 (1.09) 0.74 (0.27) <0.001 0.004
HT n (%) 48 (62.3%) 26 (48.1%) 0.107
Age adjusted % 35.2% 28.6% 0.311
DM n (%) 16 (20.8%) 11 (20.4%) 0.955
Age adjusted % 37.2% 32.1% 0.355
CKD n (%) 36 (46.8%) 12 (21.8%) 0.003
Age adjusted % 41.3% 25.0% 0.117
GFR (ml/min) Mean (st. dev) 59.3 (19.9) 80.3 (14.9) <0.001 0.003
NYHA≥3 n (%) 20 (26.0%) 11 (20.4%) 0.458
Age adjusted % 41.1% 29.3% 0.197
LVH n (%) 65 (85.5%) 39 (73.6%) 0.091
Age adjusted % 38.4% 27.9% 0.220
LV mass (g) Mean (st. dev) 203.3 (55) 262.8 (54.4) <0.001 <0.001
LV mass index (g/m2) Mean (st. dev) 123.2 (30.7) 138.5 (29.6) 0.084 0.033
BSA= body surface area; HT= hypertension; DM= diabetes mellitus; CKD= chronic kidney disease; GFR= glomerular filtration rate (MDRD formula); NYHA= 
functional class of New York Heart Association; LVH= left ventricle hypertrophy. Results are presented as mean (standard deviation) unless otherwise noted.
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Forty patients had determination of serum biomarkers of extracellular matrix (ECM) remodeling (see 
table 4 for demographic characterization). There were no differences between genders in serum CTGF, 
TGF β, MMP1 and MMP9, as well as TIMP 1 and TIMP2 levels (table 5). Female gender had a trend for 
higher serum levels of PIP (775.7±250.2 ng/ml vs 649.1±94.1 ng/ml, p=0.067), reflecting higher myo-
cardial synthesis of collagen type I. Moreover, in women baseline indexed LVM positively correlated 
with TIMP1/MMP1 levels (rs=0.681, p=0.003) and tended to correlate with PIP levels (rs=0.465, p=0.052). 
The development of excessive LVM in women also tended to correlate with higher levels of TIMP1/
MMP1 (rs=0.582, p=0.060), favoring collagen deposition. An opposite trend was seen in men (rs=-0.617, 
p=0.077). Importantly, female patients with higher baseline levels of TIMP2 and TIMP1/MMP1 experi-
enced significantly less 6 months LVM regression, but this pattern was not seen in men (table 6). 
Gender
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,00
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60,00
Male
Fig 2. Comparison by 
gender of collagen volume 
fraction (%) measurement by 
picrosirius-red staining of 56 
myocardial biopsies.
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RESULTS
Table 4: Clinical characterization of aortic stenosis patients with serum biomarkers measurement, 
according to gender.
    Female (n=26) Male (n=14) p Age-adjusted p
Age Mean (st. dev) 69.6 (9.0) 64 (11.9) 0.066
BMI Mean (st. dev) 28.7 (4.8) 28.4 (4.8) 0.832 0.108
BSA Mean (st. dev) 1.68 (0.16) 1.91 (0.17) <0.001 <0.001
Euroscore II Mean (st. dev) 1.81 (1.18) 1.08 (0.70) 0.029 0.168
HT n (%) 23 (60.5%) 6 (40.0%) 0.176
Age adjusted % 60.5% 46.4% 0.176
DM n (%) 11 (28.9%) 2 (13.3%) 0.305
Age adjusted % 28.8% 16.2% 0.171
CKD n (%) 15 (39.5%) 2 (12.5%) 0.051
Age adjusted % 38.0% 15.5% 0.052
GFR (ml/min) Mean (st. dev) 65.8 (19.4) 71.8 (12.8) 0.291 0.537
NYHA≥3 n (%) 8 (21.1%) 3 (20.0%) 0.932
Age adjusted % 19.4% 26.4% 0.713
LVH n (%) 34 (91.9%) 13 (81.3%) 0.351
Age adjusted % 92.4% 81.1% 0.113
LV mass (g) Mean (st. dev) 212.8 (46.7) 260.1 (57.9) 0.003 0.005
LV mass index (g/m2) Mean (st. dev) 126.6 (25.5) 135.5 (27.0) 0.256 0.231
BSA= body surface area; HT= hypertension; DM= diabetes mellitus; CKD= chronic kidney disease; GFR= glomerular filtration rate (MDRD formula); NYHA= 
functional class of New York Heart Association; LVH= left ventricle hypertrophy. Results are presented as mean (standard deviation) unless otherwise noted.
Table 5: Serum biomarkers levels in aortic stenosis patients according to gender.
Female Male p
MMP9 (ng/ml) 157.8 (145.7) 195.5 (189.5) 0.669
MMP1 (ng/ml) 2.98 (1.53) 3.21 (2.02) 0.633
TIMP2 (ng/ml) 6.88 (13.46) 5.59 (11.62) 0.926
TIMP1 (ng/ml) 124.4 (48.4) 132.4 (77.8) 0.925
TIMP1 / MMP1 60.20 (25.92) 65.37 (36.93) 0.920
TIMP1 / MMP9 1.87 (1.57) 1.57 (1.54) 0.715
TIMP2 / MMP1 11.84 (9.82) 4.91 (4.34) 0.355
TIMP2 / MMP9 0.29 (0.15) 0.23 (0.22) 0.669
PIP (ng/ml) 775.7 (250.2) 649.1 (94.1) 0.067
MMP= metalloproteinase; TIMP= tissue inhibitor of metalloproteinase; PIP= procollagen type I carboxy-terminal peptide. Results are presented as mean (standard 
deviation)
6 months follow-up
At 6 months follow-up, overall there was a significant absolute decrease in LVM index of 20.22±30.83 g/
m2 and a relative decrease of 12.04±25.52%. Even so, 56.3% of patients still had residual LVH after AVR.
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RESULTS
Women continued to have higher Zva, although they tended to have a greater relative increase in 
indexed effective orifice area (EOAi). There were no differences between genders in indexed LVM 
decrease (22.07±28.22 g/m2 in women vs 27.35±33.04 g/m2 in men, p=0.76), but at 6 months women 
continued to have a higher excess in LVM than men (% observed/predicted LVM: 170.15±47.15% vs 
141.36±32.89%, age-adjusted p=0.019). Moreover, after surgery women more frequently had residual 
LVH (68.8% vs 39.6%, age-adjusted p=0.002) and regression of LVH was impaired when compared 
with men (LVH improvement: 33.3% vs 61.7%, p=0.003).
In a multivariate model for predicting residual LVH after surgery (table 7), including gender, age, 
arterial hypertension (HT), diabetes mellitus (DM), CKD, baseline LVM (continuous variable or di-
vided in terciles) and % observed/predicted LVM (continuous variable or dichotomized >142%), only 
the female gender [OR: 4.83(1.58-14.77)], hypertension [OR: 3.39(1.23-9.36)] and baseline LVM [OR: 
1.04(1.02-1.06) per 1 g/m2 increase] were independent predictors of residual LVH after surgery. A 
higher baseline valvuloarterial impedance, although associated with persistent LVH, did not reach 
statistical significance. The combination of being female, a history of HT and the baseline LVM (con-
tinuous- model 1, or the second or third upper tercile- model 2) had a high predictive value for 
residual LVH [model 1 AUC 0.836 (95%CI:0.761-0.911), model 2 AUC 0.823 (95%CI:0.744-0.903), fig3].
Fig 3. ROC curve for the multivariate logistic model for residual LVH: a) Model 1 (arterial hypertension, 
female gender, basal indexed left ventricular mass) ; b) Model 2 (arterial hypertension, female gender, 
second or third upper terciles of basal indexed left ventricular mass). 
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RESULTS
Discussion
In our study, women had a significantly higher excess in LVM than men, considering what would be ex-
pected according to height, load and gender. Likewise, six months after AVR, women had more residual 
LVH. Moreover, women had a trend for higher serum levels of PIP than men, reflecting higher synthesis of 
collagen type I, and only women had imbalance of TIMP1/MMP1 favoring inhibition of collagen degrada-
tion, which positively correlates with baseline LVM values. At histological level women with AS presented 
more interstitial fibrosis than their men counterparts, confirming their plasmatic ECM biomarker profile.
Relevance of inappropriate left ventricular mass increase
In this study we describe gender differences in hypertrophic response, with a higher excess of LVM 
in women. Some degree of hypertrophy is expected under chronic pressure overload to normalize 
wall stress and preserve systolic function. But in some patients this increase in LVM is maladaptive 
and produces an unfavorable concentric phenotype associated with diastolic dysfunction and worse 
prognosis (20). The appropriateness of LVM increase, measured by the ratio between the observed 
and the predicted LVM (considering workload, gender and body size), has been proposed as valuable 
tool to help to distinguish between compensatory from maladaptive (and often irreversible) left 
ventricular hypertrophy (4). Inappropriate LVM has been associated with worse cardiovascular 
outcomes both in hypertension (21) and asymptomatic severe AS (5). Moreover, its presence was 
associated with concentric LV geometry and LV systolic and diastolic abnormalities, even in the 
absence of LV hypertrophy (22), supporting the hypothesis that it can identify a more advanced 
stage of myocardial disease, probably beyond the compensatory phase. But the problem remains in 
its definition, since there is no consensus in its cutoff value and different cutoffs have been used in 
different populations (5,22,23). For this reason we used % observed/predicted LVM as a continuous 
variable in our analysis.  
Considering the worse outcomes of patients with inappropriate LVM, known from previous studies, 
early surgery could be considered in AS patient with an excessive hypertrophic response, in particular 
in women. Its cutoff value is yet to be determined. 
Gender differences in left ventricular remodeling in aortic stenosis
Elderly women with AS respond to pressure overload with smaller, more hypertrophic and stiffer ven-
tricles, and often have supranormal ejection fraction (8,12). Conversely, men have higher levels of wall 
stress and worse systolic function than women under similar load conditions (8). These distinctive LV 
remodeling responses to pressure overload can be partially explained by the effect of sex hormones. 
Estrogens seem to have antiproliferative effects on cardiac fibroblasts (15) and vascular smooth–muscle 
cells, while androgens have opposite effects (24). In animal models, estrogens down regulate prolifera-
tion of cardiac fibroblasts and gene expression of collagens type I and III in female, but have opposite 
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effect in male (14,25). Therefore, estrogens may prevent the up regulation of collagen in women with 
pressure overload until menopause. Given that older patients have relative hypogonadal hormone 
concentrations, with a decrease in estrogens and ovarian production of androgens in postmenopausal 
women, it is expected that this protective effect is lost with aging in women.
A faster early regression of LVM has been described in women, and their lower gene expression of 
collagen I and III and MMP2 (in a 10 patients subgroup) was considered as a possible explanation (14). 
In a comparable cohort of AS patients, we found that women had a similar degree of LVM regression 
but more residual LVH than men 6 months after AVR. This apparent contradiction may be due to the 
existence of coronary artery disease (CAD) and differences in the moment of evaluation of regression. 
In the study by Petrov et al (14) there was a trend for higher prevalence of CAD in men. The coexistence 
of CAD can influence regression and it was an exclusion criteria in our study. Moreover, results may 
be different if the evaluation is performed in the first days after AVR or at six months after surgery. One 
can speculate that women might regress faster than men before discharge after AVR, but there can be 
a slower but more significant regression overall in men.
Postoperative changes in myocardial structure are characterized by an initial decrease in muscle 
fiber diameter and a relative increase in interstitial fibrosis, whereas in a later phase, LVM regression 
continues more slowly, with no further change in muscle fiber diameter but an additional reduction 
in collagen volume fraction (26). Therefore, differences on gene expression of ECM components 
are unlikely to be responsible for early regression, but it is plausible that they can influence later 
remodeling. The presence of a profibrotic pattern of ECM biomarkers and evidence of more fibrosis 
in surgical biopsies of our elderly AS women can explain the existence of a more inappropriate 
increase in LVM and the persistence of LVH after AVR, since this is the myocardial component that 
takes longer to regress and some of these changes can even be irreversible.
Limitations
This is a prospective observational study and we were unable to match for age and body surface 
area between genders. Still, age-adjustment was performed for clinical and echocardiographic pa-
rameters and differences were considered in the multivariate analysis. The small sample size and the 
fact that determinations of plasmatic biomarkers and fibrosis were done in only some patients, may 
have limited our ability to find differences. However, this is a frequent constraint in similar studies, 
and only multi-center registries or large scale randomized clinical trials can overcome this limitation. 
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RESULTS
Conclusions
Among AS patients, women have a higher excess in hypertrophic response than men under similar 
workload conditions, and female gender is an independent predictor of residual hypertrophy after 
AVR. A gender-specific ECM remodeling, favoring interstitial fibrosis in women, might help to explain 
these differences. Identifying potential causes for gender differences in LV remodeling may raise 
hypothesis for distinct therapeutic interventions.
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Abstract
Objectives: To evaluate if residual left ventricular (LV) hypertrophy is associated with clinical out-
comes after aortic valve replacement (AVR) for severe aortic stenosis (AS).
Background: Persistent LV hypertrophy (LVH) after surgery is frequent but its clinical relevance is 
controversial.
Methods: We analyzed clinical and echocardiographic parameters before and after AVR, in a prospec-
tive cohort of 132 severe AS patients. Mean follow-up was 6.0±1.5 years. Clinical endpoints were 
all-cause death and combined all-cause death and non-fatal cardiovascular hospitalization. At time 
of AVR, myocardial biopsies for collagen volume fraction (CVF) evaluation were done in 56 random 
patients.
Results: Residual LVH was present in 44% of patients after AVR. Patients with residual LVH were 
older, more frequently women and had hypertension (HT). Preoperatively, they had higher indexed 
LV mass (LVMI), higher E/e’ and indexed left atrial volume, as well as lower peak systolic annular 
velocity (Sm). Female gender, HT, LVMI and E/e´ were independent predictors of persistent LVH. CVF 
at the time of surgery was higher in those with residual LVH (20.0±14.6% vs 13.2±11.5%, p=0.027). 
The risk of all-cause death and non-fatal cardiovascular hospitalization was higher in patients with 
residual LVH [OR 2.89 (95%CI:1.12-7.44); p=0.035], but there were no differences in all-cause mortality. 
Residual LVH was associated with a worse outcome in women but not in men.
Conclusions: Residual LVH after AVR is common and is associated with worse prognosis, particularly 
in women. In addition, HT, higher baseline LVM and worse diastolic dysfunction can help to identify 
patients at risk for incomplete mass normalization.
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Introduction:
In chronic pressure overload, left ventricular hypertrophy (LVH) is an adaptive mechanism that con-
tributes for normalization of systolic wall stress 1, 2. In aortic stenosis (AS) patients, severe LVH is re-
lated with worse left ventricular (LV) function and higher early and late mortality, even after success-
ful aortic valve replacement (AVR) 3, 4. Likewise, incomplete regression of LVH, commonly observed 
in these patients 5, 6, may be a marker of irreversible remodeling and, as so, of worse prognosis.
Our aim was to evaluate the prognostic impact of residual LVH late after surgery and identify baseline 
independent predictors of its occurrence. 
Methods: 
Patient selection and follow-up
Between January 2006 and December 2009 we included 141 consecutive patients over 18 years 
old with severe symptomatic AS (aortic valve area <1 cm2 or mean transaortic gradient ≥40 mmHg) 
referred for AVR at the Cardiothoracic Surgery Department of Centro Hospitalar São João, Porto, 
Portugal. We excluded patients with aortic regurgitation >II/IV or other significant valve diseases 
(>mild), significant coronary artery disease (lesions >50% on coronary angiography) or previous car-
diac surgery. All patients were in sinus rhythm at the time of inclusion.  From the initial 141 patients, 
132 were considered for this prospective analysis: one was refused for surgery, other died before 
surgery from non-cardiovascular reason (cholangitis with sepsis), and there was incomplete clini-
cal data in seven of them. All patients had clinical follow-up up-to 8.2 years and echocardiographic 
follow up was achieved in 123 (93.2%) patients. There were 2 perioperative deaths (one fatal stroke 
and one due to sepsis) and 3 sudden deaths in the first 30 days after surgery. These patients had 
no echocardiographic evaluation after AVR. Four additional patients refused coming to our hospital 
for echocardiographic evaluation, 3 of them were alive at the end of follow-up but one had died 4 
months after surgery from non-cardiovascular cause). Mean follow-up was 6.0±1.5 years for clinical 
outcomes and final echocardiographic evaluation was performed 5.0±2.2 years after surgery. 
Clinical endpoints were defined as all-cause of death and a composite of all-cause of death or non-
fatal cardiovascular hospitalization (heart failure, myocardial infarction, re-operation for prosthesis 
dysfunction, new-onset atrial fibrillation or advanced AV block requiring hospitalization). 
Surgical technique 
All surgeries were performed using standard procedure for AVR. The patients were placed on cardio-
pulmonary bypass and cardiac arrest was induced and maintained with cold blood cardioplegia. The 
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majority of patients received a bioprosthesis (73.3%). Two patients also had ascending aorta aneurism 
and underwent aortic root replacement with valved composite grafts (Bentall technique).  At the time of 
surgery, 56 random patients underwent myocardial biopsy from the LV interventricular septum.
Echocardiographic studies
Echocardiographic examination was performed by a trained cardiologist and recorded on digital support. 
All recordings were examined by an experienced echocardiographer, in an accredited independent echo-
cardiography laboratory (Hospital Clínico San Carlos in Madrid, Spain), blinded to patient details. Studies 
were performed using Phillips IE-33 equipment with a S5-1 transducer and M-mode, two dimensional, 
pulsed, continuous, color-flow and tissue Doppler capabilities. Correct orientation of imaging planes, 
cardiac chambers dimensions and function measurements were performed according to the European 
Association of Echocardiography (EAE)/American Society of Echocardiography (ASE) recommendations 7.
LV mass was estimated according to the joint recommendations of the ASE and EAE using Devereux’s 
formula for ASE measurements in diastole: LV mass=0.8 x (1.04 x ([LV internal dimension + posterior wall 
thickness + interventricular septal thickness] 3 – [LV internal dimension] 3) + 0.6 g . Left ventricular hyper-
trophy was defined by LV mass index greater than 115 g/m2 in men and greater than 95 g/m2 in women. 
Relative wall thickness (RWT) was calculated for the assessment of LV geometry using the formula 2x 
posterior wall thickness/ LV diastolic diameter. Increased RWT was present when this ratio was greater 
than 0.42. Left atrium (LA) volume was measured at LV end-systole in the frame preceding mitral valve 
opening. The volume was measured using the biplane area length method and corrected for body 
surface area. Aortic valve area was estimated using quantitative Doppler by the continuity equation. 
Mitral inflow was assessed in the apical 4-chamber view using pulsed wave Doppler with the sample 
volume placed at the tips of mitral leaflets during diastole. From the mitral inflow profile, the peak flow 
velocity of early filling (E wave), peak flow velocity of atrial contraction (A wave), the E/A ratio, and early 
filling deceleration time (DT) were measured. Doppler tissue imaging (DTI) of the mitral annulus was 
obtained from the apical 4-chamber using a sample volume placed in the septal mitral valve annulus. 
Peak systolic annular velocity (Sm) and early diastolic septal velocity (e’) were determined, and the E/e’ 
ratio was derived. As a measure of global LV load, we calculated the valvuloarterial impedance: Zva 
=SAP+ MG)/SVI, where SAP is the systolic arterial pressure and MG is the mean transvalvular pressure 
gradient and SVI is stroke volume index. 
Histological determination of fibrosis
Light microscopic quantification of fibrosis has previously been described and validated. Fibrosis anal-
ysis of myocardial biopsies was performed using picrosirius-red–stained, 4-μm-thick-sections of tissue 
(± 5 sections of each sample). Images of these sections were acquired with a projection microscope 
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(x50). Subsequent image analysis with Slidebook 4.0 software (3I, Denver, Colo) was performed to de-
termine the extent of reactive interstitial fibrosis, which was expressed as collagen volume fraction (%). 
Areas of reparative and perivascular fibrosis were excluded. Myocardial fibrosis was calculated as the 
sum of all connective tissue areas divided by the sum of connective tissue and muscle areas averaged 
over 4 to 6 representative fields of the section of 56 random AS patients (18 male and 38 female). In our 
laboratory, normal values of fibrosis for LV myocardial biopsy material are 5.4±2.2% 8. 
Statistical analysis
Categorical variables were expressed as percentages and continuous variables as mean ± standard 
deviation, unless otherwise specified. Continuous variables were compared between groups using an 
unpaired t-test (for normally distributed variables) or the Mann–Whitney U-test (for non-normally distrib-
uted variables). For comparison between baseline and follow-up a paired Student’s t-test was applied or 
a Wilcoxon test (for non-normally distributed variables). Chi-square test (or Fisher exact test) was used to 
compare categorical variables. Spearman’s rank correlation was used for the assessment of correlations 
between LVM index and its variation and clinical, echocardiographic and molecular continuous variables. 
Univariable and multivariable binary logistic regression models (Wald backward stepwise method, p=0.05 
for covariate inclusion and p=0.20 for exclusion) were used for predicting residual LVH and the outcome 
of all-cause death and cardiovascular hospitalization. The Kaplan-Meier and Cox models were used to 
evaluate survival times after surgery for both all-cause death and for all-cause death and cardiovascular 
hospitalization, and the log-rank test was used to compare survival curves. All reported probability values 
are two-tailed, and P <0.05 was considered statistically significant. Analyses were performed with the 
IBM® SPSS® Statistics software package (version 21.0) (SPSS Inc, Chicago, IL, USA).
Results
The study group included 132 patients with a mean age of 66±12 years, 58% were women and 81% 
had left ventricular hypertrophy (LVH) before surgery. Most patients had preserved ejection fraction 
(EF) with a mean value of 62±10%. Detailed demographic, clinical and echocardiographic (before and 
after AVR) characterization can be found in tables 1 and 2.
A bioprosthesis was implanted in 73% of patients and in all cases that a mechanical valve was chosen 
it was bileaflet. The valve size was >21 mm in 42% of cases (size 19 mm: 14; size 20 mm: 1; size 21 mm: 
61; size 23 mm: 37; size 25 mm: 19). There were 2 perioperative deaths (1.5%), and the median time of 
hospitalization was 6 days. Non-fatal post-surgery complications were atrial fibrillation in 30 patients 
(22.7%), perioperative renal failure in 24 patients (defined as a fall in GFR >25% from baseline, 18.2%), 
pacemaker implantation due to AV block in 9 patients (6.8%), bleeding needing surgical reexploration 
in 2 patients (1.5%), stroke in 2 patients (1.5%), and respiratory infection in 2 patients (1.5%). No patient 
needed inotropic support beyond 24 hours.
76
DETERMINANTS OF LEFT VENTRICULAR HYPERTROPHY BEFORE AND AFTER SURGICAL TREATMENT OF AORTIC STENOSIS
A final echocardiographic evaluation was performed 5.0±2.2 years after surgery. After AVR, we ob-
served significant improvement in transprosthetic gradients, in EOAI and a significant reduction in 
LVMI (table 2), but 54 (44 %) of patients still had LVH.
Table 1: Clinical characterization of aortic stenosis (AS) patients.
AS patients (n=132)
Age 66.6 (±12.0)
Female 77 (58%)
BSA 1.8 (±0.2)
Euroscore II 1.6 (±1.4)
HT [n (%)] 74 (56.5%)
DM [n (%)] 27 (20.6%)
CKD [n (%)] 48 (36.4%)
GFR (ml/min) 68.9 (±18.5)
NYHA≥3 [n (%)] 31 (23.7%)
LVH  baseline [n (%)] 104 (80.6%)
BSA= body surface area; HT= hypertension; DM= diabetes mellitus; CKD= chronic kidney disease; GFR= glomerular filtration rate; NYHA= functional class of New 
York Heart Association; LVH= left ventricle hypertrophy. 
Table 2: Baseline and follow-up echocardiographic characterization of aortic stenosis (AS) patients. 
Baseline Follow-up p*
LV geometry
Interventricular septum (cm) 1.46 (±0.25) 1.33 (±0.2) <0.001
Posterior wall (cm) 1.09 (±0.18) 0.99 (±0.16) <0.001
Relative wall thickness 0.47 (±0.1) 0.43 (±0.08) <0.001
LV mass index (g/m²) 130.95 (±32.47) 107.8 (±31.23) <0.001
LV end-diastolic volume index (ml/m²) 51.48 (±16.08) 50.61 (±17.86) 0.282
LV end-systolic volume index (ml/m²) 20.75 (±11.85) 20.08 (±11.83) 0.530
Aortic/Prosthesis stenosis severity
Maximal transaortic velocity (cm/s) 463.78 (±60.92) 261.69 (±59.06) <0.001
Medium transaortic gradient (mmHg) 54.25 (±14.34) 15.95 (±7.11) <0.001
Effective orifice area index (cm/m²) 0.42 (±0.12) 0.86 (±0.24) <0.001
Increase in effective orifice area (%) 121.79 (±85.36)
Hemodynamic load
Valvuloarterial impedance (mm Hg/ml/m²) 6.43 (±2.29) 5.45 (±1.92) 0.003
Peak LV wall stress (dynes/cm²) 226.17 (±78.61) 175.58 (±44.5) <0.001
Systolic function
Ejection fraction (%) 61.68 (±10.3) 63.58 (±7.68) 0.114
Peak systolic annular velocity (cm/s) 5.49 (±1.24) 6.3 (±1.31) <0.001
Values are mean (±SD) unless otherwise indicated. Bold values indicate statistical significance. * Wilcoxon test
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Residual left ventricular hypertrophy after AVR
Patients with residual LVH after AVR were older (69.2±10.6 vs 64.5±12.5 years, p=0.036), more fre-
quently women (72.2% vs 27.8%; p=0.002), hypertensive (71.7% vs 28.3%; p=0.006), had higher surgi-
cal risk and tended to have lower glomerular filtration rate (GFR) (table 3).
Table 3: Patients Clinical and Echocardiographic characterization, by the presence of residual left 
ventricular hypertrophy after surgery. 
Normal LVM Residual LVH p*
Age mean (±SD) 64.5 (±12.5) 69.2 (±10.6) 0.029
Women n (%) 30 (44.1%) 39 (72.2%) 0.002
HT n (%) 32 (47.1%) 38 (71.7%) 0.006
DM n (%) 12 (17.6%) 13 (24.5%) 0.354
euroSCORE II mean (±SD) 1.33 (±0.78) 2.13 (±1.97) 0.003
GFR (ml/min) mean (±SD) 71.5 (±16.6) 65.9 (±20.6) 0.093
LVEDVI (ml/ m²) mean (±SD) 52.0 (±15.5) 53.5 (±17.1) 0.745
LVESVI (ml/ m²) mean (±SD) 20.0 (±9.4) 23.5 (±14.6) 0.347
RWT mean (±SD) 0.48 (±0.1) 0.47 (±0.11) 0.730
LVMI (g/m²) mean (±SD) 121.2 (±27.3) 143.5 (±34.7) <0.001
ΔLVMI (g/ m²) mean (±SD) -33.5 (±28.7) -10.3 (±41.8) 0.001
LAVI (ml/ m²) mean (±SD) 31.7 (±10.9) 40.8 (±13.7) <0.001
Max Ao vel (m/s) mean (±SD) 454.9 (±55.3) 466.1 (±63.9) 0.307
EOAI (cm²/m²) mean (±SD) 0.42 (±0.13) 0.41 (±0.11) 0.511
ΔEOAI (%) mean (±SD) 123.4 (±88.1) 119.8 (±82.8) 0.923
Zva mean (±SD) 5.92 (±1.56) 6.91 (±2.27) 0.019
SVI (ml/m²) mean (±SD) 32.3 (±7.7) 29.6 (±8.2) 0.111
Sm (cm/s) mean (±SD) 214.1 (±59.4) 231.8 (±81.3) 0.001
E/e’ mean (±SD) 14.5 (±5.2) 19.0 (±7.4) 0.002
EF (%) mean (±SD) 63.1 (±8.5) 58.6 (±12.3) 0.030
PPM n (%) 33 (50.8%) 27 (52.9%) 0.816
HT= hypertension; DM= diabetes mellitus; GFR= glomerular filtration rate (MDRD formula) ; LVEDVI = left ventricle end-diastolic volume index; LVESVI= left 
ventricle end-systolic volume index; RWT=relative wall thickness; LVMI= left ventricular mass index;  Δ LVMI= baseline LVMI-final LVMI; LAVI= left atrial volume 
index; Max Ao vel= maximal aortic velocity; EOAI= effective orifice area index; Δ EOAI= (baseline EOAI-final EOAI)/baseline EOAI*100; Zva= valvuloarterial 
impedance; SVI= stoke volume index; Sm=  peak systolic annular velocity; EF= ejection fraction; PPM= patient prosthesis mismatch; *Mann-Whitney test, except 
for age and EF where the t-Student test was used, n (%) compared using Chi-square test.
When analyzing baseline echocardiographic parameters, patients with residual LVH had higher base-
line left ventricular mass index (LVMI) and valvuloarterial impedance (Zva), but no differences in 
mean gradient or indexed aortic valve area (AVAI). Moreover, these patients had worse diastolic 
function with higher values of E/e’ and indexed LA volume, as well as worse LV systolic function, 
given the lower peak systolic annular velocity (Sm) and lower EF (table 1). Patients with residual LVH 
had less relative mass regression after surgery, with a median decrease of 8.3% (P25-75: 21.9%-6.5%) 
vs 25.7% (P25-75: 41.3%-13.9%) in those with normalization of LV mass (p<0.001). The frequency of 
PPM (defined as an indexed effective orifice area ≤0.85 cm2) was not different in patients with and 
without residual LVH (52.9% vs 50.8%; p=0.82).
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In a multivariate Cox regression model (table 4), including age, gender, hypertension (HT), Euroscore 
II value, baseline GFR, and baseline LVMI, Zva, Sm, EF and E/e’ (table 2), the independent predictors 
of residual LVH were female gender, history of hypertension, higher baseline LVMI and higher LV fill-
ing pressures evaluated by E/e’. Lower values of peak systolic annular velocity also showed a trend 
to predict residual LVH.
Table 4: Univariate and multivariate Cox regression analyses for prediction of residual left ventricular 
hypertrophy. 
Univariate analysis Multivariate analysis
OR (95%CI) p OR (95%CI)  p
Gender (Female) 3.293 (1.534-7.070) 0.002 3.797 (1.047-13.771) 0.042
Age (10 years increment) 1.439 (1.031-2.010) 0.033
HT (Yes) 2.850 (1.327-6.119) 0.007 4.160 (1.255-13.792) 0.020
Euroscore II 1.768 (1.179-2.650) 0.006
GFR (MDRD) 0.984 (0.964-1.004) 0.112
LVMI (10 units increment) 1.272 (1.113-1.454) <0.001 1.350 (1.067-1.708) 0.010
Zva 1.332 (1.055-1.682) 0.016
EF 0.958 (0.922-0.996) 0.030
E/e’ (1 unit increment) 1.123 (1.049-1.201) 0.001 1.117 (1.024-1.219) 0.013
Sm (1 unit decrease) 1.969 (1.311-2.957) 0.001 1.653 (0.990-2.755) 0.055
CVF ≥15.4% 5.2 (1.475-18.332) 0.010 7.076 (1.406-35.604) 0.018
Fibrosis and residual hypertrophy after surgery
Fifty-six random patients underwent myocardial biopsy at the time of surgery for fibrosis determina-
tion. There were no clinical differences between these patients and the overall group (table 5).
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Table 5: Clinical and echocardiographic characterization of aortic stenosis patients with and without 
fibrosis determination.
Without fibrosis determination With fibrosis determination p*
n=76 (57.6%) n=56 (42.4%)
Echo Follow-up time (months) 70.1±16.6 71.5±14.7 0.45
Age 66.9 ±12.4 66.3±11.5 0.80
Women 39 (51.3%) 38 (67.9%) 0.057
HT 47 (62.7%) 27 (48.2%) 0.099
DM 17 (22.7%) 10 (17.9%) 0.50
euroSCORE II 1.73±1.65 1.54±1.06 0.71
GFR (ml/min) 70.9±16.5 66.2±20.8 0.20
LVMI (g/m2) 133.2±34.5 128.1±30.9 0.28
LAVI (ml/ m2) 36.0±12.7 35.7±13.3 0.89
Max Ao vel (m/s) 457.1±52.8 463.2±65.6 0.77
EOAI (cm2/m2) 0.42±0.12 0.41±0.12 0.27
Zva 6.28±1.71 6.51±2.23 0.96
SVI (ml/m2) 31.5±8.1 30.2±7.8 0.42
E/e’ 16.5±7.2 16.8±6.1 0.500
EF (%) 59.1±12 63.6±7.6 0.013
PPM 36 (52.9%) 25 (51%) 0.84
HT= hypertension; DM= diabetes mellitus; GFR= glomerular filtration rate; LVMI= left ventricular mass index; LAVI= left atrial volume index; Max Ao vel= maximal 
aortic velocity; EOAI= effective orifice area index; Zva= valvuloarterial impedance; SVI= stroke volume index; EF= ejection fraction; PPM= patient prosthesis 
mismatch
From the patients who had a determination of collagen volume fraction (CVF) at the time of surgery, those 
with residual LVH had a significantly higher level of CVF (20.0±14.6% vs 13.2±11.5%, p=0.027) (Fig. 1).
Left ventricular hipertrophy after AVR
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Fig. 1 Levels of collagen 
volume fraction (CVF) 
according to the existence of 
residual LVH after surgery.
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Clinical outcomes
After 6.0±1.5 years of follow-up, 17 patients (12.9%) had died and 12 patients had a non-fatal cardio-
vascular hospitalization (5 for heart failure, 3 re-operations for prosthesis dysfunction, 2 for symp-
tomatic new-onset atrial fibrillation, and 2 for advanced AV block requiring pacemaker implantation). 
Patients with residual LVH after surgery had no differences in the risk of all-cause mortality (HR 1.88, 
95% CI:0.56-6.28; p=0.366) , as well as no differences in the risk of cardiovascular death (HR 2.00, 
95% CI:0.56-7.10; p=0.283), but had a significantly higher risk of non-fatal cardiovascular hospitaliza-
tion (HR 3.82, 95%CI:1.03-14.13, p=0.045) and the combination of all-cause mortality and non-fatal 
cardiovascular hospitalization (HR 2.89, 95%CI:1.12-7.44; p=0.035), when compared with those with 
normal LVM. 
Event-free survival curves for each group are displayed in Fig. 2 . Patients with residual LVH after sur-
gery had worse results for survival free of non-fatal cardiovascular hospitalization (83.3% vs 95.6%, 
p=0.032) and the composite endpoint of all-cause mortality and non-fatal cardiovascular hospitaliza-
tion, compared with those with normal LVM (60.0% vs 86.5%, p=0.039). There was no significant 
difference for all-cause mortality between the groups (78.1% vs 90.6%, p=0.289). 
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Fig 2. Kaplan-Meier survival curves for all-cause death, for all-cause death and cardiovascular 
hospitalization and for non-fatal cardiovascular hospitalization, by the presence of residual left 
ventricular hypertrophy (LVH)
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2B) 2A) 
2C) 
time 0 12 24 36 48 60 72 84 96 >96
number at risk
normal LVM 67 67 65 65 63 63 62 62 62 62
Residual LVH 53 51 51 49 49 48 48 46 46 46
time 0 12 24 36 48 60 72 84 96 >96
number at risk
normal LVM 67 64 64 64 64 64 64 64 64 64
Residual LVH 53 49 49 47 47 47 46 44 44 44
time 0 12 24 36 48 60 72 84 96 >96
number at risk
normal LVM 67 64 62 62 60 60 59 59 59 59
Residual LVH 53 48 48 44 44 43 42 38 38 38
2A) Patients with normal LVM have similar survival free of all-
cause death compared to the ones with residual LVH.
2B) Patients with normal LVM have significantly better survival 
free of all-cause death and cardiovascular hospitalization com-
pared to the ones with residual LVH.
2C) Patients with normal LVM have significantly better survival 
free of non-fatal cardiovascular hospitalization compared to the 
ones with residual LVH.
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Fig 3. Kaplan-Meier survival curves for cardiovascular death according to the presence of residual left 
ventricular hypertrophy (LVH). Patients with normal LVM have similar survival free of cardiovascular 
death compared to the ones with residual LVH.
 
time 0 12 24 36 48 60 72 84 96 >96
number at risk
normal LVM 67 67 66 66 64 64 64 63 63 63
Residual LVH 53 51 51 49 49 48 48 48 47 47
There was a difference in event-free survival in those with residual LVH, according to gender (Fig. 4 
and 5). Women with residual LVH have lower event-free survival for the combined endpoint (50.0% vs 
93.2%, p=0.019) and a trend for lower survival free of all-cause death (67.8% vs 96.4%, p=0.059) and 
cardiovascular mortality  (84.6% vs 96.7%, p=0.086), when compared with women with normal final 
LVM. This result was not seen in men, as there was no significant difference in event-free survival, 
between those with and without residual LVH. 
Time (months)
96847260483624120
Su
rv
iv
al
 P
ro
ba
bi
lit
y f
re
e o
f c
ar
di
ov
as
cu
la
r d
ea
th
1.0
0.8
0.6
0.4
0.2
0.0
Normal LVH
Residual LVH
p=0.273
83
RESULTS
Fig 4. Gender specific Kaplan-Meier survival curves for all-cause death or for all-cause death and 
cardiovascular hospitalization by the presence of residual left ventricular hypertrophy (LVH). 
4A) Female with normal LVM have similar survival compared with female with residual LVH.
4B) Male with normal LVM have similar survival compared with male with residual LVH.
4C) Female with normal LVM have significantly better survival free of all-cause death and cardiovascular hospitalization compared 
with female with residual LVH.
4D) Male with normal LVM have similar survival free of all-cause death and cardiovascular hospitalization compared with male with 
residual LVH.
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Fig 5. Gender specific Kapplan-Meier survival curves for cardiovascular death by the presence of 
residual left ventricular hypertrophy (LVH). 
Female patients showed a trend to higher cardiovascular mortality if they have residual LVH (5A) while cardiovascular mor-
tality was not different in men with or without residual LVH (5B).  
Discussion
We analyzed a prospective cohort of patients with isolated severe AS who underwent AVR, with 
echocardiographic follow-up at 5 years and clinical follow-up at 6.0±1.5 years. In our study residual 
LVH was present in 44% of patients late after AVR and was associated with a worse prognosis, with 
nearly a three-fold increase in the risk of death or non-fatal cardiovascular hospitalization. We also 
found that female gender, history of hypertension, higher baseline LVMI and higher baseline LV fill-
ing pressures were independent predictors of residual LVH. Moreover, in women the persistence of 
LVH late after AVR was associated with a worse outcome. This was not seen in men, suggesting that 
the prognostic impact of residual LVH is gender-specific.
The association of residual LVH in AS with worse prognosis is controversial. Others have described 
this association including patients with other types of valve lesions and coexisting coronary artery 
disease (CAD), which may have influenced results. Indeed, the coexistence of CAD has been consid-
ered as an independent predictor of clinical outcomes after AVR 6 and the presence of aortic insuf-
ficiency can elicit a different remodeling response9. In our study we excluded these patients.
Time (months)
96847260483624120
Su
rv
iv
al
 P
ro
ba
bi
lit
y f
re
e o
f c
ar
di
ov
as
cu
la
r d
ea
th 1.0
0.8
0.6
0.4
0.2
0.0
Normal LVH
Residual LVH
Female
p=0.086
Time (months)
96847260483624120
Su
rv
iv
al
 P
ro
ba
bi
lit
y f
re
e o
f c
ar
di
ov
as
cu
la
r d
ea
th
1.0
0.8
0.6
0.4
0.2
0.0
Normal LVH
Residual LVH
Male
p=0.303
5B) 5A) 
time 0 12 24 36 48 60 72 84 96 >96
number at risk
normal LVM 29 29 29 29 28 28 28 28 28 28
Residual LVH 38 36 36 34 34 33 33 33 32 32
time 0 12 24 36 48 60 72 84 96 >96
number at risk
normal LVM 37 37 36 36 35 35 34 34 34 34
Residual LVH 14 14 14 14 14 14 14 14 14 14
85
RESULTS
The lack of normalization of LV mass after surgery occurs in nearly half of patients with AS, and it has 
been considered as a “natural” consequence of the replacement of a native valve for a somewhat 
obstructive valve substitute with a residual gradient 10. Thus the focus has been on avoiding significant 
PPM and new prostheses have been developed with better hemodynamic profiles. In our study PPM 
was frequent and occurred in nearly half of the patients, but only in about 20% of them PPM was 
severe. However, in our study residual LVH was not associated with PPM. Beach et al, described that 
high postoperative transprosthesis gradients had only a minimal effect on residual left ventricular hy-
pertrophy, in a study including a very large number of patients 5. Therefore, hemodynamic factors, such 
as type of valve and residual gradients, are not the only determinants of incomplete regression. The 
worse long-term outcome of patients with residual LVH after AVR can be explained by the existence of 
more extensive preoperative disease and persistent diastolic and/or systolic dysfunction 11, 12.
One important finding in our study was the observed differences in the prognostic impact of residual 
LVH according to gender. Only in women the absence of normalization of LVM was associated with 
worse survival free from non-fatal cardiovascular hospitalization or and all-cause mortality. Recently, 
Petrov et al 13 described that women with preoperative maladaptive LVH had worse survival than 
those with adaptive LVH, a pattern that was not seen in men. These results are in accordance with 
ours, showing a gender-specific prognosis of LVH determined before or after AVR. Thus, it seems 
that, in women, the search for early predictors of negative remodeling after AVR could be particularly 
relevant.
Predictors of residual LVH
Patients with a higher baseline LVMI and worse diastolic dysfunction (higher filling pressures evalu-
ated by E/e´) had a higher probability of having residual LVH after surgery. Moreover, those with worse 
longitudinal systolic function (evaluated by Sm) were also less likely to have LV mass normalization 
late after surgery. Our results are in accordance with those of other authors, who also found that the ex-
istence of a more severe preoperative hypertrophy 5, 14-16 and the presence of early signs of myocardial 
dysfunction, even with preserved ejection fraction, may be a surrogate of a more advanced disease17 
and could help to explain the worse long-term outcome of patients with residual LVH.
Female gender and a history of HT were also independently associated with persistent LVH. In 
previous analyses, we have found that women had more interstitial fibrosis than men. They also 
had levels of biomarkers of extracellular matrix (ECM) favoring collagen deposition, and these 
correlated negatively with LV mass regression (unpublished data). Moreover, hypertension nega-
tively impacts LV mass regression after surgery, and several authors have stressed the need for 
rigorous blood pressure control in these patients 18, 19. Nevertheless, our group has shown that this 
impairment in reverse remodeling happens independently of load, and might be related to the 
neuro-hormonal milieu 20.
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Myocardial fibrosis and residual LVH  
At the histological level, we found that a higher amount of fibrous tissue at the time of surgery is an 
independent predictor of residual LVH, altogether suggesting the presence of irreversible remodel-
ing. Our results are in accordance with earlier landmark studies that established the relationship 
between myocardial fibrosis, systolic and diastolic function and incomplete LVM regression in aortic 
stenosis 21, 22. More recently, the presence of severe fibrosis at the time of surgery has been associ-
ated with lesser functional improvement 23 and higher mortality after AVR 24, confirming its prognos-
tic importance.
Based on results from previous studies 23, 25, the worse baseline longitudinal systolic function in 
our patients with residual LVH might reflect the existence of more advanced myocardial disease 
and higher levels of fibrosis, making its evaluation an important tool for risk-stratifying AS patients 
without class I recommendation for AVR. 
Limitations
This was a single center observational study and the limited size of our cohort, although similar to 
those reported on literature about this subject, limits our statistical power. For fibrosis determination, 
we were unable to achieve myocardial biopsies for all patients. Still these patients were randomly 
chosen and are believed to be representative of the overall study group. 
Conclusion
Residual LVH late after AVR is associated with a worse prognosis, in particular in women. The pres-
ence of more severe myocardial disease, as suggested by higher LVM and worse LV diastolic and 
systolic function, can help to explain the poorer clinical outcome of these patients. Interstitial fibrosis 
could be the missing link in the pathophysiology of residual LVH.  Early intervention may be needed 
in women, those with HT and those with higher baseline LVM and worse diastolic dysfunction, in-
dependently of symptoms. Our study is hypothesis generating and brings light for the need of ad-
ditional research to evaluate the impact of earlier surgery in specific subgroups of patients with a 
higher risk of residual LVH after surgery, such as women and those with HT. 
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Background:We evaluated the impact of hypertension on the left ventricular mass regression in aortic stenosis
after aortic valve replacement.
Methods:We prospectively studied 135 patients with severe aortic stenosis at baseline and 1 year after surgery.
In 32patientswe analyzedmyocardial gene expression of collagen types I and III, connective tissue growth factor,
transforming growth factor-β1, metalloproteinase-2 and its tissue inhibitor and compared its levels vs controls.
Results: Seventy-six patients (56.3%) had a history of hypertension. Hypertensive patients were older, had higher
Euroscore-II and NYHA class, with no differences in stenosis severity. At 1 year follow-up there was a median
decrease of mass index of 14.2% (P25–75:−4.3%–30.4%; p b 0.001). Mass regression was signiﬁcantly higher
in patients without hypertension, with a median decrease of 25.9% (P25–75: 12.0%–38.7%) vs 5.4% (P25–75:
−12.5%–20.1%; p = 0.001), despite similar increase in effective oriﬁce area and no differences in valvuloarterial
impedance. After 1 year, higher baseline left ventricular mass index (p = 0.005) and the absence of hyperten-
sion (p = 0.002) or diabetes (p = 0.041) were the only independent predictors of mass regression higher
than the median. Comparing with controls, aortic stenosis patients had an increased expression of collagen
types I and III, but only hypertensive patients had higher relative expression of collagen type I vs III. In hyperten-
sive patients TIMP2 expressionwas up-regulated and correlatedwith higher baseline left ventricular mass index
(r = 0.61; p = 0.020).
Conclusions: In aortic stenosis, hypertension impairs mass regression one year after valve replacement, indepen-
dently of total afterload. Differences in the expression of extracellular matrix remodeling genesmight contribute
to this ﬁnding.
© 2013 Elsevier Ireland Ltd. All rights reserved.
1. Introduction
Hypertension (HT) is a common comorbidity in patients with aortic
valve stenosis (AS), with a previously reported prevalence of 33–72%
[1–4].
In chronic pressure overload states, like systemic HT and AS, the left
ventricle (LV) responds with hypertrophy and altered geometry as an
adaptative mechanism that helps to maintain contractile performance
despite abnormal loading conditions. LV hypertrophy (LVH) allows for
normalization of systolic wall stress and has been considered as com-
pensatory [5], but it is also associated with impaired coronary blood-
ﬂow reserve [6] and changes in cardiomyocytes and extracellularmatrix
(ECM) connective tissue, some of them irreversible [7]. Moreover, the
presence of residual hypertrophy after aortic valve replacement (AVR)
has been associated with incomplete recovery of left ventricular func-
tion and worse prognosis [8–10].
The coexistence of hypertension and valvular aortic stenosis (AS) is
common, but few studies have assessed the impact of concomitant hy-
pertension on LV structure and function in patients with AS. Moreover,
althoughwe have evidence of changes in the composition and structure
of ECM in the progression to heart failure in AS [11] and HT [4], there is
no published data comparing the expression of genes regulating ECM
production in patients with both types of pressure overload.
Therefore our aim was to evaluate the importance of HT on LV re-
modeling and LV mass regression in AS patients one year after AVR.
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Additionally, we did a subgroup analysis on myocardial expression of
genes involved in ECM remodeling in aortic stenosis patients with and
without HT, and compared its results with those of a control group.
2. Methods
2.1. Patient selection and follow-up
Between January 2006 and December 2009 we included 141 consecutive patients
over 18 years old with severe symptomatic AS (aortic valve area b 1 cm2 or mean
transaortic gradient ≥ 40 mm Hg) referred for aortic valve replacement (AVR) at the Car-
diothoracic Surgery Department of Hospital São João, Porto, Portugal. This investigation
conforms to the Declaration of Helsinki, had institutional ethical review board approval
and each study participant signed an informed consent before enrolment. We excluded
patients with aortic regurgitation N II/IV or other signiﬁcant valve diseases (Nmild), and
signiﬁcant coronary artery disease (lesions N 50% on coronary angiography). All patients
were in sinus rhythm at the time of inclusion for a more accurate evaluation of diastolic
function parameters. From the initial 141 patients, 135 were considered for this prospec-
tive analysis: one was refused for surgery, other died before surgery from cholangitis with
sepsis, and there was incomplete clinical data in four of them. One year clinical and echo-
cardiographic follow-up was achieved in 91 (67.4%) patients. The remaining patients
were not lost to follow-up, except for two cases, but had echocardiographic evaluation
at 6 months or beyond 1 year and those values were not considered. The diagnosis of
hypertension was considered whenever it was registered in the clinical records of the
assistant physician. Renal insufﬁciencywas determinedwhen estimated glomerularﬁltra-
tion rate (GFR) b60 ml/min/1.73 m2 by the Cockcroft–Gault formula and perioperative
renal failure if there was an increase in serum creatinine N25% the preoperative value.
Medical therapy was at the discretion of assistant physician.
Given the shortage of human myocardial samples in normal adults, for the control
group of the molecular substudy we recruited nine mitral stenosis (MS) patients without
coronary artery disease or signiﬁcant mitral regurgitation and/or aortic valve disease.
These patients had no signiﬁcant left ventricular overload and should have a local expres-
sion of ECM genes more similar to the normal left ventricles.
2.2. Surgical technique and biopsies
All surgeries were performed using standard procedure for aortic or mitral valve re-
placement. The patients were placed on cardiopulmonary bypass and cardiac arrest was
induced and maintained with cold blood cardioplegia. The majority of patients received
a bioprosthesis (73.3%). Two patients also had ascending aorta aneurism and underwent
aortic root replacement with valved composite grafts (Bentall technique). In 32 patients
with AS myocardial biopsies were procured at the time of surgery from the LV interven-
tricular septum. In 9mitral stenosis patients undergoingmitral valve replacement, excised
papillary muscles were collected and used as control myocardial biopsies. In both cases,
excised myocardium was immediately snap-frozen in liquid nitrogen and stored at
−80 °C.
2.3. Echocardiographic studies
Echocardiographic examinationwasperformedby a trained cardiologist and recorded
on digital support. All recordings were examined by an experienced echocardiographer in
an accredited independent echocardiography laboratory (Hospital Clínico San Carlos in
Madrid, Spain) blinded to patient details. Studies were performed using Phillips IE-33
equipment with a S5-1 transducer and M-mode, two dimensional, pulsed, continuous,
color-ﬂow and tissue Doppler capabilities. Correct orientation of imaging planes, cardiac
chamber dimension, function measurements, LV mass index and relative wall thickness
were performed according to the European Association of Echocardiography (EAE)/
American Society of Echocardiography (ASE) recommendations [12]. LV mass index
greater than 115 g/m2 inmen and greater than 95 g/m2 inwomenwas considered indic-
ative of LV hypertrophy. LA volumewasmeasured in LVend systole in the framepreceding
mitral valve opening, using the biplane area lengthmethod and corrected for body surface
area. To evaluate systolic function we used LV ejection fraction (EF), estimated using
Simpson's biplane method, and longitudinal systolic function, assessed by peak systolic
mitral annular motion.
Aortic valve area was estimated using quantitative Doppler by continuity equation.
Mitral inﬂow by pulsed wave Doppler and septal e′ tissue Doppler velocity of the mitral
annulus were obtained from the apical 4-chamber and according to ASE guidelines [13].
Patientswith anE/e′ septalN15were considered to have increasedﬁlling pressure,where-
as patients with E/e′ septal b8 were considered to have normal ﬁlling pressure. In the re-
maining patients with an indeterminate E/e′, those with LAVi ≥34 ml/m2 were
considered to have increased ﬁlling pressure. The presence of increased ﬁlling pressures
was considered indicative of diastolic dysfunction.
Peak wall stress (WS) was estimated using a previously validated formula:
WS = 0.8 × [0.334 × (SAP + MaxG) × LVID] / [PWTd × (1 + (PWTd / LVID)] −
2(×103 dyn/cm2), where SAP = systolic arterial pressure, MaxG = maximal
transvalvular pressure gradient, LVID = LV internal diameter, and PWTd = posterior
wall thickness in diastole [14]. As a measure of global LV load, we calculated the
valvuloarterial impedance: Zva = (SAP + MG) / SVI, where SAP = systolic arterial
pressure, MG = mean transvalvular pressure gradient and SVI = stroke volume index.
Blood pressure was measured before echocardiography with patients in supine position,
and a mean of 3 measurements was considered.
2.4. mRNA quantiﬁcation
For gene expression evaluation, RNAwas extractedwith TriPure (Roche) according to
the manufacturer's instructions. RT-PCR was performed with total RNA, followed by real
time PCRanalyses using theSYBRGreenmethod, in a LightCycler 2.0 (Roche) as previously
described [15]. Results are normalized for GAPDH and expressed in arbitrary unit. Speciﬁc
PCR primer pairs for the studied genes are displayed in Supplementary material.
2.5. Statistical analysis
Categorical variables were expressed as percentages and continuous variables as
mean ± standarddeviation ormedian and interquartile range, according to their distribu-
tion. Continuous variables were compared between groups using an unpaired t-test (for
normally distributed variables) or the Mann–Whitney U-test (for non-normally distribut-
ed variables). For comparison between baseline and follow-up a paired Student's t-test
was applied (normally distributed variables). Chi-square test was used to compare pro-
portions. Spearman's rank correlation was used for the assessment of correlations be-
tween LVM index and its variation and clinical, echocardiographic and molecular
continuous variables. Following univariate analysis, a stepwise binary logisticmultivariate
regressionmodel (Wald backward stepwisemethod, p = 0.05 for covariate inclusion and
0.2 for exclusion)was performed (including potential confounders) for LVM index regres-
sion analysis 1 year after AVR (relative LVM index regression variable was dichotomized
according to its median value:≤14% (no LVM index regression or regression belowmedi-
an value) and N14% (LVM index regression higher than the median).
All reported probability values are two-tailed, and p b 0.05was considered statistical-
ly signiﬁcant. Analyses were performed with the IBM®SPSS® Statistics software package
(version 19.0) (SPSS Inc, Chicago, IL, USA).
3. Results
Demographics and clinical parameters of the 135 patients with se-
vere symptomatic AS are described in Table 1. Heart failure was the
most prevalent presentation feature (81.5%), 72 (53.3%) patients had
echocardiographic evidence of LV diastolic dysfunction and most pa-
tients had LVH (68.1%) with a mean LVM index of 129.6 ± 34.0 g/m2
(Table S1, Supplementary data). Ninety nine cases (73.3%) had a
bioprosthesis implanted (size 21 mm: 46.6%; 23 mm: 27.4%; 25 mm:
14.8%; 19 mm: 10.5%; and 17 mm: 0.7%). The median time of hospital-
ization was 6.0 days (P25–75: 6.0–8.0 days) and 2 hospital deaths oc-
curred (1 from pneumonia and 1 due to stroke). At 1 year follow-up,
there was an increase in the EOA index, decrease in valvuloarterial im-
pedance and peak wall stress (Table S1), and a signiﬁcant median de-
crease in LVM index of 20.6 g/m2 (P25–75: −5.1 g/m2–40.7 g/m2)
with a median relative decrease of 14.2% (P25–75: −4.3%–30.4%;
p b 0.001).
Clinical and echocardiographic comparison between patients with
(HT + AS) and without HT (ASwHT) are described in Tables 1 and 2.
Hypertensive patients were older, had higher surgical risk and were in
higher NYHA class. However there were no differences in AS severity.
One year after aortic valve replacement LVM regression was
signiﬁcantly higher in ASwHT, with a median decrease of 25.9%
(P25–75: 12.0%–38.7%) vs 5.4% (P25–75: −12.5%–20.1%) in
HT + AS (p = 0.001). In ASwHT only 25.6% had LVH at 1 year
follow-up, but, in the presence of associated HT, 56.2% had persistent
LVH (p = 0.003). At this time-point, patients with HT + AS had
higher LVM index (118.9 ± 35.2 vs 101.0 ± 31.3 g/m2; p = 0.042)
when compared with ASwHT, despite similar increase in effective ori-
ﬁce area and similar prosthetic gradients (Table 2). LV reverse remodel-
ing at 1 year was only signiﬁcant in ASwHT (Fig. 1), with a decrease in
LV end-diastolic (92.3 ± 33.0 vs 80.5 ± 29.8 ml, p = 0.019) and
end-systolic (37.2 ± 23.0 vs 28.8 ± 12.3 ml, p = 0.004) volumes and
relative wall thickness (0.48 ± 0.09 vs 0.45 ± 0.08, p = 0.048), with
no change in indexed LA volume (Table 2). In HT + AS there was an
increase in LA volume index, although there were no signiﬁcant
changes in estimated LV ﬁlling pressure (Table 2). As expected, there
was a trend for higher systolic blood pressure in hypertensive patients
(137.6 ± 18.8 vs 130.2 ± 17.1 mm Hg; p = 0.069), but there
were no differences in valvuloarterial impedance (5.30 ± 1.60 vs
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Table 1
Demographics and clinical parameters of studied groups (HT + AS = aortic stenosiswith hypertension;ASwHT = aortic stenosiswithout hypertension; p value for HT + ASvsASwHT).
Clinical characteristics Study group HT + AS ASwHT P
(n = 135) (n = 76) (n = 59)
Baseline
Age 66.7 ± 11.9 69.4 ± 9.1 63.1 ± 14.2 0.004
Women [n (%)] 78 (57.8) 48 (63.2) 30 (50.8) 0.151
BSA (m2) 1.75 ± 0.19 1.76 ± 0.19 1.75 ± 0.18 0.861
Diabetes [n (%)] 27 (20) 14 (18.4) 13 (22) 0.603
Renal Insufﬁciency [n (%)] 46 (34.1) 25 (32.9) 21 (35.6) 0.743
Glomerular ﬁltration rate CKD-EPI (ml/min) 71.6 ± 19.3 69.4 ± 19.2 74.5 ± 19.2 0.141
Euroscore II (%) [Me (P25–P75)] 1.25 (0.75–1.99) 1.39 (0.99–2.19) 0.94 (0.69–1.64) 0.003
Heart Failure [n (%)] 110 (81.5) 68 (89.5) 42 (71.2) 0.007
NYHA class [n (%)] 0.016
I 23 (17) 8 (10.5) 15 (25.4)
II 81 (60) 44 (57.9) 37 (62.7)
III 30 (22.2) 23 (30.3) 7 (11.9)
IV 1 (0.7) 1 (1.3) –
LVH [n (%)] 93 (81.6) 50 (79.4) 43 (84.3) 0.498
Diastolic dysfunction [n (%)] 72 (73.5) 44 (75.9) 28 (70) 0.518
Surgery/perioperatory period
Bioprosthesis (%) 99 (73.3) 59 (77.6) 40 (67.8) 0.202
Atrial ﬁbrilation (%) 28 (22.4) 19 (27.5) 9 (16.1) 0.126
Deﬁnite pacemaker (%) 7 (5.6) 2 (2.9) 5 (8.9) 0.151
Renal failure (%) 25 (20.2) 16 (23.5) 9 (16.1) 0.303
Death (%) 2 (1.6) – 2 (3.5) 0.119
Discharge (days) [Me (P25–P75)] 6 (6–8) 6 (6–8) 6 (6–8) 0.450
Study group HT + AS ASwHT
(n = 91) (n = 48) (n = 43)
1 year
NYHA class [n (%)] 0.019
I 72 (79.1) 34 (70.8) 38 (88.4)
II–III 19 (20.9) 14 (29.2) 5 (11.6)
LVH [n (%)] 38 (51.4) 27 (67.5) 11 (32.4) 0.003
Diastolic dysfunction [n (%)] 48 (72.7) 29 (82.9) 19 (61.3) 0.0496
Current therapy
ACE/ARB [n (%)] 48 (51.6) 30 (60) 18 (41.9) 0.081
Beta blockers [n (%)] 63 (67.7) 34 (68) 29 (67.4) 0.954
Spironolactone [n (%)] 3 (3.2) 3 (6) – 0.103
Diuretics [n (%)] 35 (37.6) 23 (46) 12 (27.9) 0.073
Calcium channel blockers [n (%)] 21 (23.1) 19 (39.6) 2 (4.7) 0.001
Statins [n (%)] 50 (53.8) 28 (56) 22 (51.2) 0.641
Table 2
Echocardiographic characterization of aortic stenosis patients according toHT status, before and after AVR (HT + AS = aortic stenosiswith hypertension; ASwHT = aortic stenosiswith-
out hypertension; p value for baseline vs 1 year).
HT + AS ASwTH
Baseline 1 year p baseline 1 year p
Aortic/prosthesis stenosis severity
Maximal transaortic velocity (m/s) 4.63 ± 0.65 2.69 ± 0.62 b0.001 4.68 ± 0.63 2.64 ± 0.65 b0.001
Medium transaortic gradient (mm Hg) 54.67 ± 15.22 16.73 ± 10.61 b0.001 56.62 ± 14.46 16.23 ± 8.43 b0.001
Effective oriﬁce area index (EOAi, cm2/m2) 0.39 ± 0.12 0.81 ± 0.21 b0.001 0.39 ± 0.1 0.82 ± 0.23 b0.001
% increase EOAi [Me (P25–P75)] 93.5 (71.3–150.3)a 119.6 (57.9–179.1)a
Hemodynamic load
Systolic blood pressure (mm Hg) 135.14 ± 21.69 137.14 ± 17.98 0.647 128.72 ± 20.01 130.67 ± 17.04 0.576
Valvulo-arterial impedance (mm Hg/ml/m2) 6.9 ± 2.57 5.3 ± 1.61 0.006 6.34 ± 1.81 6.16 ± 2.03 0.692
Peak LV wall stress (103 dyn/cm2) 248.89 ± 101.29 175.81 ± 42.97 0.002 211.49 ± 57.78 164.73 ± 37.28 b0.001
Systolic function
EF (%) 59.12 ± 12.28 62.06 ± 10.19 0.099 61.61 ± 9.8 64.42 ± 5.82 0.126
Stoke volume index (ml/m2) 29.13 ± 7.75 30.47 ± 7.03 0.412 31.1 ± 7.99 26.56 ± 6.6 0.031
Systolic velocity mitral annulus (cm/s) 5.51 ± 1.27 6.14 ± 2.11 0.088 5.44 ± 1.41 6 ± 1.31 0.082
Diastolic function
E/A 0.85 ± 0.43 0.97 ± 0.32 0.065 0.84 ± 0.3 1.07 ± 0.52 0.003
E-wave deceleration time (ms) 239 ± 79.83 257.85 ± 75.15 0.262 231.88 ± 68.08 246.06 ± 77.78 0.298
e′ (cm/s) 5.32 ± 2.22 6.24 ± 2.26 0.059 5.59 ± 2.36 6.37 ± 1.89 0.020
E/e′ 16.75 ± 6.72 15.71 ± 5.8 0.333 15.48 ± 6.19 15.23 ± 6.26 0.785
Isovolumetric relaxation time (ms) 104.05 ± 26.82 171.76 ± 196.28 0.042 97.59 ± 26.28 162.76 ± 188.81 0.074
LA volume index (ml/m2) 37.59 ± 12.61 43.81 ± 13.96 0.051 32.66 ± 12.44 32.69 ± 7.18 0.987
a Mann–Whitney U-test, p = 0.692.
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6.15 ± 2.02 mm Hg/ml/m2; p = 0.104) or peak wall stress
(175.8 ± 43.0 vs 164.1 ± 36.8 103 dyn/cm2; p = 0.223). Patients
with HT + AS had a trend for higher rates of prescription of angio-
tensin converting enzyme inhibitors (ACEIs) or angiotensin recep-
tor blockers (ARBs) (62.5% vs 41.8%; p = 0.098), but this medical
therapy had no correlation with one year LVM regression (median
LVM regression with ACE/ARB 12.3% (P25–75: −5.8–25.3) vs
18.9% without (P25–75: −3.7–32.3); p = 0.538).
3.1. Predictors of LVM regression 1 year after AVR
The LVM regression outcome was considered to be relative LVM
index decrease higher than the median (N14%). Baseline LVM index
(p = 0.008) and the absence of HT (p = 0.002) were the only predic-
tors of LVM regression at one year follow-up in univariate binary logistic
analysis. After performing a multivariate logistic analysis, including
potential confounders such as age, gender, diabetes mellitus, baseline
LV ejection fraction, one year valvuloartial impedance, and the use
of ACEI/ARB, the absence of HT (p = 0.002) and diabetes mellitus
(p = 0.041) as well as higher baseline indexed LVM (p = 0.005)
remained the only independent predictors of signiﬁcant LVM regression
(Table 3). Aortic stenosis patients without HT had a 6 fold higher prob-
ability of LV mass regression than patients without HT. ACEI/ARB
prescription had no inﬂuence on LVM regression (Table 3).
4. Correlations between clinical data and myocardial expression of
extracellular matrix remodeling components
We analyzed mRNA expression in the LV of 9 controls and 32 pa-
tients with severe AS, 19 of which also had hypertension (Figs. 2 & 3).
Comparing with controls, patients with AS had signiﬁcantly higher
levels of collagen types I (AS 2.57 ± 0.34 vs CTRL 1.00 ± 0.14;
p b 0.001) and III expression (AS 1.94 ± 0.25 vs CTRL 1.00 ± 0.13;
p = 0.003), with no differences in the expression of CTGF, TGFβ1,
MMP2 or TIMP2. BothHT + AS andASwHThave an increase expression
in collagens type I (HT + AS: 2.88 ± 1.68 vs 1.00 ± 0.14 AU,
p = 0.002; ASwHT: 2.07 ± 1.30 vs 1.00 ± 0.14 AU, p = 0.06) and
type III (HT + AS: 1.71 ± 0.84 vs 1.00 ± 0.13 AU, p = 0.03; ASwHT:
2.36 ± 1.24 vs 1.00 ± 0.13 AU, p = 0.04), but only the HT + AS
have shown signiﬁcant differences in collagen turnover with higher ex-
pression of TIMP2 (1.55 ± 0.63 vs 1.00 ± 0.18 AU; p = 0.047) and a
trend for higher expression of MMP2 (2.28 ± 1.91 vs 1.00 ± 0.20 AU,
p = 0.08). Moreover, the presence of hypertension was associated
with a preponderance of collagen type I vs type III, which was not
seen in ASwHT (collagen I/III in HT + AS: 1.51 ± 0.50 vs 0.99 ± 0.19,
p = 0.03; ASwHT: 1.08 ± 0.67 vs 0.99 ± 0.19, p = 0.76, Fig. 3).
When directly comparing HT + AS with ASwHT, there is an upregula-
tion of TIMP2 mRNA expression in the former (1.55 ± 0.63 vs
0.73 ± 0.36 AU; p = 0.001), which correlates with higher baseline LV
Fig. 1. Left ventricle remodeling before and after AVR (*p b 0.05, **p b 0.01, ***p b 0.001).
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mass index (r = 0.61, p = 0.020), with no differences in the expres-
sion of other studied genes.
5. Discussion
This is a prospective study of patientswith isolated severeAS analyz-
ing the impact of HT on LV mass regression and reverse remodeling.
Overall, baseline LVM index and the absence of HT and DM were the
only independent predictors of LVM regression at one year follow-up.
In addition, we report two major ﬁndings. First, HT impairs LV mass
regression and reverse remodeling after AVR, independently of total
LV afterload. Secondly, the combination of HT with AS is associated
with a different pattern of expression of genes related to ECM remodel-
ing favoring collagen accumulation and higher relative levels of collagen
type I, which could help to explain its negative impact on reverse
remodeling.
Although it was not the objective of this study, we found that the
presence of DM is also a predictor of impaired LVM regression. It is
known that the presence of DM is associated with higher LV mass and
worse systolic function in AS, independently of pressure overload and
gender [16]. Moreover, our group has already described structural
changes in AS diabetic patients with increased ﬁbrosis, advance
glycation end-product (AGE) deposition and raised cardiomyocyte
passive force, which can explain their worse diastolic LV dysfunction
[17]. What is less studied is if it also inﬂuences LV mass regression
after valve replacement, and this should warrant further study.
5.1. HT impact on LV mass regression and reverse remodeling after AVR
After successful AVR, LV pressure and wall stress are signiﬁcantly
reduced (44) and LVH regression is expected. Even so, nearly half of pa-
tientswith AS have residual LVH late after surgery [8,18]. This persistent
increase in LVM is an independent predictor of cardiac-related morbid-
ity [8] and mortality [9,19], making LVM regression a target for achiev-
ing a good outcome.
When investigating hemodynamic factors that inﬂuence LVM re-
gression after AVR, most studies focused solely on pressure gradient
and valve related parameters, but these can only explain a small part
of the observed variability of LV load and LV mass regression [20,21].
In fact, the trigger stimulus for LVH is not pressure gradient itself but
the elevated LV pressure, which also depends on systemic blood pres-
sure [21]. This led some authors to propose combined indices of systolic
load such as the valvuloarterial impedance, which has proven useful for
stratiﬁcation of prognosis in patients with asymptomatic AS [22].
Hypertension and AS frequently coexist. In our study we found a
prevalence of HT of 56.3% and these patients had more severe heart
Table 3
Risk factors for LVM index regression (outcome: LVM index regression N14%): uni- and multivariate logistic regression analysis.
Univariate Multivariatea (n = 70)
Variable p OR [95%CI] p OR [95%CI]
Gender, male 0.231 1.79 [0.69–4.65]
age, 1 year increase 0.488 0.99 [0.95–1.03]
HT, without 0.002 4.79 [1.70–13.19] 0.002 6.19 [1.93–19.88]
DM, without 0.152 2.4 [0.72–7.95] 0.041 4.45 [1.06–18.66]
LV mass index, 1 g/m2 increase 0.008 1.02 [1.01–1.04] 0.005 1.03 [1.01–1.06]
Valvulo-arterial impedance (1 year), 1 mm Hg/ml/m2 increase 0.152 1.27 [0.92–1.75]
EF baseline, 1% increase 0.560 0.99 [0.94–1.03]
ACE/ARB, without 0.260 1.77 [0.65–4.82]
Area under the curve (ROC curve) 0.821 [0.721–0.922]
% of correctly predicted outcome 75.70%
a Variable(s) entered on step 1: gender (male), age, hypertension (without HT), diabetes (without DM), baseline left ventricular mass index, baseline ejection fraction, one year
valvuloarterial impedance, one year use of ACEI (without).
Fig. 2. Myocardial expression of collagen types I (A; ***p b 0.001 vs CTRL e p = 0.06 vs CTRL) and III (B; *p b 0.05, **p b 0.01 vs CTRL), connective tissue growth factor (CTGF, C),
transforming growth factor-β1 (TGF-β1, D), matrix metaloprotease-2 (MMP2, E) and MMP2 speciﬁc tissue inhibitor (TIMP2, F). HT + AS = aortic stenosis with hypertension;
ASwHT = aortic stenosis without hypertension.
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failure symptoms when compared to non-hypertensive AS patients
with the same echocardiographic parameters of AS severity.
Data on systemic blood pressure before and after AVR is absent in
most studies on incomplete LVH regression and only recently some au-
thors have reported its relation to postoperative LVM [23–26]. In a ret-
rospective observational study with 79 pure AS patients, the only
independent predictors of postoperative LVM index were preoperative
LVM and postoperative systolic blood pressure (deﬁned as normal if
b130 mm Hg) [23]. Uncontrolled hypertension was not only related
to higher LVM after AVR but also with worse survival, with higher inci-
dence of heart failure and bleeding as causes of death [26]. These obser-
vations resulted in a general recommendation for strict blood pressure
control after AVR [23,26].
What is less understood is if the existence of HT per se can inﬂuence
LVM regression even under similar load conditions. Our results suggest
that HT blunts LVM normalization and reverse remodeling after AVR for
isolated AS independently of load. As expected, there was a trend for
higher systolic blood pressure in hypertensive patients, but the total
LV afterload, evaluated by valvuloarterial impedance, that takes into ac-
count systolic blood pressure, prosthetic gradient and stoke volume,
was not signiﬁcantly different between patients with and without HT.
One can speculate that this could be due to the systemic nature of hy-
pertensive disease, with a generalized neurohumoral activation, with
particular focus on the renin–angiotensin–aldosterone system (RAAS)
and sympathetic nervous system (SNS), which directly promote
myocyte hypertrophy and matrix deposition independently of their ef-
fects on systemic arterial pressure [27]. These same factors, promote
both hypertension and LVH and there is the possibility that increased
blood pressure is the consequence, rather than the cause, of LVH and as-
sociated vascular structural changes. Data from the Framingham Heart
Study demonstrated a direct and continuous relationship between
LVM and the subsequent development of hypertension in previously
normotensive subjects [28]. Also, in a study in young healthy subjects,
plasma angiotensin II was an independent predictor of LVM and its ef-
fect was independent of systolic blood pressure and body size [29].
Moreover, the magnitude of LVH regression achieved by inhibiting the
RAAS and SNS is greater than that produced by comparable BP reduction
alone [30]. All this data supports the hypothesis that neuroendocrine
mechanisms are important in the regression of LVH, independently of
blood pressure.
5.2. HT and extracellular matrix remodeling in AS
In chronic pressure overload, the development of LVH is simulta-
neous with remodeling of the ECMwith progressive interstitial ﬁbrosis,
reduced ventricular compliance and diastolic dysfunction [7,31,32].
Altered levels of matrix metalloproteinases (MMPs) and their speciﬁc
tissue inhibitors (TIMPs) are crucial in remodeling of the ECM during
LV hypertrophy and in the failing heart [33,34].
In LVH associated with AS, there is an increased in collagen produc-
tion and inhibition of collagen degradation [11,35,36]. When compared
with controls, myocardial biopsies of our AS patients have higher colla-
gen synthesis, in accordancewith previous reports [11,35]. The levels of
MMPs and their inhibitors (TIMPs), however, were not different in the
total study group vs controls. In the literature results in the MMP and
TIMP expression in AS are variable [11,36], but their balance is always
favoring decreased ECM degradation.
In isolated hypertension, a growing number of studies have shown
imbalanced MMP activity, conﬁrming ﬁndings obtained with animal
models [37]. Most of these studies have concentrated on circulating
levels ofMMPs and TIMPs and a considerable number of themhave pro-
vided inconsistent results [38–43]. What is not well established is if the
coexistence of HT and AS can inﬂuence MMP/TIMP balance.
To the best of our knowledge this is the ﬁrst report on themyocardi-
al expression of MMPs and their tissue inhibitors in combined HT and
AS. In our study only HT + AS patients have an upregulation of TIMP
2 and an increase in collagen type I/type III ratio, suggesting a shift
towards collagen accumulation and a stiffer form of collagen mesh-
work. When comparing patients with and without hypertension, it
becomes clear that collagen degradation seems to be more impaired
in HT + AS given the higher levels of TIMP2 expression and this ﬁnding
is accompanied by higher levels of LVM index.
6. Study limitations
Although our study is hypothesis generating, it has some limitations:
(1) Our evaluationwas doneoneyear after AVR because in the literature
signiﬁcant LVM regression is maximal after the ﬁrst year, and has only a
non-signiﬁcant slight decrease after 18 months to 10 years [25,44,45].
To know if HT deﬁnitely impairs LV mass regression or if it only makes
it slower a longer follow-up period is needed. (2) At follow-up blood
pressure values were determined only at ofﬁce visit. Given blood pres-
sure values are labile, for a more accurate evaluation of the impact of
blood pressure on the hypertrophic response, it would have been im-
portant to have more determinations at other time points. (3) Medical
therapy, namely ACEI/ARB, was prescribed in a non-randomized man-
ner and can be a cause of bias. (4) The small number of patients enrolled
may have precluded the identiﬁcation of other factors inﬂuencing LVM
regression besides baseline LVM, HT and DM. (5) Moreover, the molec-
ular substudy included only 32 AS patients and had no statistical power
to ﬁnd correlations between ECM gene expression and clinical and
echocardiographic data.
7. Conclusions
Our results, showing that HT in AS is associated with ECM remodel-
ing favoring collagen deposition and higher LVM, togetherwith the neg-
ative impact of HT on LV mass regression and reverse remodeling after
AVR, gives strength to the concept of modulation of the RAAS system in
AS, particularly if HT is also present. Therefore, therapeutic intervention
with antagonists of the RAAS is very appealing, especially considering
the pro-hypertrophic and pro-ﬁbrotic effects of angiotensin II. New
and large scale randomized clinical trials, includingmorbidity andmor-
tality endpoints, are needed to establish the role of RAAS blockade after
AVR.
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5.5 Prognostic implications of fibrosis in low risk aortic stenosis patients
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Abstract
Background: Among aortic stenosis (AS) patients, interstitial fibrosis has been associated with the 
progression to heart failure and is a marker of worse prognosis.
Objectives: We aimed to evaluate the impact of myocardial fibrosis on clinical events after aortic 
valve replacement (AVR) in low risk severe AS.
Methods: We prospectively followed 56 severe AS patients with ejection fraction (EF) >40%, who 
underwent AVR with simultaneous myocardial biopsies and collagen volume fraction (CVF) determi-
nation. Mean follow-up was 5±2 years. Outcomes were all-cause death and the combined endpoint 
of all-cause death or non-fatal cardiovascular hospitalization after 8 years of follow-up.
Results: Patients’ mean age was 66±12 years, 67.9% women, mostly mildly symptomatic (NYHA 
class II:76.8%), They had low risk of operative mortality  (Euroscore II:1.5±1.0%), and EF was normal 
or mildly compromised (EF:63.7±7.6%). At follow-up, there was a significant decrease in transaor-
tic gradients and wall stress, as well as regression in indexed LV mass (LVMI). Mean value of CVF 
was 16.9±13.5%. There were 7 deaths (12.5%) and 4 non-fatal cardiovascular hospitalizations (7.1%). 
Baseline clinical characteristics, aortic stenosis severity, LVMI and EF, were similar between patients 
with or without an event. Patients who suffered a fatal event or the combined endpoint had higher 
degree of fibrosis (27.1±20.7% vs 15.4±11.8%, p=0.035; 24.0±18.2% vs 15.3±12.0%, p=0.038, respec-
tively). Patients with CVF≥15.4% had lower survival (37.5% vs 97.0%, p=0.001) and survival free of the 
combined endpoint (0 vs 91.2%, p<0.001). On Cox regression analysis, CVF was the only independent 
predictor of all-cause death (HR1.88; 95%CI:1.08-3.29 for 10% increase; p=0.026) and all-cause death 
or cardiovascular hospitalization (HR1.73; 95%CI:1.03-2.911 for 10% increase; p=0.038).
Conclusions: In low risk AS patients, higher levels of fibrosis are independent predictors of all-cause 
death and the composite of all-cause death and non-fatal cardiovascular hospitalization. Further ad-
vances on anti-fibrotic therapies in the setting of AS are needed.
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Introduction:
In chronic pressure overload states, like systemic hypertension (HT) and AS, the left ventricle (LV) responds 
with hypertrophy and altered geometry as an adaptive mechanism that helps to maintain contractile 
performance despite abnormal loading conditions.  Concomitantly,  there are changes in cardiomyocytes 
and extracellular matrix connective tissue, some of them irreversible, which may help to explain the 
deterioration of diastolic and systolic function that take place after longstanding overload 1. 
Aortic valve replacement increases long-term survival, which becomes similar to age-matched popu-
lation, reduces symptoms and improves quality of life in patients with aortic valve stenosis 2, 3. Late 
outcome after AVR depends mainly on the stage of heart disease before surgery, prosthetic related 
complications, and co-morbidities. 
At histopathological level, fibrosis has been implicated in the progression from the compensate 
phase to heart failure 4 and those with higher grades of fibrosis have more severe myocardial disease 
and lower long-term survival rates 5, 6.
Our aim was to determine if fibrosis levels, in patients with severe aortic stenosis but milder forms 
of remodeling and EF >40%, had any impact in long-term clinical outcomes.
Methods: 
Patient selection and follow-up
Between January 2006 and December 2009 we included consecutive patients over 18 years old with 
severe symptomatic AS (aortic valve area <1 cm2 or mean transaortic gradient ≥40 mmHg) referred for 
aortic valve replacement (AVR) at the Cardiothoracic Surgery Department of Centro Hospitalar São João, 
Porto, Portugal. We excluded patients with aortic regurgitation > II/IV or other significant valve diseases 
(> mild), significant coronary artery disease (lesions > 50% on coronary angiography), ejection fraction ≤ 
40%, or previous cardiac surgery. All patients had to be in sinus rhythm at the time of inclusion.  From the 
initial 141 patients included in a prospective cohort, at time of AVR, 56 random patients were submitted 
to myocardial biopsies for collagen volume fraction evaluation and were considered for this prospective 
analysis. Clinical and echocardiographic follow up was achieved in all patients. Mean clinical follow-up 
was 5.0±2.2 years and mean final echocardiographic follow-up was 4.0±1.8 years.
The diagnosis of hypertension was performed by the clinical records of the assistant physician. Renal 
insufficiency was determined when creatinine clearance <60 ml/kg by the Cockcroft-Gaul formula.
Clinical endpoints were defined as all-cause death and a composite of all-cause death or non-fatal 
cardiovascular hospitalization (for heart failure, myocardial infarction, stroke, new-onset atrial fibril-
lation or advanced AV block requiring hospitalization). 
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Surgical technique 
All surgeries were performed using standard procedure for AVR. The patients were placed on car-
diopulmonary bypass and cardiac arrest was induced and maintained with cold blood cardioplegia. 
The majority of patients received a bioprosthesis (64.3%) and prosthesis sizes used were <21 mm 
in 12.5%, 21 mm in 39.3%, 23 mm in 32.1% and 25 mm in 16.1%. At the time of surgery, patients 
underwent myocardial biopsies  from the LV interventricular septum.
Echocardiographic studies
Echocardiographic examination was performed by a trained cardiologist and recorded on digital 
support. All recordings were examined by an experienced echocardiographer in an accredited in-
dependent echocardiography laboratory (Hospital Clínico San Carlos in Madrid, Spain) blinded to 
patient details. Studies were performed using Phillips IE-33 equipment with a S5-1 transducer and 
M-mode, two dimensional, pulsed, continuous, color-flow and tissue Doppler capabilities. Correct 
orientation of imaging planes, cardiac chambers dimensions and function measurements were 
performed according to the European Association of Echocardiography (EAE)/American Society of 
Echocardiography (ASE) recommendations 7.
LV mass was estimated according to the joint recommendations of the ASE and EAE using Devereux’s 
formula for ASE measurements in diastole: LV mass=0.8 x (1.04 x [LV internal dimension + posterior wall 
thickness + interventricular septal thickness]3 – [LV internal dimension]3) + 0.6 g 7. Left ventricular hyper-
trophy was defined by LV mass index greater than 115 g/m2 in men and greater than 95 g/m2 in women. 
Relative wall thickness (RWT) was calculated for the assessment of LV geometry using the formula 
2x posterior wall thickness/ LV diastolic diameter. Increased RWT was present when this ratio was 
greater than 0.427. LA volume was measured in LV end systole in the frame preceding mitral valve 
opening. The volume was measured using the biplane area length method and corrected for body 
surface area. Aortic valve area was estimated using quantitative Doppler by continuity equation. 
Mitral inflow was assessed in the apical 4-chamber view using pulsed wave Doppler with the sample 
volume placed at the tips of mitral leaflets during diastole. From the mitral inflow profile, the peak 
flow velocity of early filling (E wave), peak flow velocity of atrial contraction (A wave), the E/A ratio, 
and early filling deceleration time (DT) were measured. Doppler tissue imaging (DTI) of the mitral 
annulus was obtained from the apical 4-chamber using a sample volume placed in the septal mitral 
valve annulus. The peak systolic annular velocity (Sm) and early diastolic septal velocity (e’) was 
determined, and the E/e’ ratio was derived. 
As a measure of global LV load, we calculated the valvuloarterial impedance: Zva =(SAP+ MG)/SVI, 
where SAP is the systolic arterial pressure and MG is the mean transvalvular pressure gradient and 
SVI is stroke volume index 8.
107
RESULTS
Histological determination of fibrosis
Light microscopic quantification of fibrosis has previously been described and validated 9. Fibrosis 
analysis of myocardial biopsies was performed using picrosirius-red–stained, 4-μm-thick-sections 
of tissue (± 5 sections of each sample). Images of these sections were acquired with a projection 
microscope (x50). Subsequent image analysis with Slidebook 4.0 software (3I, Denver, Colo) was 
performed to determine the extent of reactive interstitial fibrosis, which was expressed as collagen 
volume fraction (%). Areas of reparative and perivascular fibrosis were excluded. Myocardial fibrosis 
was calculated as the sum of all connective tissue areas divided by the sum of connective tissue and 
muscle areas averaged over 4 to 6 representative fields of the section in 18 male and 38 female AS 
patients. In our laboratory, normal values of fibrosis for LV myocardial biopsy material is 5.4±2.2%.
Statistical analysis
Categorical variables were expressed as percentages and continuous variables as mean±standard 
deviation unless otherwise specified. Continuous variables were compared between groups using 
an unpaired t-test (for normally distributed variables) or the Mann–Whitney U-test (for non-normally 
distributed variables). For comparison between baseline and follow-up a paired Student’s t-test was 
applied or a Wilcoxon test (for non-normally distributed variables). Chi-square test (or Fisher exact 
test) was used to compare categorical variables. Univariable binary logistic regression models (Wald 
method, p=0.05/0.20 for covariate inclusion/exclusion) were used in conjunction with the area under 
the curve (ROC) to assess the best cutoff-point (highest sensibility and specificity) of a continuous 
variable to predict a particular outcome of all-cause death and all-cause death and cardiovascular hos-
pitalization. The Kaplan-Meier and Cox models were used to evaluate survival times after surgery for 
all-cause death, for non-fatal cardiovascular hospitalization, and for all-cause death and cardiovascular 
hospitalization, and the log-rank test was used to compare survival curves. All reported probability 
values are two-tailed, and P<0.05 was considered statistically significant. Analyses were performed 
with the IBM® SPSS® Statistics software package (version 22.0) (SPSS Inc, Chicago, IL, USA).
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Results
Patients were mainly women (67.9%) and mean age was 66.3±11.5 years (table 1). They had severe 
aortic stenosis (aortic valve area of 0.41±0.13 cm2), the majority were mildly symptomatic (NYHA 
class II in 76.8%), had low risk of operative mortality (mean Euroscore II of 1.5±1.0%), and global sys-
tolic function was normal or mildly compromised,  with a mean LV ejection fraction (EF) of 63.7±7.6% 
(3 patients had EF<50 % and the minimum was 42.7%).
Table 1: Clinical characterization of aortic stenosis patients. 
n=56
Sex (Female) [n (%)] 38 (67.9%)
Age 66.3±11.5
BSA 1.7±0.2
Euroscore II 1.5±1.0
HT [n (%)] 27 (48.2%)
DM [n (%)] 10 (17.9%)
CKD [n (%)] 22 (39.3%)
GFR (ml/min) 66.2±20.8
NYHA≥3 [n (%)] 13 (23.2%)
LVH basal [n (%)] 47 (83.9%)
LVH final [n (%)] 24 (47.1%)
BSA= body surface area; HT= hypertension; DM= diabetes mellitus; CKD= chronic kidney disease; GFR= glomerular filtration rate; NYHA= functional class of New 
York Heart Association; LVH= left ventricle hypertrophy. Results are presented as mean± standard deviation unless otherwise noted.
In final echocardiographic evaluation, performed 4.0±1.8 years after surgery, patients experienced a 
significant decrease in transaortic gradients and wall stress, as well as regression in indexed LV mass 
(LVMI) (table 2). The median absolute and relative decrease in LVMI was 20.9 g (P25-75: 1.0-39.9 g) 
and 17.2% (P25-75: 1.0-26.9%), respectively.
Mean value of collagen volume fraction (CVF), evaluated at the time of surgery, was 16.9±13.5% 
(median 12.8%, P25-75: 7.7-18.8%). There was no correlation between CVF and preoperative LVMI, 
LV diameters or volumes, relative wall thickness or EF. Although patients in NYHA class ≥ III before 
surgery had higher levels of myocardial fibrosis, this difference was not statistically significant (CVF 
21.2±15.8% vs 15.6±12.7%, p=0.327). When comparing final with baseline NYHA class, patients with 
functional improvement after AVR had lower values of CVF at the time of surgery (11.5±9.3% vs 
17.3±8.4%, p=0.036) (Fig.1).
Collagen volume fraction (CVF) was higher in patients with persistence of left ventricular hypertro-
phy (LVH) late after aortic valve replacement (20.0±14.6% vs 13.2±11.5%, p=0.027).
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Table 2: Baseline and final echocardiographic characterization of aortic stenosis patients. 
Basal Final p
LV geometry
Interventricular septum (cm) 1.45 ±0.26 1.27 ±0.23 <0.001
Posterior wall (cm) 1.08 ±0.18 1.02 ±0.17 0.033
Relative wall thickness 0.47 ±0.1 0.45 ±0.09 0.126
LV mass index (g/m2) 129.5 ±31.9 109.8 ±30.8 0.000
LV end-systolic volume index (ml/m2) 17.8 ±7 18.5 ±8.8 0.779
LV end-diastolic volume index (ml/m2) 48.2 ±12.5 49.4 ±17.2 0.819
Aortic/Prosthesis stenosis severity
Maximal transaortic velocity (cm/s) 472.4 ±69.8 263 ±73.6 <0.001
Maximal transaortic gradient (mmHg) 89.6 ±26.2 29.4 ±17.6 <0.001
Medium transaortic gradient (mmHg) 54.7 ±16.5 16.1 ±8.7 <0.001
Effective orifice area index (cm/m2) 0.41 ±0.13 0.86 ±0.27 <0.001
Increase effective orifice area (%) 124.5 ±83.3
Hemodynamic load
Valvuloarterial impedance (mm Hg/ml/m²) 6.6 ±2.6 5.8 ±2.3 0.072
Peak LV wall stress (dynes/cm2) 227.1 ±89.6 168.3 ±41.6 0.005
Systolic function
Ejection fraction (%) 63.7 ±7.6 64.3 ±6.9 0.525
Systolic annular velocity (cm/s) 5.53 ±1.11 6.01 ±1.10 0.159
Values are mean±SD unless otherwise indicated. 
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Fig. 1  Levels of collagen 
volume fraction (CVF) 
in patients according to 
improvement in NYHA class 
after AVR. 
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Clinical outcomes
At the end of 5.0±2.2 years of follow-up, there were 7 deaths (12.5%) and 4 non-fatal cardiovascular 
hospitalizations (7.1%, 2 patients for heart failure, 1 for de novo atrial fibrillation and 1 for biologic 
prosthesis dysfunction). 
Table 3: Baseline characterization according to the occurrence of all-cause death or non-fatal 
cardiovascular hospitalization. 
All-cause death or non-fatal cardiovascular hospitalization
No (n=46) Yes (n=10) p
Sex (Female) [n (%)] 30 (65.2%) 8 (80.0%) 0.474
Age 64.7±11.6 73.8±8.0 0.260
Euroscore II 1.58±0.74 1.15±0.18 0.414
HT [n (%)] 21 (45.7%) 6 (60.0%) 0.497
DM [n (%)] 8 (17.4%) 2 (20.0%) 1.000
CKD [n (%)] 17 (37.0%) 5 (50.0%) 0.490
GFR (ml/min) 59.0±16.8 79.4±30.3 0.293
NYHA≥3 [n (%)] 10 (21.7%) 3 (30.0%) 0.682
LVH basal [n (%)] 38 (82.6%) 9 (90.0%) 1.000
LVH final [n (%)] 17 (37.0%) 7 (70.0%) 0.042
LV geometry
LV end-diastolic diameter index (cm/m2) 2.66±0.38 2.65±0.29 0.563
LV end-systolic diameter index (cm/m2) 1.76±0.28 1.63±0.12 0.078
Relative wall thickness 0.46±0.10 0.43±0.01 0.422
LV mass index (g/m2) 120.6±34.5 119.1±8.5 0.684
LV end-diastolic volume index (ml/m2) 48.7±12.2 26.6±5.2 0.147
LV end-systolic volume index (ml/m2) 19.2±6.7 8.4±1.0 0.095
Aortic/Prosthesis stenosis severity
Maximal transaortic velocity (cm/s) 456.4±58.9 500.1±85.8 0.283
Effective orifice area index (cm/m2) 0.38±0.11 0.41±0.05 0.974
Hemodynamic load
Valvuloarterial impedance (mm Hg/ml/m²) 6.7±1.6 10.1±3.5 0.404
Peak LV wall stress (dynes/cm2) 227.3±51.7 241.1±52.4 0.699
Diastolic function
E/A 0.77±0.26 1.03±0.64 0.181
e’ 5.2±1.7 5.1±1.9 0.836
E/e’ 17.6±6.3 21.8±0.35 0.240
Systolic function
Ejection fraction (%) 61.0±7.9 68.3±2.3 0.330
Systolic annular velocity (cm/s) 5.37±1.13 4.38±0.56 0.031
Collagen volume fraction (%) 24.0±18.2 15.3±12.0 0.038
HT= hypertension; DM= diabetes mellitus; CKD= chronic kidney disease; GFR= glomerular filtration rate; NYHA= functional class of New York Heart Association; 
LVH= left ventricle hypertrophy. Results are presented as mean± standard deviation unless otherwise noted.
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Patients with an event (all-cause death or cardiovascular hospitalization) had no significant differences 
in baseline clinical characteristics (table 3) comparing with those without events. In preoperative echo-
cardiogram, these patients had worse longitudinal function, with a lower value of peak systolic annular 
velocity (Sm) (table 3), and no differences in aortic stenosis severity, LV mass or ejection fraction.
There was a positive association between the level of fibrosis, evaluated by CVF, and clinical out-
comes (Fig.2). Patients who died had significantly higher degree of fibrosis at the time of surgery 
(27.1±20.7% vs 15.4±11.8%, p=0.035), and the same trend was observed for non-fatal cardiovascu-
lar hospitalization (24.8±17.7% vs 6.7±3.2%, p=0.114). Myocardial fibrosis levels were also higher 
in those with the composite outcome of all-cause death or non-fatal cardiovascular hospitalization 
(24.0±18.2% vs 15.3±12.0%, p=0.038).
After multivariate Cox regression analysis, CVF was the only independent predictor of all-cause death 
(HR 1.88; 95%CI:1.08-3.29, for each 10% increase; p=0.026) and all-cause death or cardiovascular hos-
pitalization (HR 1.73; 95%CI:1.03-2.911, for each 10% increase; p=0.038) (table 4). 
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Fig. 2. Levels of collagen volume fraction 
(CVF) in patients with clinical outcomes. A- 
all-cause death, B- non-fatal cardiovascular 
hospitalization, C- all-cause death or non-fatal 
cardiovascular hospitalization.
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RESULTS
Kaplan-Meier survival analysis
A cut-off of 15.4% for CVF was used to calculate survival probability free of events. This value was cho-
sen after ROC curve analysis to assess the best cutoff-point of CVF to predict the outcome of all-cause 
death (AUC 0.75, p=0.036) and all-cause death and cardiovascular hospitalization (AUC 0.92, p= 0.038). 
Comparative characteristics of patients with CVF ≥15.4% vs CVF <15.4% can be seen in tables 5 and 
6. Patients with CVF ≥15.4% had lower probability of survival free of all-cause death (37.5% vs 97.0%, 
p=0.001), non-fatal cardiovascular hospitalization (84.4% vs 94.1%, p=0.018) and the composite of all-
cause death or non-fatal cardiovascular hospitalization (0% vs 91.2%, p<0.001) (Fig. 3).
Table 5: Clinical characterization according to the value of collagen volume fraction (CVF). 
CVF ≥15.4% CVF <15.4% p
Sex (Female) n (%) 16 (76.2%) 22 (62.9%) 0.301
Age (year) 68.4±11.3 65.1±11.8 0.297
BSA 1.7±0.2 1.8±0.2 0.799
Euroscore II (%) 1.9±1.4 1.4±0.7 0.182
HTA n (%) 11 (52.4%) 16 (45.7%) 0.629
DM n (%) 6 (28.6%) 4 (11.4%) 0.152
CKD n (%) 10 (47.6%) 12 (34.3%) 0.323
GFR (ml/min) 61.2±20.7 69.3±20.6 0.130
NYHA≥3 n (%) 7 (33.3%) 6 (17.1%) 0.201
LVH basal n (%) 19 (90.5%) 28 (80%) 0.459
LVH final n (%) 13 (72.2%) 11 (33.3%) 0.008
BSA= body surface area; HT= hypertension; DM= diabetes mellitus; CKD= chronic kidney disease; Cr clear= creatinine clearance; GFR= glomerular filtration rate; 
NYHA= functional class of New York Heart Association; LVH= left ventricle hypertrophy. Results are presented as mean± standard deviation unless otherwise
Patients with residual LVH after surgery had a lower survival free of a combined event (all-cause 
death or non-fatal cardiovascular hospitalization), when compared with those with normal LVM 
(70.8% vs 92.6%, p=0.037) (Fig. 4). Moreover, patients with Sm of <4.9 cm/s had significantly worse 
survival (81.6% vs 100.0%, p=0.021) and worse survival free from death or non-fatal cardiovascular 
hospitalization (55.8% vs 96.3%, p=0.017; AUC 0.77, p=0.027) (Fig. 5). 
Discussion
We found that, in our low risk cohort of patients with severe AS, higher levels of fibrosis have a 
negative prognostic impact with lower survival free of all-cause death or the composite of all-cause 
death or non-fatal cardiovascular hospitalization. Moreover, it was a predictor of events, independent 
of other well established prognostic factors such as EF, age, baseline LVMI or NYHA class. For our 
patients, a cut-off value of 15% of CVF had a good performance as a predictor of clinical events.
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RESULTS
Others have already described the prognostic importance of myocardial fibrosis (MF) in aortic steno-
sis, either using histological assessment or noninvasive evaluation by cardiovascular magnetic reso-
nance (CMR) with late gadolinium enhancement (LGE) 5, 6,10-12. However, most of these studies have 
analyzed patients with worse preoperative NYHA class and more advanced forms of myocardial 
disease when compared with our cohort. Patients usually had lower values of EF, higher LV volumes 
and dimensions and higher levels of histological interstitial fibrosis, suggesting more extensive re-
modeling 5, 6, 10. Likewise, the inclusion of aortic regurgitation patients 5 or the coexistence of other 
cardiovascular comorbidities, such as atrial fibrillation and coronary artery disease 10, 12, which were 
excluded in our study, may have influenced outcomes.
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Fig. 3 Amount of collagen volume fraction (CVF) 
and long-term survival free of events after aortic 
valve replacement.
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Milano and coworkers6 have performed a very similar study in a group of 99 patients with AS in 
which fibrosis was calculated from myocardial biopsies obtained during surgery. In their retrospec-
tive analysis, 10 years survival rate was lower in patients with severe fibrosis (defined as fibrous in-
dex > 50%) and no significant improvement in NYHA class was seen in this the group. We also found 
worse long-term survival and lesser NYHA class improvement in those with more severe fibrosis, 
but ours was a prospective study and our cut-off was much lower. According to Milano and cowork-
ers’ criteria (no or mild fibrosis if < 20% and moderate fibrosis if 20-50%), most of our patients would 
have been included in the group with mild fibrosis. This can help to explain why our patients with 
higher level of fibrosis have less ventricular remodeling and dysfunction (only 9.5% of those with 
CVF ≥15.4% have EF<50%) comparing with their group with moderate or severe fibrosis. Moreover, 
not surprisingly, we didn´t find a significant correlation between fibrosis level and LV diameters, RWT 
or EF, which was described in the aforementioned work. It is expected for these correlations to be 
stronger in more severe grades of fibrosis. Even with lesser severe form of myocardial disease, we 
could still find an increase in events in our AS patients with increasing levels of fibrosis.
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Fig. 4  Residual left ventricular hypertrophy 
(LVH) and long-term survival free of events after 
aortic valve replacement.
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RESULTS
Myocardial fibrosis in aortic stenosis
Fibrosis is an early morphological alteration in patients with AS and has been pointed as one of the 
reasons for impaired LVH regression after AVR 13. Once established, fibrosis is a major determinant of 
diastolic and systolic dysfunction and it is one of the structural substrates for arrhythmogenicity, thus 
playing a major role for sudden death and the progression of HF 4, 14. While myocyte hypertrophy is 
dependent on load, fibrosis seems also to be regulated by non-hemodynamic factors such as neuro-
hormones 15.
In LVH associated with aortic stenosis, there is an increased production of collagen and a shift towards 
inhibition of collagen degradation 16-18. When compared with controls, myocardial biopsies of aortic 
stenosis patients have higher expression of collagens and an up-regulation of TIMP 1 and 2 mRNA, 
favoring inhibition of collagen degradation, which significantly correlates with the degree of fibrosis 
18. Experimental studies have described total regression of MMP and TIMP gene expression as well 
as an association between changes in LVMI and MMP/TIMP gene expression after corrective surgical 
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replacement
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therapy and LV hypertrophy regression 19. The renin-angiotensin-aldosterone (RAA) system seems to 
be a key factor in this process. Mechanical stretch induces local production of angiotensin II, which in 
turn stimulates the release of multiple growth factors and cytokines from cardiac fibroblasts that act 
in an autocrine and paracrine fashion, affecting the progression of hypertrophy and remodeling 20-22.
Non invasive assessment of myocardial fibrosis 
The noninvasive evaluation of the level of myocardial fibrosis has been object of several studies, 
using surrogate echocardiographic parameters or cardiac resonance LGE technic.
CMR imaging using LGE allows for noninvasive evaluation of replacement fibrosis and it has been 
shown that, in moderate and severe AS, specific patterns like midwall fibrosis are associated with 
a more advanced hypertrophic response and increase mortality 12. Late gadolinium enhancement is 
usually associated with more advanced forms of myocardial disease, worse systolic function and 
higher LV end-diastolic volumes 23, 24, and, therefore, worse prognosis 5. But LGE has the limitation 
of only identifying regional differences in replacement myocardial fibrosis, and can miss diffuse 
interstitial fibrosis, which is an earlier event in disease progression. However, the more recent CMR 
contrast-enhanced T1 mapping enables detection of this kind of fibrosis and its prognostic value 
is being tested in a prospective observational study in patients with AS (The Role of Myocardial 
Fibrosis in Patients with Aortic Stenosis, NCT01755936). 
In severe AS, the degree of myocardial fibrosis is crucial in the transition from compensated hyper-
trophy to heart failure 4. With worsening of fibrosis, LV filling pressures increase and, later on, EF 
decreases. However, EF is reduced only in end-stage disease since it is related with global radial 
function 25 and fibrotic changes in AS hypertrophic hearts are initially subendocardial and affect basal 
segments (where regional wall stress is highest). This will impact mainly longitudinal function, which 
is not well represented by ejection fraction 11. Mitral ring displacement and strain imaging seem to 
have overcome EF limitations in evaluation of early changes in systolic function. In a recent study, 
in patients with symptomatic AS and severe fibrosis, radial function was relatively preserved, while 
mitral ring displacement, a surrogate of overall longitudinal function of the septum, was reduced and 
predicted functional improvement11. Furthermore, using strain imaging, evidence of subclinical sys-
tolic LV dysfunction with decreased LV strain and strain-rate (radial, circumferential, and longitudinal) 
can be seen in patients with severe AS and preserved LVEF 26. 
In our study we used peak systolic annular velocity (Sm) to evaluate longitudinal function and found 
that patients with Sm <4.9 cm/s had worse survival and survival free of death or non-fatal cardiovas-
cular hospitalization. Our data support the prognostic importance of evaluating early parameters of 
systolic function in AS.
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Limitations
This was a single center study and the small size of our cohort can have precluded the identification 
of other predictors of clinical events. Moreover, the limited number of events in our study can result 
in overfitted multivariate model. These  limitations have been described by other groups with pub-
lished results on this topic and who have included similar sample sizes. Obtaining biologic samples 
for histological analysis and conducting prospective studies with long-term follow-up can be chal-
lenging and only overcome by multicentric collaboration.
Conclusions
We have confirmed the prognostic relevance of myocardial fibrosis in severe AS, and extended this 
evidence to low risk patients with a less severe form of myocardial remodeling. Fibrosis is an omi-
nous sign in AS in the continuous of myocardial structural changes and should be actively sought 
for risk stratification, not only in asymptomatic patients with preserved ejection fraction, but also in 
symptomatic patients undergoing AVR. After AVR, the use of additional medical therapy modulating 
the RAA system in patients with non-invasive evidence of fibrosis  should be tested in large-scale 
randomized trials.
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Abstract
Background: Transcatheter aortic valve implantation (TAVI) is an alternative to surgical aortic valve replacement
(SAVR) in patients with aortic stenosis (AS) and high surgical risk. Hemodynamic performance after TAVI is superior,
but the impact of reverse remodeling on clinical improvement is controversial. We aim to address the differences in
hemodynamic changes between SAVR and TAVI, and its correlation with LV remodeling and clinical improvement
at 6 months follow-up.
Methods: Forty-two patients treated by TAVI were compared with 45 SAVR patients with a stented bioprosthesis.
Clinical, 2D and 3D echocardiographic data were prospectively obtained before and six months after intervention.
Results: Patients had similar distribution for sex, body surface area and AS severity. TAVI patients were older, more
symptomatic and had more comorbidities. They also had higher LV filling pressures, larger 3D indexed left atrium
volume, but similar 3D indexed LV mass. At 6 months, TAVI patients had greater clinical improvement and higher
effective orifice area index (EAOI), but only SAVR patients already had a significant decrease in 3D indexed LV mass
and diastolic volume. In univariate analysis older age, NYHA class ≥ III, increase in EAOI and TAVI were related with
functional class improvement. After multivariate analysis only NYHA class ≥ III (OR 8.81, CI:2.13-36.52; p = 0.003) and
an increase in EAOI ≥ 105% (OR 3.87, CI:1.02-14.70; p = 0.04) were predictors of clinical improvement.
Conclusions: At 6 months, functional class improvement was greater after TAVI. Higher initial NYHA class and an
increase in EAOI ≥ 105% were independently associated with functional enhancement. It is debatable if left
ventricular remodeling is determinant for functional class improvement.
Keywords: Aortic stenosis, Transcatheter aortic valve replacement, Surgical aortic valve replacement, Left ventricular
mass, Reverse remodeling, Clinical improvement
Background
Aortic stenosis (AS) is the most prevalent of all valvular
diseases in developed countries and its increase has a
direct relation with population aging [1]. In elderly pa-
tients cardiac surgery can be challenging by the increased
number of comorbidities, making transcatheter aortic
valve implantation (TAVI) an atractive alternative treat-
ment modality [2].
Surgical aortic valve replacement (SAVR) nearly nor-
malizes long-term survival and improves quality of life
in AS patients [3,4] but late outcomes depend mainly on
the stage of heart disease before surgery, prosthetic re-
lated complications, and comorbidities. Although there
is a significant reduction of wall stress and left ventricu-
lar (LV) pressure after SAVR, nearly half of patients have
residual LV hypertrophy (LVH) late after surgery [5,6].
This persistent increase in LV mass is an independent
predictor of cardiac-related morbidity [6] and mortality
[7] making reverse remodeling an important outcome
after surgery.
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Similarly, TAVI has shown good mid-term results, not
inferior to SAVR in high-risk patients [2] and superior
to medical therapy [8]. TAVI patients have higher effect-
ive orifice areas (EOA) and lower transprosthetic gradi-
ents but, in spite of remarkable clinical improvement,
LV mass regression and reverse remodeling are less con-
sistent in comparison with SAVR [9-11].
In this study we aim to address the differences in
hemodynamic changes between SAVR and TAVI pa-
tients, and its correlation with LV remodeling and clin-
ical improvement at 6 months follow-up.
Methods
Patient selection and follow-up
The present study is a comparison of two prospective
cohorts of patients with symptomatic degenerative se-
vere AS (defined as aortic valve area ≤1 cm2) and LV
ejection fraction (EF) ≥ 40%, who underwent SAVR with
a stented bioprosthesis or TAVI. This was a collabora-
tive work from two distinct institutions since one of
them didn’t have a TAVI program at the time of pa-
tient inclusion.
Patients with aortic regurgitation > II/IV, moderate to
severe mitral or tricuspid regurgitation, significant cor-
onary artery disease (lesions >50% on coronary angiog-
raphy) or previous cardiac surgery were excluded. All
patients had a clinical and echocardiographic evaluation
before and at 6 months after the procedure, if alive.
This investigation conforms to the Declaration of
Helsinki, had institutional ethical review board approval
and each study participant signed an informed consent
before enrolment.
TAVI group
Forty-two consecutive patients with severe aortic sten-
osis and preserved LV systolic function, submitted to
successful TAVI in one tertiary center, Hospital Clinico
San Carlos, from April 2009 to April 2010, were inclu-
ded. These patients were obtained from a series of 97
consecutive patients who underwent TAVI, after exclud-
ing those with significant LV systolic dysfunction, con-
comitant moderate to severe mitral valve disease or
aortic regurgitation, and those with significant coronary
artery disease.
Patients were referred for TAVI due to an excessive
risk for SAVR, which was estimated using the logistic
EuroSCORE and/or clinical judgment.
Vascular access was obtained either by percutaneous
approach through the common femoral artery (30 pa-
tients) or transapical approach (12 patients).
The procedure was performed under fluoroscopy and
transesophageal echocardiography (TEE) guidance using
the techniques described in detail in previous reports
[12]. Among all, 31 (73.8%) patients were implanted with
an Edwards SAPIEN (Edwards Lifesciences, Irvine, CA,
USA). The CoreValve (Medtronic CoreValve Percutaneous
System, Medtronic CV) was implanted in 11 (26.2%) pa-
tients exclusively by retrograde transfemoral approach.
Two valve sizes were available, 23- and 26-mm expanded
diameter for Edwards SAPIEN valve and 26- and 29-mm
for CoreValve. The prosthesis size was decided according
to annulus diameter, measured by TEE. The deployment
was performed under the agreement of the interventionist
and the echocardiographer. Device success was defined as
stable device placement and function as assessed by angi-
ography and echocardiography. All patients with develop-
ing new grade III atrioventricular block were implanted
with a permanent pacemaker within 3 days after valve
implantation.
SAVR group
Between January 2009 and December 2009, among 141
consecutive patients with isolated symptomatic AS referred
for SAVR at the Cardiothoracic Surgery Department of
Centro Hospitalar São João, Porto, Portugal we included
45 patients with 3D echocardiographic evaluation. All sur-
geries were performed using standard procedure for aortic
valve replacement. Patients were placed on cardiopulmo-
nary bypass and cardiac arrest was induced and maintained
with cold blood cardioplegia. The prosthetic substitutes
used in this study were Carpentier-Edwards Perimount
pericardial valve (Edwards Lifesciences, Irvine, CA) and
the St Jude Medical Epic porcine valve (St Jude Medical,
Inc, St Paul, Minn). Valve sizes were 19 mm (n = 4;8.9%),
21 mm (n = 25;55.6%), 23 mm (n = 11;24.4%) and 25 mm
(n = 5;11.1%).
Echocardiographic studies
Echocardiographic examination was performed by a
trained cardiologist and recorded on digital support. All
recordings were examined by an experienced echocardi-
ographer in an accredited independent echocardiography
laboratory (Hospital Clínico San Carlos in Madrid, Spain),
blinded to patient details. Studies were performed using
Phillips iE-33 equipment with a S5-1 transducer with
M-mode, two dimensional, pulsed, continuous, color-flow
and tissue Doppler capabilities, and an X3-1 transducer
for 3D imaging. Imaging analysis was performed with
Xcelera and QLab software. All measurements were per-
formed in accordance with the recommendations of the
American Society of Echocardiography [13]. Peak trans-
valvular gradient was estimated using the simplified
Bernoulli equation. Aortic valve area (or effective orifice
area, EOA) was estimated using quantitative Doppler by
the continuity equation. The EOA values were then in-
dexed to body surface area (EAOI). Patient prosthesis mis-
match was considered present if EAOI ≤0.85 cm2/m2 and
severe when EAOI ≤ 0.65 cm2/m2.
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The presence, degree, and type (paravalvular vs trans-
valvular) of aortic regurgitation (AR) were classified as
trivial, mild, moderate, or severe according to The Valve
Academic Research Consortium (VARC) II [14].
Mitral inflow was assessed in the apical 4-chamber
view using pulsed wave Doppler with the sample volume
placed at the tips of mitral leaflets during diastole. From
the mitral inflow profile, the peak flow velocity of early
filling (E wave), peak flow velocity of atrial contraction
(A wave), the E/A ratio, and early filling deceleration
time (DT) were measured. Doppler tissue imaging of the
mitral annulus was obtained from the apical 4-chamber
using a sample volume placed in the septal mitral valve
annulus. The septal e’ velocity value was determined,
and the E/e’ ratio was derived.
Left atrium (LA) volume, LV systolic and diastolic vol-
umes, and resulting ejection fraction were calculated
with direct 3D volumetric analysis.
All indexed values were obtained by dividing by body
surface area according to the formula of Mosteler.
Statistical analysis
Categorical variables were expressed as percentages and
continuous variables as mean ± standard deviation or
median and interquartile range, according to their distri-
bution. Continuous variables were compared between
groups using an unpaired t-test (for normally distributed
variables) or the Mann–Whitney U-test (for non-normally
distributed variables). For comparison between base-
line and follow-up a paired Student's t-test was ap-
plied (normally distributed variables) and a Wilcoxon
test (for non-normal distributed variables). Chi-square test
was used to compare proportions. Following univariate
analysis, a stepwise binary logistic multivariate regression
model (Wald backward stepwise method, p = 0.05 for co-
variate inclusion and 0.1 for exclusion) was performed, in-
cluding potential confounders for NYHA improvement
regression analysis 6 months after AVR. NYHA improve-
ment was analyzed as worse or equal vs better. Of note,
patients in baseline NYHA class I but symptomatic
(angina or syncope) were considered improved if these
additional symptoms disappeared.
All reported probability values are two-tailed, and p <
0.05 was considered statistically significant. Analyses were
performed with the IBM®SPSS® Statistics software package
(version 21.0) (SPSS Inc, Chicago, IL, USA).
Results
Patient’s baseline clinical characteristics are described in
Table 1. TAVI patients were older, had more comor-
bidities and higher logistic Euroscore. Patients who un-
derwent TAVI had worse functional class at baseline,
although they had similar baseline severity of aortic
stenosis (Table 2). Before intervention, when comparing
to SAVR patients, TAVI patients had similar 3D LV mass
index but, after normalizing LV mass to LV end-diastolic
volume (LVMI/LVDVI), they had more concentric geo-
metry (3.0 (P25-75:2.1-4.4) vs 2.4 (P25-75:1.8-3.0) g/ml;
p = 0.044) due to smaller LV end-diastolic index volumes.
TAVI patients also had worse diastolic dysfunction, with
higher LV filling pressures and larger indexed LA volume
(Table 3).
At 6 months follow-up, 5 TAVI patients had died, 3
during hospitalization for TAVI, and 2 after hospital dis-
charge from non-cardiovascular causes. There were no
deaths in the SAVR group.
Changes in LV remodeling and functional class after
aortic valve replacement
At 6 months (Table 2), TAVI patients had a higher ef-
fective orifice area index (EAOI) and lower transpros-
thetic maximal velocity and mean gradient, as well as a
greater absolute increase in EAOI. Patient-prosthesis mis-
match (PPM) was more frequent in the SAVR patients
and there were no severe PPM cases in the TAVI group.
There was a significant increase in ejection fraction (EF)
in both groups and, when considering LV remodeling
(Table 3), although there was a decrease in LV mass index
(LVMI) and LV diastolic volume index (LVDVI) in both
groups, only in SAVR patients this decrease was signifi-
cant when compared with baseline values (Figure 1).
The presence of patient-prosthesis mismatch had no
correlation with changes in LVMI, LVDVI, LV end-systolic
volume index (LVSVI), or LA volume index (Additional
file 1: Table S1). Moreover, EAOI increase was not re-
lated to final LVMI (r = 0.082, p = 0.512), LVDVI (r = 0.015,
p = 0.925), LVSVI (r = 0.154, p = 0.331), or LAVI (r = 0.187,
p = 0.143).
Table 1 Baseline clinical characteristics of SAVR vs TAVI
patients
SAVR (n = 45) TAVI (n = 42) p-value
Age (years) [Me (P25-P75)] 73 (68 - 78) 83.5 (79 - 87) <0.001
Female gender [n(%)] 28 (62.2) 26 (61.9) 0.976
BSA (m2) [Me (P25-P75)] 1.76 (1.57 - 1.86) 1.75 (1.6 - 1.8) 0.639
Hypertension [n(%)] 28 (62.2) 35 (83.3) 0.028
Diabetes mellitus [n(%)] 13 (28.9) 11 (26.2) 0.778
Dislipidemia [n(%)] 28 (62.2) 26 (61.9) 0.976
COPD [n(%)] 12 (26.7) 19 (45.2) 0.071
PAD [n(%)] 3 (6.7) 12 (28.6) 0.007
Atrial Fibrilation [n(%)] 0 (0) 7 (16.7) 0.004
Logistic Euroscore 6.18 ± 2.71 17.86 ± 9.55 <0.001
NYHA class III-IV [n(%)] 12 (26.7) 37 (88.1) <0.001
BSA = body surface area; COPD = chronic obstructive pulmonary disease;
PAD = peripheral artery disease; NYHA = New York Heart Association; values
are mean ± SD or median (P25-P75) according to distribution, or n (%).
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Table 2 Baseline and 6 months 2D echocardiographic data on SAVR vs TAVI patients
SAVR (n = 45) TAVI (n = 42) SAVR vs TAVI p-value
mean ± SD Me (P25-P75) mean ± SD Me (P25-P75)
AV annulus (cm)
Baseline 21.34 ± 2.18 21 (20 - 22.75) 20.73 ± 2.39 21 (19 - 22) 0.337b
AV peak velocity (cm/sec)
Baseline 4.81 ± 0.60 4.76 (4.36 - 5.13) 4.76 ± 0.61 4.81 (4.36 - 5.16) 0.909b
6 months 2.69 ± 0.74 2.51 (2.21 - 3.00) 2.07 ± 0.51 2.11 (1.72 - 2.31) <0.001a
p-value* <0.001 <0.001
AV mean gradient (mmHg)
Baseline 57.89 ± 13.91 54.9 (47.13 - 66.45) 54.67 ± 15.77 52.5 (44.0 - 60.3) 0.317a
6 months 17.21 ± 12.05 13.9 (11 - 21) 8.86 ± 4.72 8.1 (5.7 - 11.4) <0.001a
p-value** <0.001 <0.001
AVA (EOA, cm2)
Baseline 0.69 ± 0.2 0.7 (0.52 - 0.83) 0.62 ± 0.15 0.6 (0.51 - 0.7) 0.070a
6 months 1.5 ± 0.42 1.4 (1.2 - 1.75) 1.95 ± 0.54 1.8 (1.5 - 2.2) <0.001a
p-value** <0.001 <0.001
AVA index (EAOI cm2/m2)
Baseline 0.40 ± 0.11 0.38 (0.32 - 0.47) 0.37 ± 0.1 0.37 (0.31 - 0.42) 0.229b
6 months 0.87 ± 0.24 0.82 (0.68 - 1.00) 1.16 ± 0.39 1.05 (0.88 - 1.36) <0.001a
p-value* <0.001 <0.001
Δ EAOI (cm2/m2) 0.47 ± 0.28 0.46 (0.3 - 0.59) 0.79 ± 0.37 0.65 (0.55 - 1.03) <0.001a
PPM [n (%)] 24 (58.6) 9 (23.1) <0.001
Severe PPM [n (%)] 7 (17.1) 0 0.012
Paravalvular AR 6m [n (%)] 3 (6.7) 23 (59) <0.001
E/A ratio
Baseline 0.79 ± 0.34 0.72 (0.61 - 0.89) 1.38 ± 0.87 1.07 (0.74 - 1.74) <0.001b
6 months 0.85 ± 0.25 0.81 (0.69 - 0.93) 1.34 ± 1.22 0.73 (0.57 - 1.74) 0.703b
p-value* 0.044 0.212
E-wave deceleration time (ms)
Baseline 235.11 ± 73.97 240 (180 - 280) 207.69 ± 79.97 198 (148 - 238.5) 0.039b
6 months 264.51 ± 72.84 250 (218.5 - 300) 251.82 ± 66.02 260 (190 - 295) 0.755b
p-value* <0.001 <0.001
IVRT (ms)
Baseline 99.09 ± 26.85 100 (80 - 120) 73.4 ± 33.91 70 (50 - 100) 0.001a
6 months 116.43 ± 20.41 110 (100 - 130) 102.19 ± 28.93 100 (82.5 - 127.5) 0.034a
p-value** 0.049 <0.001
e’ (cm/s)
Baseline 4.77 ± 1.8 4.4 (3.6 - 5.8) 5.56 ± 2.55 5 (4.1 - 6.1) 0.157b
6 months 5.59 ± 1.52 5.4 (4.6 - 6.73) 7 ± 3.07 6.1 (4.78 - 8.7) 0.033a
p-value* 0.005 0.495
E/e’
Baseline 18.62 ± 7.11 16.9 (13.27 - 23.68) 23.55 ± 10.88 25.36 (15.99 - 30.78) 0.024b
6 months 16.73 ± 5.96 15.75 (13.02 - 19.86) 16.36 ± 10.77 11.72 (8.33 - 23.06) 0.153b
p-value* 0.096 0.177
AV = aortic valve; AVA = aortic valve area; EAOI = effective orifice area index; Δ EAOI = absolute increase in EAOI; PPM = patient-prosthesis mismatch; IVRT =
Isovolumetric relaxation time; 6m = six months; values are mean ± SD or median (P25-P75) or n (%). a,b – different letters stand for significant differences in mean
or median values according to t-test (a) or the Mann–Whitney U test (b).*Wilcoxon test; **Paired-sample t-test.
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After intervention, NYHA class was better in 30 (71.4%)
TAVI patients compared with 22 (48.8%) SAVR patients
(p = 0.001, Figure 2). Patients exhibiting a better NYHA
class were more likely to have no PPM (81.6% vs 60.0%,
p = 0.049) and a greater relative increase in EAOI (163.2%
(P25-75: 118.9-234.8) vs 103.0% (P25-75: 52.1-170.2);
p = 0.030). In univariate analysis, older age, baseline NYHA
class ≥ III, a higher increase in EAOI and TAVI procedure
were related with functional class improvement (Table 4).
Moreover, we found no correlation between functional
class improvement and parameters of LV reverse remodel-
ing like the decrease in LV volumes or mass, or improve-
ment in diastolic function suggested by the decrease in
left atrial volume and E/e’ (Table 4). After a stepwise lo-
gistic multivariate regression analysis, the only independ-
ent predictors of NYHA class improvement were initial
NYHA class ≥ III (OR 8.81, CI: 2.13-36.52; p = 0.003) and
relative increase in EAOI ≥ 105% (OR 3.87, CI: 1.02-14.70;
p = 0.04).
Paravalvular regurgitation was more frequent after TAVI
(59% vs 6.7%, p < 0.001), mostly of mild degree. Only 5
TAVI patients (5.8%) had moderate aortic regurgitation at
six months. Paravalvular regurgitation had no correla-
tion with the variation of indexed LVM, LVDV or LVSV
(Additional file 2: Table S2). NYHA class improvement
was similar in patients with and without paravalvular re-
gurgitation (83.3% vs 66.7%, p = 0.241).
Discussion
In this study we found that, at 6 months, TAVI patients
had a better hemodynamic result and greater clinical im-
provement than those submitted to SAVR, but LV re-
verse remodeling was of a less significant degree than in
SAVR patients.
Reverse remodeling after aortic valve replacement
At 6 months follow-up, TAVI patients had a more favor-
able hemodynamic performance but the decrease in LVMI
Table 3 Baseline and 6 months 3D echocardiographic data on SAVR vs TAVI patients
SAVR (n = 45) TAVI (n = 42) SAVR vs TAVI p-value*
mean ± SD Me (P25-P75) mean ± SD Me (P25-P75)
LVEDVi (ml/m2)
Baseline 61.77 ± 21.81 59 (43.49 - 75.58) 46.29 ± 13.47 46.59 (34.44 - 55.74) 0.007
6 months 51.28 ± 16.63 47.64 (38.69 - 59.1) 42.07 ± 12.87 38.89 (33.58 - 48.67) 0.030
p-value** 0.001 0.173
LVESVi (ml/m2)
Baseline 27.32 ± 14.68 21.7 (16.56 - 34.86) 20.91 ± 9.81 18.54 (13.98 - 28.44) 0.115
6 months 21.17 ± 11.46 19.54 (13.55 - 24.99) 16.29 ± 7.99 13.56 (10.68 - 23.01) 0.074
p-value** 0.002 0.004
EF (%)
Baseline 57.63 ± 9.38 60.1 (54.8 - 63.5) 55.73 ± 10.15 55.45 (49.45 - 59.83) 0.079
6 months 61.28 ± 8.98 61.7 (58.55 - 66.95) 61.27 ± 11.35 61 (53.5 - 70.2) 0.841
p-value** 0.037 0.005
LVMI (g/m2)
Baseline 135.3 ± 37.5 120.1 (108.4 - 160.2) 137.46 ± 47.76 123.13 (97.5 - 173.89) 0.877
6 months 119.5 ± 36.8 110.7 (96.5 - 128.0) 124.44 ± 44.55 112.53 (98.75 - 155) 0.588
p-value** 0.002 0.537
LVMI/LVDVI
Baseline 2.49 ± 0.81 2.35 (1.84 - 2.96) 3.48 ± 1.7 3 (2.05 - 4.4) 0.038
6 months 2.46 ± 0.68 2.56 (1.9 - 2.92) 3.01 ± 1.53 2.82 (1.81 - 3.65) 0.334
p-value** 0.557 0.424
LAVI (ml/m2)
Baseline 39.94 ± 14.27 37.27 (31.15 - 47.99) 48.42 ± 14.81 47.5 (35.36 - 57.14) 0.008
6 months 38.16 ± 11.9 36.17 (30.19 - 45.24) 40.99 ± 12.7 42.63 (29.44 - 50) 0.425
p-value** 0.465 0.006
LVDVI = left ventricular end-diastolic volume index; LVSVI = left ventricular end-systolic volume index; EF = ejection fraction; LVMI = left ventricular mass index;
LAVI = left atrial volume index; *Mann–Whitney test; **Wilcoxon test.
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and LV volumes, although showing the same trend as
SAVR patients, was less extensive.
A greater decrease in transvalvular gradients and in-
crease in effective orifice area was seen after TAVI. It
would be expected that patients undergoing this proce-
dure had faster remodeling if load was the most impor-
tant determinant of mass regression, but in our study
EAOI increase was not associated with changes in LV
mass and volumes after AVR. We can speculate that the
baseline differences we have found, with older age and
more comorbidities in TAVI patients, could have contrib-
uted to this result. Moreover, TAVI patients were “sicker”,
with worse diastolic dysfunction and worse functional
class, despite similar severity of AS and EF, possibly due to
Figure 1 Six months changes in parameters of remodeling in TAVI and SAVR groups. A- change in left ventricular mass index (LVMI);
B- change in ratio LVMI/left ventricular end-diastolic volume index (LVDVI); C- change in ejection fraction (EF); D- change in left atrial volume
index (LAVI); E- change in LVDVI; F- change in left ventricular end-systolic volume index (LVSVI).
Figure 2 Six months changes in NYHA class in TAVI and SAVR groups.
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longer time of LV overload exposure. This could explain a
restricted ability of the myocardium to recover from pre-
intervention changes.
Various groups have focused on the hemodynamic and
structural effects of TAVI [10,15-18] with consistent re-
sults in afterload reduction and symptomatic improve-
ment, but with conflicting results on reverse remodeling.
Previous reports comparing the impact of TAVI and
SAVR on LV remodeling addressed heterogeneous popu-
lations, including patients with coronary artery disease,
different levels of EF, and several types of aortic pros-
thesis, including mechanical, stented and stentless bio-
prosthesis [9,11,19].
Clavel et al. [20] compared hemodynamic perfor-
mances of TAVI or SAVR with stentless and stented bio-
prosthesis. At 6 to 12 months the increase in EAOI and
reduction in transvalvular gradients in TAVI patients
was similar to that obtained with stentless bioprosthesis
and there was a clear advantage of TAVI in preventing
PPM in patients with small annulus (≤20 mm). However,
data on clinical improvement or reverse remodeling is
absent.
Fairbairn et al. [19], using cardiac magnetic resonance
imaging, showed a decrease in LVMI and indexed LV
systolic volume at 6 months in both groups, but only
SAVR patients had a decrease in indexed LV diastolic
volume. The authors considered that the smaller reduc-
tion in LV end-diastolic volume post-TAVI could be re-
lated to a greater burden of coronary artery disease in
these patients. In our study we found that, at 6 months,
only SAVR patients had a significant decrease in LV
mass and LV end-diastolic volume. Since we excluded
patients with coronary artery disease, the absence of sig-
nificant remodeling post-TAVI at this time point could
indicate the existence of irreversible disease. Constantino
et al. [18] compared reverse remodeling 2 months after
TAVI and SAVR, and concluded that there was a more
significant reduction in LVMI and relative wall thickness
(RWT) in TAVI patients. These results are conflicting
with ours, but were obtained in an earlier time point
and the lack of adjustment for differences in baseline
LVMI could have influenced results. Moreover, the au-
thors found that these structural changes were paralleled
by reduction in estimated filling pressures after TAVI.
We also found a reduction in E/e´ after TAVI, but this
occurred in absence of favorable remodeling and had no
correlation with clinical improvement. Its association
with prognosis is yet to be seen.
In the Cohort A of the PARTNER trial, LV diastolic
volume was higher in TAVI patients in the first year of
follow-up, but these differences were no longer present
at two years. LV mass regression was faster in the SAVR
group, although there were no significant differences
after 6 months [11]. These results are similar to those
reported in our study, suggesting that reverse remodel-
ing can also occur in TAVI patients, but the process is
slower than after SAVR, even after matching for age and
major comorbidities.
Aortic regurgitation after TAVI, mostly paravalvular, is
a common event [2,21] and has come to our attention
because of its impact on mortality. Post-procedural mo-
derate to severe AR increased in-hospital mortality in
comparison with no or only mild AR [21] and, in the
randomized PARTNER trial, there was a positive correl-
ation between AR severity and long-term mortality [22].
The pathophysiology underlying this increase is mortal-
ity is unclear. It has been speculated that significant pa-
ravalvular aortic regurgitation can overload the LV and
impair reverse remodeling [23], therefore worsening prog-
nosis. In our study, the presence of paravalvular aortic re-
gurgitation had no correlation with the variation in LV
volumes or mass. Once only 5 patients had moderate re-
gurgitation, the lack of association with ventricular re-
modeling could be due to the small sample size. Longer
Table 4 Univariate and multivariate analysis of clinical
and echocardiographic determinants of NYHA class
improvement
NYHA improvement Univariate
analysis
Multivariate
analysis
OR (95% CI) p p
Female gender
[n(%)]
0.92 (0.31-2.67) 0.87
Age (years) 1.09 (1.01-1.17) 0.02
ΔEF (%) 0.99 (0.94-1.04) 0.62
ΔLVMI (g/m2) 0.99 (0.97-1.01) 0.49
ΔLAVI (ml/m2) 1.01 (0.99-1.02) 0.38
ΔLVDVI (ml/m2) 0.98 (0.94-1.02) 0.28
ΔLVSVI (ml/m2) 0.99 (0.93-1.05) 0.64
ΔEAOI (%) 8.81 (0.90-86.10) 0.06 3.87 (1.02-14.70) 0.004
ΔE/e’ 1.01 (0.94-1.08) 0.85
Hypertension [n(%)] 1.70 (0.60-5.15) 0.35
Diabetes Mellitus
[n(%)]
0.48 (0.15-1.48) 0.20
COPD [n(%)] 2.55 (0.75-8.66) 0.14
PAD [n(%)] 0.80 (0.22-2.96) 0.74
NYHA class ≥ III
[n(%)]
11.33 (2.93-43.78) <0.001 8.81 (2.13-36.52) 0.003
TAVI [n(%)] 7.08 (1.86-27.04) 0.004
Aortic regurgitation
6m [n(%)]
2.35 (0.69-8.03) 0.17
LVDVI = left ventricular end-diastolic volume index; LVSVI = left ventricular
end-systolic volume index;; LVMI = left ventricular mass index; LAVI = left atrial
volume index; Δ EF = baseline- 6 months ejection fraction; Δ LVDVI = baseline-
6 months LVDVI; Δ LVSVI = baseline- 6 months LVSVI; Δ LVMI = baseline- 6
months LVMI; Δ LAVI = baseline- 6 months LAVI; Δ EAOI = relative increase in
EAOI at 6 months; Δ E/e’ = baseline- 6 months E/e’; COPD = chronic obstructive
pulmonary disease; PAD = peripheral artery disease; TAVI = transcatheter aortic
valve implantation.
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follow-up and larger numbers are needed to take any def-
inite conclusion on its impact in remodeling.
Predictors of clinical improvement
In our sample, the increase in EAOI to more than the
double was a strong predictor for clinical improvement,
independent of changes in parameters of reverse remodel-
ing. Conversely, the presence of patient-prosthesis mis-
match (PPM) was correlated with impaired improvement
in NYHA class.
Several studies reported that PPM is an independ-
ent predictor of cardiac events after AVR [24,25] while
others failed to demonstrate a significant impact on out-
comes [26,27].
Some authors found that persistent PPM results in less
regression [28,29] but even patients with PPM or small
prosthesis can have significant reduction in LVM [30,31].
The extent of regression is largely dependent on the ex-
tent of EOA increase after AVR [32]. Given the curvilinear
relation of indexed EOA and transprosthetic gradients
the degree of regression seems to be dependent on the ori-
ginal and final positions of an individual patient on the
indexed EOA-gradient curve [33]. Although we found no
correlation between PPM and impaired LVMI regression,
we did find that the increase in valve area to more than
twice the initial value was crucial for clinical improve-
ment. This can be particularly important in elderly pa-
tients whose main concern is the achievement of a better
quality of life.
Finally, as expected, patients who were in worse NYHA
class before intervention more frequently experienced a
clinical improvement. Using NYHA class to evaluate clin-
ical improvement, although extensively used, has limita-
tions and it is easier to demonstrate an improvement
when a patient is class III/IV than NYHA class II/I. This
fact can also help to explain the better improvement in
the clinical status of patients undergoing TAVI, as they
were in worse NYHA class than SAVR patients, before the
intervention.
Limitations
Since this was an observational study, we were not able
to match patients for age, comorbidities or prosthesis
size. These factors were considered in the multivariate
model used for prediction of clinical improvement, but
the authors recognize that, although logistic multivariate
analysis is commonly used, it can’t correct for all pos-
sible confounders.
In addition, we selected our population by excluding
patients with concomitant coronary artery disease and
significant associated valvular disease to reduce intro-
duction of further bias. The limited number of patients
included in this analysis has limited statistical power to
detect small differences between groups.
The evaluation of functional improvement using NYHA
class is subjective and a more objective method, like six-
minute walk test, could have allowed a quantitative assess-
ment. Nevertheless, in clinical practice, NYHA class is the
most widely use classification of function status and has
been proven useful over the years.
Conclusions
At six months after aortic valve intervention, better
hemodynamic result was seen after TAVI, but LV reverse
remodeling was of a less significant degree than after
SAVR. Older age, comorbidities and the existence of a
more extensive myocardial disease, as suggested by worse
diastolic dysfunction and worse functional class in TAVI
patients, despite similar severity of AS and EF, could ex-
plain a restricted ability of the myocardium to recover
even after load relief. Moreover, six months may be too
early to draw definitive conclusions, namely regarding the
consequences of paravalvular aortic regurgitation.
Mid-term clinical improvement was strongly related to
the increase in EAOI and had no association with LV re-
modeling parameters. Thus, doubling the initial aortic
valve area seems to be a key point to achieve clinical im-
provement after valve replacement, a particularly im-
portant endpoint in the elderly.
This study raises some important new questions but
longer follow-up and large-scale randomized trials are
needed to confirm these results.
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6. DISCUSSION
We have followed for 8.2 years a cohort of 132 patients with severe symptomatic AS referred for AVR. 
Most patients had sex-specific criteria for LVH before surgery and, at echocardiographic evaluation, 5 
years after surgery, only 66% achieved LVM normalization, despite a significant reduction in transval-
vular gradients and total hemodynamic load. This raises the question if some of these patients may 
have a maladaptive response to chronic overload, dependent of non-hemodynamic factors, which 
impairs LVM regression and, presumably, impacts prognosis.
The event rate was low, with 17 deaths (1.6%/year) and 12 non-fatal cardiovascular hospitalizations 
(1.1%/year) at 8 years follow-up, which is in accordance with the low risk profile of our patients.  Even 
so, we could find that an excess in LVM, above the predicted value for load, body size and gender, was 
an independent predictor of all-cause death and non-fatal cardiovascular hospitalization, after adjust-
ment for important prognostic factors such as age, GFR, baseline LVM or EF. Moreover, higher baseline 
LV filling pressure, estimated by the ratio E/e’, was also a predictor of the composite endpoint of death 
or non-fatal cardiovascular hospitalization.
The existence of inappropriate LVM, defined as an observed value above 78% of the predicted, was 
associated with worse event-free survival. Moreover, these patients presented more severe myocar-
dial disease, probably irreversible, which can justify their worse prognosis. 
 
Prognostic relevance of excessive LVM
During childhood and adolescence, there is a close relationship between body size and LV mass, with 
no differences between genders, since body growth is the main determinant of cardiac development 8. 
With advancing age, the discrepancy between the value of observed LVM and that predicted for body 
size increases. This variability is due to hemodynamic load, which becomes the fundamental stimulus 
for LV mass in adulthood 2. At this time in life, the ratio of stroke work (SW), as a measure of hemody-
namic load, to LVM is lower in men and gender differences exist in measured LVM. 
In a normal-weight and normotensive cohort, de Simone et al have found that, 82% of the variance in 
LVM can be explained by SW (stroke volume times systolic pressure), height 2.7 and gender 2. A mul-
tiple linear equation was then derived to calculate the predicted LVM. Still, about 18% of variance has 
to be attributed to non-hemodynamic factors such as genetics and other environmental influences.
The excess in LVM is associated with a specific phenotype of concentric LV geometry, depressed 
midwall systolic shortening and prolonged LV relaxation, in situations of chronic pressure overload 
such as hypertension and aortic stenosis 9-12, even in the absence of echocardiographic criteria of LV 
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hypertrophy 11. Moreover, patients with inappropriate LVM have worse prognosis both in hyperten-
sion 13, 14 and in aortic stenosis 3, suggesting that this patients have a “maladaptive” response to 
increased LV load. Indeed, it has been advocated that this excess in LVM can identify a more ad-
vanced stage of myocardial disease, probably beyond the compensatory phase, and could be a sign 
of impending heart failure 15, 16.
Although the concept of inappropriate LVM has been studied mainly in the context of hypertension, 
where the cutoff was set at the 95th percentile of normal distribution, corresponding to an excess of 
28% of the predicted value, some evidence exists suggesting its applicability in aortic stenosis 3, 12, 17 
and, more recently in type 2 DM 18 and CKD 19. 
In aortic stenosis, it has been used to help to predict the timing of surgery in asymptomatic patients, 
where those with an excess of LVM 10% above the predicted had a higher rate of the combined event 
of death from all causes, aortic valve replacement or hospital admission for non-fatal myocardial 
infarction and/or congestive heart failure 3. Furthermore, in a sub-analysis of the SEAS (Simvastatin 
Ezetimibe in Aortic Stenosis) study, in patients with asymptomatic mild-moderate aortic stenosis, in-
appropriate LVM (defined an excess of 28% above the predicted LVM) was present in 16.6% and was 
associated with combined concentric geometry and reduced left-ventricular myocardial contractility, 
again suggesting that it is a marker of more advanced myocardial disease 17.
We have extended the evidence of excess of LVM usefulness to symptomatic severe aortic stenosis 
patients, describing a continuous gradient of risk with an adjusted HR of 1.02 (95%CI:1.01-1.04) for all-
cause mortality, 1.02 (95%CI:1.00-1.04) for non-fatal cardiovascular hospitalization, and 1.01 (95%CI: 
1.00-1.02) for the combined endpoint, for each 1% increase in excess LVM. Using the cutoff of 78% 
excess in LVM, we could identify a subgroup of patients with worse diastolic and systolic function 
and lower survival free of events, probably due to more advanced and irreversible myocardial dis-
ease. Inconsequence earlier intervention eventually might be beneficial in patients with an excessive 
LVM response to pressure overload to improve long-term outcomes after AVR.   
E/e’ and outcomes after AVR
In our study, non-invasive evaluation of left ventricular filling pressures was based on the ratio be-
tween early diastolic mitral inflow and mitral annular velocity (E/e’) since, in aortic stenosis, it has 
a good correlation with invasive determination of filling pressures 20. Increased values of E/e´ are 
associated with the existence of diastolic dysfunction, worse functional class and pulmonary hyper-
tension21. In our study, E/e´ was an independent predictor of the combined event all-cause mortality 
or non-fatal cardiovascular hospitalization, suggesting that patients with more severe diastolic dys-
function have worse long-term prognosis. This is in accordance with previous results reporting that 
increased E/´e levels are associated with more in-hospital cardiovascular complications and worse 
mid-term cardiovascular event-free survival 22.
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Gender differences in hypertrophic response to aortic stenosis 
In our study, non-invasive evaluation of left ventricular filling pressures was based on the ratio between 
early diastolic mitral inflow and mitral annular velocity (E/e’), which is well correlated with invasive de-
termination of filling pressures 20. Increased values of E/e´ are associated with the existence of diastolic 
dysfunction, worse functional class and pulmonary hypertension 21. In our study, E/e´ was an indepen-
dent predictor of the combined event all-cause mortality or non-fatal cardiovascular hospitalization, 
suggesting that patients with more severe diastolic dysfunction have worse long-term prognosis. This 
is in accordance with previous results reporting that increased E/´e levels are associated with more in-
hospital cardiovascular complications and worse mid-term cardiovascular event-free survival 22.
Elderly women with AS respond to pressure overload with smaller, more hypertrophic and stiffer 
ventricles, and often have supranormal ejection fraction 23, 24. Conversely, men have higher levels of 
wall stress and worse systolic function than women under similar load conditions 23. These distinc-
tive LV remodeling responses to pressure overload can be partially explained by the effect of sex 
hormones. Estrogens seem to have antiproliferative effects on cardiac fibroblasts 25 and vascular 
smooth–muscle cells, while androgens have opposite effects 26. In animal models, estrogens down 
regulate proliferation of cardiac fibroblasts and gene expression of collagens type I and III in female, 
but have opposite effect in male 27, 28. Therefore, estrogens may prevent the up regulation of collagen 
in women with pressure overload until menopause. Given that older patients have relative hypogo-
nadal hormone concentrations, with a decrease in estrogens and ovarian production of androgens in 
postmenopausal women, it is expected that this protective effect is lost with aging in women.
The presence of a profibrotic pattern of ECM biomarkers and evidence of more fibrosis in surgical 
biopsies of our elderly AS women can explain the existence of a more inappropriate increase in LVM 
and the persistence of LVH after AVR, since this is the myocardial component that takes longer to 
regress and some of these changes can even be irreversible. It is possible that women may benefit 
from earlier surgery before irreversible myocardial disease develops.
Relevance of residual left ventricular hypertrophy after surgery for isolated aortic stenosis 
In our study residual LVH was present in 44% of patients late after AVR and was associated with a 
worse prognosis, with nearly a three-fold increase in the risk of death or non-fatal cardiovascular 
hospitalization. We also found that women, history of hypertension, higher baseline LVMI and higher 
baseline LV filling pressures were independent predictors of residual LVH. Moreover, in women the 
persistence of LVH late after AVR was associated with a worse outcome. This was not seen in men, 
suggesting that the prognostic impact of residual LVH is gender-specific.
The lack of normalization of LV mass after surgery occurs in nearly half of patients with AS, and it has 
been considered as a “natural” consequence of the substitution of a native valve for a somewhat ob-
structive valve substitute with a residual gradient 29. Thus the focus has been on avoiding significant 
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PPM and new prostheses have been developed with better hemodynamic profiles. Nevertheless, 
in our study residual LVH was not associated with PPM. Beach et al, described that high postopera-
tive transprosthesis gradients had only a minimal effect on residual left ventricular hypertrophy, in 
a study including a very large number of patients 30. Therefore, hemodynamic factors are not the 
only determinants of incomplete regression. We found that patients with a higher baseline LVMI and 
worse diastolic dysfunction had a higher probability of having residual LVH after surgery. Moreover, 
those with worse longitudinal systolic function were also less likely to have LV mass normalization 
late after surgery. Our results are in accordance with that of other authors, who also found that the 
existence of a more severe preoperative hypertrophy 30-33 and the presence of early signs of myo-
cardial dysfunction, even with preserved ejection fraction, might be a surrogate of a more advanced 
disease 34. At the histological level, our finding that a higher amount of fibrosis at the time of surgery 
is an independent predictor of residual LVH, reinforces the hypothesis that a more severe, and prob-
ably irreversible, form of myocardial disease is behind the lack of LVM normalization.
Female gender and a history of HT were also independently associated with persistent LVH. In the 
previous analysis, we had found that women had more interstitial fibrosis than men, had a profile 
of extracellular matrix (ECM) biomarkers favoring collagen deposition, and that these correlated 
negatively with LV mass regression, giving a plausible theory for the existence of more residual 
LVH in women. Moreover, hypertension negatively impacts LV mass regression after surgery, and 
several authors have stressed the need for rigorous blood pressure control in these patients 35, 36. 
Nevertheless, our group has shown that this impairment in reverse remodeling happens indepen-
dently of load, and might be related to the neuro-hormonal milieu37.
The association of residual LVH in AS with worse prognosis is controversial. Others have described 
this association including patients with other types of valve lesions and coexisting coronary artery 
disease (CAD), which may have influenced results. Indeed, the coexistence of CAD has been con-
sidered as an independent predictor of clinical outcomes after AVR 38 and the presence of aortic 
insufficiency can elicit a different remodeling response 39. In our study we excluded these patients.
The worse long-term outcome of patients with residual LVH after AVR can be explained by the exis-
tence of more extensive preoperative disease and persistent diastolic and/or systolic dysfunction 40, 41. 
Based on results from previous studies 42, 43, the worse baseline longitudinal systolic function in our 
patients with residual LVH might reflect the existence of more advanced myocardial disease and higher 
levels of fibrosis.
One important finding in our study was the differences in the prognostic impact of residual LVH ac-
cording to gender. Only in women the absence of normalization of LVM was associated with worse 
survival free of hospitalization or all-cause mortality. Recently, Petrov et al 44 described that women 
with preoperative maladaptive LVH had worse survival than those with adaptive LVH, a pattern that 
was not seen in men. These results are in accordance with ours, showing a gender-specific prognosis 
of LVH determined before or after AVR. Thus, it seems that, in women, the search for early predictors 
of negative remodeling after AVR could be particularly relevant.  
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Load independent impairment of reverse remodeling after valve replacement in hypertensive 
aortic stenosis patients
Hypertension and AS frequently coexist. In our study we found a prevalence of HT of 56.3% and these 
patients had more severe heart failure symptoms when compared to non-hypertensive AS patients 
with the same echocardiographic parameters of AS severity. Moreover, in our cohort HT impaired LV 
mass regression and reverse remodeling after AVR, independently of total LV afterload. The combi-
nation of HT with AS was associated with a different pattern of expression of genes related to ECM 
remodeling favoring collagen accumulation and higher relative levels of collagen type I, which could 
help to explain its negative impact on reverse remodeling.
Data on systemic blood pressure before and after AVR is absent in most studies on incomplete LVH 
regression and only recently some authors have reported its relation to postoperative LVM 35, 36, 45, 46. 
In a retrospective observational study with 79 pure AS patients, the only independent predictors of 
postoperative LVM index were preoperative LVM and postoperative systolic blood pressure (defined 
as normal if <130 mmHg) 36. Uncontrolled hypertension was not only related to higher LVM after AVR 
but also with worse survival, with higher incidence of heart failure and bleeding as causes of death 
35. These observations resulted in a general recommendation for strict blood pressure control after 
AVR 35, 36.
It is not as well understood if the existence of HT per se can influence LVM regression even under 
similar load conditions. Our results suggest that HT blunts LVM normalization and reverse remodel-
ing after AVR for isolated AS independently of load. As expected, there was a trend for higher sys-
tolic blood pressure in hypertensive patients, but the total LV afterload, evaluated by valvuloarterial 
impedance, that takes into account systolic blood pressure, prosthetic gradient and stoke volume, 
was not significantly different between patients with and without HT. One can speculate if this could 
be due to the systemic nature of hypertensive disease, with a generalized neurohumoral activation, 
with particular focus on the renin-angiotensin-aldosterone system (RAAS) and sympathetic nervous 
system (SNS), which directly promote myocyte hypertrophy and matrix deposition independently 
of their effects on systemic arterial pressure 47. These same factors, promote both hypertension and 
LVH and there is the possibility that increased blood pressure is the consequence, rather than the 
cause, of LVH and associated vascular structural changes. Data from the Framingham Heart Study 
demonstrated a direct and continuous relationship between LVM and the subsequent development 
of hypertension in previously normotensive subjects 48. Also, in a study in young healthy subjects, 
plasma angiotensin II was an independent predictor of LVM and its effect was independent of systolic 
blood pressure and body size 49. Moreover, the magnitude of LVH regression achieved by inhibiting 
the RAAS and SNS is greater than that produced by comparable BP reduction alone 50. All this data 
supports the hypothesis that neuroendocrine mechanisms are important in the regression of LVH, 
independently of blood pressure 
To the best of our knowledge we were the first to report myocardial expression of MMPs and their tis-
sue inhibitors in combined HT and AS. In our study only HT+AS patients had an up regulation of TIMP 
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2 and an increase in collagen type I/type III ratio, suggesting a shift towards collagen accumulation 
and a stiffer form of collagen meshwork. When comparing patients with and without hypertension, 
it becomes clear that collagen degradation seems to be more impaired in HT+AS given the higher 
levels of TIMP2 expression and their correlation with LVMI. This different pattern of ECM remodeling 
can help to explain the differences in LV remodeling in the presence of HT.
Prognostic implications of fibrosis in low risk aortic stenosis patients 
We found that, in our low risk cohort of patients with severe AS, higher levels of fibrosis had a 
negative prognostic impact with lower survival free of all-cause death or the composite of all-cause 
death or non-fatal cardiovascular hospitalization. Moreover, it was a predictor of events, independent 
of other well established prognostic factors such as EF, age, baseline LVMI or NYHA class. For our 
patients, a cut-off value of 15% of CVF had a good performance as a predictor of clinical events.
Fibrosis is an early morphological alteration in patients with AS and has been pointed as one of the 
reasons for impaired LVH regression after AVR 51. Once established, fibrosis is a major determinant 
of diastolic and systolic dysfunction and it is one of the structural substrates for arrhythmogenicity, 
thus playing a major role for sudden death and the progression of HF 52, 53. While myocyte hypertro-
phy is dependent on load, fibrosis seems also to be regulated by non-hemodynamic factors such as 
neurohormones 54.
In LVH associated with aortic stenosis, there is an increased production of collagen and a shift towards 
inhibition of collagen degradation 55-57. When compared with controls, myocardial biopsies of aortic 
stenosis patients have higher expression of collagens and an up-regulation of TIMP 1 and 2 mRNA, 
favoring inhibition of collagen degradation, which significantly correlates with the degree of fibro-
sis57. Experimental studies have described total regression of MMP and TIMP gene expression as well 
as an association between changes in LVMI and MMP/TIMP gene expression after corrective surgical 
therapy and LV hypertrophy regression 58. The renin-angiotensin-aldosterone (RAA) system seems to 
be a key factor in this process. Mechanical stretch induces local production of angiotensin II, which in 
turn stimulates the release of multiple growth factors and cytokines from cardiac fibroblasts that act 
in an autocrine and paracrine fashion, affecting the progression of hypertrophy and remodeling 59-61.
Others have described the prognostic importance of myocardial fibrosis (MF) in aortic stenosis, ei-
ther using histological assessment or noninvasive evaluation by cardiovascular magnetic resonance 
(CMR) with late gadolinium enhancement (LGE) 42, 62-65. However, most of these studies have analyzed 
patients with worse preoperative NYHA class and more advanced forms of myocardial disease when 
compared with our cohort. Patients usually had lower values of EF, higher LV volumes and dimen-
sions and higher levels of histological interstitial fibrosis, suggesting more extensive remodeling 62-
64. Likewise, the inclusion of aortic regurgitation patients 62 or the coexistence of other cardiovascular 
comorbidities, such as atrial fibrillation and coronary artery disease 64, 65, which were excluded in our 
study, may have influenced outcomes.
143
DISCUSSION
Milano and coworkers 63 have performed a very similar study in a group of 99 patients with AS in 
which fibrosis was calculated from myocardial biopsies obtained during surgery. In their retrospec-
tive analysis, 10 years survival rate was lower in patients with severe fibrosis (defined as fibrous 
index >50%) and no significant improvement in NYHA class was seen in this the group. We also 
found worse long-term survival and lesser NYHA class improvement in those with more severe 
fibrosis, but ours was a prospective study and our cut-off was much lower. . According to Milano et 
al. criteria (no or mild fibrosis if <20% and moderate fibrosis if 20-50%), most of the patients in our 
study would have been included in the group with mild fibrosis. This can help to explain why in our 
study, patients with higher level of fibrosis have less ventricular remodeling and dysfunction (only 
9.5% of those with CVF ≥15.4% have EF<50%) comparing with their group with moderate or severe 
fibrosis. Moreover, not surprisingly, we did not find a significant correlation between fibrosis level 
and LV diameters, RWT or EF, which was described in the aforementioned work. It is expected for 
these correlations to be stronger in more severe grades of fibrosis. Even with lesser severe form 
of myocardial disease, we could still find an increase in events in our AS patients with increasing 
levels of fibrosis.
Fibrosis is an ominous sign in AS in the continuous of myocardial structural changes associated with 
aortic stenosis and should be actively sought for risk stratification, not only in asymptomatic patients 
with preserved ejection fraction, but also in symptomatic patients undergoing AVR. After AVR, the 
use of additional medical therapy modulating the RAA system in patients with non-invasive evidence 
of fibrosis is very appealing and deserves further investigation.
Determinants of clinical improvement after surgical replacement or transcatheter aortic 
valve implantation for isolated aortic stenosis 
In this study we found that, at 6 months, TAVI patients had a better hemodynamic result and greater 
clinical improvement than those submitted to SAVR, but LV reverse remodeling was of a less signifi-
cant degree than in SAVR patients. 
A greater decrease in transvalvular gradients and increase in effective orifice area was seen after 
TAVI. It would be expected that patients undergoing this procedure had faster remodeling if load 
was the most important determinant of mass regression, but in our study EAOI increase was not 
associated with changes in LV mass and volumes after AVR. We can speculate that the patients’ 
baseline differences could have contributed to this result, as TAVI patients were “sicker”, with worse 
diastolic dysfunction and worse functional class, despite similar severity of AS and EF, possibly due 
to longer time of LV overload exposure. This could explain a restricted ability of the myocardium to 
recover from pre-intervention changes.  
Various groups have focused on the hemodynamic and structural effects of TAVI 66-70, with consistent 
results in afterload reduction and symptomatic improvement, but with conflicting results on reverse 
remodeling. Previous reports comparing the impact of TAVI and SAVR on LV remodeling addressed 
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heterogeneous populations, including patients with coronary artery disease, different levels of EF, 
and several types of aortic prosthesis, including mechanical, stented and stentless bioprosthesis 71-73.
In the only randomized trial performed in high-risk patients, LV mass regression was faster in the 
SAVR group, although there were no significant differences after 6 months 71. These results are simi-
lar to those reported in our study, suggesting that reverse remodeling can also occur in TAVI patients, 
but the process is slower than after SAVR, even after matching for age and major comorbidities. 
In our study, the presence of paravalvular aortic regurgitation had no correlation with the variation 
in LV volumes or mass. Once only 5 patients had moderate regurgitation, the lack of association 
with ventricular remodeling could be due to the small sample size. Older age, comorbidities and 
the existence of a more extensive myocardial disease, as suggested by worse diastolic dysfunction 
and worse functional class in TAVI patients, despite similar severity of AS and EF, could explain a 
restricted ability of the myocardium to recover, even after load relief. 
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This was a single center observational study and the limited size of our cohort, although similar to 
those reported on literature about this subject, limits our statistical power. Moreover, the limited 
number of events can result in overfitted multivariate models. 
We were unable to achieve myocardial biopsies fibrosis determination in all patients. Still these 
patients were randomly chosen and are believed to be representative of the overall study group.
 
The use of strain (S) and strain rate (SR) for detection of early and subclinical systolic LV dysfunction 
would be of value, but, at the time we began patient inclusion, this imaging technics were not avail-
able at our center.  Moreover, the systematic use of CMR with LGE to evaluate replacement fibrosis 
would have complemented our results. In fact, we were able to achieve this data in 40 patients but 
software limitations have delayed their analysis and, therefore, these data was not included. 
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• In patients with severe aortic stenosis, inappropriate LV hypertrophy can identify patients with 
worse diastolic and systolic function and lower survival free of events after AVR, probably due to 
more advanced and irreversible myocardial disease.
• Among AS patients, women have higher excess in LV hypertrophic response than men under 
similar workload conditions, and female gender is an independent predictor of residual hypertro-
phy after AVR. A gender-specific ECM remodeling, favoring interstitial fibrosis in women, might 
help to explain these differences. 
• Residual LVH late after AVR is associated with a worse prognosis, in particular in women. The 
presence of more severe myocardial disease, as suggested by higher LVM and worse LV diastolic 
and systolic function, can help to explain the poorer clinical outcome of these patients. 
• The coexistence of HT with AS is associated with ECM remodeling favoring collagen deposition 
and higher LVM. Moreover, HT impairs LV mass regression and reverse remodeling after AVR. 
This data reinforces the concept of modulation of the RAAS system in AS, particularly if HT is 
present. 
• We have confirmed the prognostic relevance of myocardial fibrosis in severe AS, and extended 
this evidence to low risk patients with a less severe form of myocardial remodeling. Fibrosis is 
an ominous sign in AS in the continuous of myocardial structural changes and should be actively 
sought for risk stratification, not only in asymptomatic patients with preserved ejection fraction, 
but also in symptomatic patients undergoing AVR. 
• At six months after aortic valve intervention, better hemodynamic result was seen after TAVI, but 
LV reverse remodeling was of a less significant degree than after SAVR. Older age, comorbidi-
ties and the existence of a more extensive myocardial disease, as suggested by worse diastolic 
function and worse functional class in TAVI patients, despite similar severity of AS and EF, could 
explain the restricted ability of the myocardium to recover after load relief. Mid-term clinical 
improvement was strongly related to the increase in EAOI and had no association with LV remod-
eling parameters. Thus, doubling the initial aortic valve area seems to be a key point to achieve 
clinical improvement after valve replacement, a particularly important endpoint in the elderly.
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Left ventricular hypertrophy in aortic stenosis results from the progressive increase in afterload and 
LV wall stress, and it is an adaptive response to avoid afterload mismatch and consequent LV dys-
function. However, the degree of LVH is only weakly related to the severity of valve obstruction 74-76 
and patients who respond with a more severe degree of hypertrophy have worse prognosis after 
valve replacement. Thus, in some patients there seems to be a maladaptive response to chronic 
overload, dependent of non-hemodynamic factors, which induces a specific phenotype, impairs LVM 
regression and impacts prognosis.
The work included in this thesis brings additional evidence that excessive LV hypertrophy, in response 
to similar degrees of AS severity, is associated with a worse prognosis and a more advanced form of 
myocardial disease. Older age, comorbidities and the existence of worse pre-intervention diastolic 
function and functional class, as occurs with TAVI patients, can limit the ability of the myocardium 
to recover, even after load relief. The lack of normalization of LV mass after surgery helps to identify 
patients that might merit additional intervention, besides surgery. 
We found that some specific subgroups of patients are particularly vulnerable to this maladaptive 
response, such as women and hypertensive patients, and these may benefit of additional studies ad-
dressing the impact of an earlier surgical intervention, independently of symptoms or ejection fraction. 
At the structural and molecular level, we have described differences in ECM remodeling and higher de-
grees of interstitial fibrosis in those with impaired reverse remodeling and those with worse outcomes. 
Moreover, we found a more severe preoperative fibrosis and evidence of a specific ECM remodeling in 
women, which may justify the study of gender-specific therapeutic interventions. 
Considering the pro-hypertrophic and pro-fibrotic effects of angiotensin II in pressure overload 60, 77, 78, 
the use of medical therapy modulating the renin-angiotensin-aldosterone system in addition to surgery, 
particularly in patients with non-invasive evidence of preoperative fibrosis, could be a game changer. 
 
Our results have led us to new questions and on the road for answers.  Two projects are ongoing 
trying to answer to the following question:
— Do micro RNAs (miR) influence reverse remodeling?
We performed a microarray analysis of miR expression in myocardial biopsies of 14 patients 
from our cohort and 5 explanted normal hearts that were used as controls. The expression of 
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selected miR genes will be measured in the beginning of 2015. Correlations with the degree of 
hypertrophy and LV reverse remodeling will be performed. 
— Can the block of RAA system lead to a faster and more complete reverse remodeling after 
load relief? At what level should the block occur?
Using an animal model of banding and debanding, already implemented at our research unit, 
we will evaluate if pharmacologic blockade of RAA system impacts the hypertrophic response 
during banding and reverse remodeling after debanding. To evaluate if the level of RAA system 
blockade can influence results, we will use 3 groups: sham group, ACE inhibitor group and 
aldosterone receptors block group.
Finally, hypothesizing a beneficial effect of RAAS blockade on cardiovascular outcomes after AVR, we 
aim to conduct a national, multicenter and randomized trial, using RAAS blockade in patients with 
isolated aortic stenosis undergoing AVR.
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